data_2ls1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2ls1 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.1 m . . . . . 0 CA--C 1.504 -0.796 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.8 m -132.92 -168.51 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.6 t-105 -139.19 143.57 38.15 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 174.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.43 58.69 2.25 Favored Glycine 0 C--N 1.356 1.68 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.84 172.79 22.93 Favored Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 -177.178 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -90.62 -40.13 12.1 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 124.765 1.226 . . . . 0.0 110.023 -171.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -114.32 -144.61 0.39 Allowed 'General case' 0 C--N 1.354 0.772 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -170.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 45.2 m -140.95 144.4 35.11 Favored 'General case' 0 C--N 1.355 0.845 0 N-CA-C 105.739 -1.948 . . . . 0.0 105.739 -169.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.81 -98.46 0.08 Allowed 'General case' 0 C--N 1.367 1.343 0 N-CA-C 104.238 -2.504 . . . . 0.0 104.238 165.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.02 147.96 22.4 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.5 tp -85.44 124.78 32.42 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.48 -23.33 26.82 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -176.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.77 -67.03 0.83 Allowed 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.51 -164.07 29.93 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 107.902 -2.079 . . . . 0.0 107.902 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 35.8 p -88.61 -176.4 5.26 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 126.047 1.739 . . . . 0.0 108.809 -178.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.272 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 167.083 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 16.8 m -127.07 -174.05 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.787 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 169.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 40.8 t90 -119.45 139.5 51.95 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 176.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.78 59.1 2.7 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.47 171.55 22.22 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -178.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -92.84 -43.51 8.96 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 124.17 0.988 . . . . 0.0 109.147 -173.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.9 p -106.88 -137.78 0.37 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -167.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.1 m -144.51 142.69 30.41 Favored 'General case' 0 C--N 1.356 0.858 0 N-CA-C 105.518 -2.031 . . . . 0.0 105.518 -170.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.15 -98.71 0.09 Allowed 'General case' 0 C--N 1.364 1.208 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 166.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.51 144.81 26.53 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 166.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.49 124.06 30.35 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 -177.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.67 -28.72 9.71 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.9 t -84.27 -65.69 0.98 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.7 -163.28 26.24 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 p -90.36 -175.35 4.46 Favored 'General case' 0 N--CA 1.421 -1.917 0 C-N-CA 126.566 1.946 . . . . 0.0 109.458 -175.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.223 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 171.043 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 CA--C 1.507 -0.709 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.0 m -132.97 -170.55 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.811 0 N-CA-C 103.368 -2.827 . . . . 0.0 103.368 168.087 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.3 t-105 -137.97 147.46 44.29 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.24 47.92 5.02 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -127.81 171.57 19.11 Favored Glycine 0 C--N 1.352 1.455 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -175.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.4 m-20 -93.28 -39.49 10.94 Favored 'General case' 0 N--CA 1.44 -0.932 0 C-N-CA 124.994 1.318 . . . . 0.0 109.852 -172.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.0 p -113.54 -145.19 0.4 Allowed 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -170.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -139.3 144.78 38.48 Favored 'General case' 0 C--N 1.357 0.892 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 -170.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p30 -88.49 -100.7 0.09 Allowed 'General case' 0 C--N 1.368 1.385 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 165.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -92.05 158.72 16.07 Favored 'General case' 0 N--CA 1.436 -1.138 0 C-N-CA 126.234 1.814 . . . . 0.0 107.323 174.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.1 mt -82.49 123.29 29.03 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.74 -6.56 79.79 Favored Glycine 0 C--N 1.354 1.553 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 178.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 18.1 t -89.7 -69.81 0.7 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -176.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.69 -164.62 29.15 Favored Glycine 0 CA--C 1.489 -1.533 0 N-CA-C 107.612 -2.195 . . . . 0.0 107.612 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.9 p -88.48 179.45 6.3 Favored 'General case' 0 N--CA 1.417 -2.105 0 C-N-CA 125.862 1.665 . . . . 0.0 108.515 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.341 0 N-CA-C 104.247 -2.501 . . . . 0.0 104.247 166.806 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 92.9 m . . . . . 0 CA--C 1.504 -0.793 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 m -133.39 -167.23 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 103.824 -2.658 . . . . 0.0 103.824 167.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.5 t-105 -140.35 143.7 35.9 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 175.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.5 55.4 2.59 Favored Glycine 0 C--N 1.354 1.56 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.7 168.27 24.79 Favored Glycine 0 CA--C 1.49 -1.484 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -176.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -91.35 -34.84 14.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 124.771 1.228 . . . . 0.0 110.434 -173.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -111.12 -153.93 0.53 Allowed 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -169.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.8 m -139.59 144.5 37.79 Favored 'General case' 0 C--N 1.355 0.832 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -169.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -88.12 -98.36 0.09 Allowed 'General case' 0 C--N 1.365 1.269 0 N-CA-C 104.206 -2.516 . . . . 0.0 104.206 166.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.05 147.78 22.56 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 167.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.4 tp -85.19 124.58 32.01 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 -177.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.7 -23.61 25.71 Favored Glycine 0 C--N 1.354 1.556 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.61 -67.0 0.83 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 -177.318 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.02 -164.13 29.77 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.0 p -88.95 -173.05 3.93 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.075 1.75 . . . . 0.0 108.692 -177.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.269 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 171.06 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 CA--C 1.499 -1.016 0 CA-C-O 121.759 0.79 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -124.89 -165.19 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.812 -3.033 . . . . 0.0 102.812 165.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.9 t-105 -138.7 143.94 39.35 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.25 55.88 2.81 Favored Glycine 0 C--N 1.355 1.589 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.46 170.55 22.63 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -176.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -91.27 -39.5 12.04 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 124.944 1.298 . . . . 0.0 109.957 -171.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.9 p -114.59 -145.47 0.4 Allowed 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -169.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 40.8 m -141.33 143.64 34.14 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 -170.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -88.78 -100.21 0.09 Allowed 'General case' 0 C--N 1.364 1.226 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 167.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -88.17 155.75 19.6 Favored 'General case' 0 N--CA 1.436 -1.17 0 C-N-CA 126.842 2.057 . . . . 0.0 107.268 172.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 72.8 mt -81.78 123.68 28.99 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -176.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -17.83 58.59 Favored Glycine 0 C--N 1.355 1.598 0 C-N-CA 123.517 0.58 . . . . 0.0 111.669 176.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.4 t -84.69 -65.43 1.01 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.288 -1.005 . . . . 0.0 108.288 -175.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.18 -164.14 27.21 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.2 p -89.78 -177.83 5.35 Favored 'General case' 0 N--CA 1.418 -2.038 0 C-N-CA 126.354 1.862 . . . . 0.0 108.945 -177.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.332 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 167.785 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.4 m . . . . . 0 CA--C 1.504 -0.791 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 17.6 m -133.71 -172.66 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 36.9 t90 -125.97 141.85 51.78 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 176.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.52 60.85 2.72 Favored Glycine 0 C--N 1.354 1.581 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 174.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.43 173.41 22.02 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 -176.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -88.09 -42.13 12.59 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 124.442 1.097 . . . . 0.0 110.184 -171.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 81.4 m -117.57 -133.37 0.33 Allowed 'General case' 0 C--N 1.357 0.893 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -168.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.7 m -145.43 144.67 30.76 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.932 -2.247 . . . . 0.0 104.932 -169.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.71 -98.25 0.09 Allowed 'General case' 0 C--N 1.364 1.227 0 N-CA-C 104.281 -2.488 . . . . 0.0 104.281 166.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -90.81 149.39 21.99 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 166.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.1 tp -84.52 125.32 32.29 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.55 -19.56 44.63 Favored Glycine 0 C--N 1.354 1.537 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -177.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -86.5 -68.16 0.76 Allowed 'General case' 0 C--N 1.357 0.907 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -176.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.36 -165.07 29.67 Favored Glycine 0 C--N 1.351 1.391 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.5 p -88.97 -173.29 4.02 Favored 'General case' 0 N--CA 1.42 -1.947 0 C-N-CA 126.268 1.827 . . . . 0.0 108.854 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.24 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.278 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.5 -0.972 0 CA-C-O 121.839 0.828 . . . . 0.0 109.418 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.7 m -125.1 -167.08 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 102.307 -3.22 . . . . 0.0 102.307 164.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.5 t-105 -137.74 147.57 44.86 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 175.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.6 47.96 4.92 Favored Glycine 0 C--N 1.353 1.52 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -128.42 166.88 20.81 Favored Glycine 0 C--N 1.353 1.506 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -91.86 -39.5 11.71 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 124.794 1.238 . . . . 0.0 109.128 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.1 p -109.38 -145.49 0.4 Allowed 'General case' 0 C--N 1.354 0.796 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 -169.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.4 m -141.19 142.92 33.97 Favored 'General case' 0 C--N 1.356 0.855 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 -170.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -88.24 -99.02 0.09 Allowed 'General case' 0 C--N 1.365 1.249 0 N-CA-C 104.613 -2.366 . . . . 0.0 104.613 166.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -89.77 149.11 22.86 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 126.056 1.742 . . . . 0.0 106.319 169.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.1 mp -84.32 125.73 32.55 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.62 -28.4 13.48 Favored Glycine 0 C--N 1.354 1.58 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.0 t -83.3 -65.04 1.06 Allowed 'General case' 0 C--N 1.358 0.97 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -174.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.09 -164.56 28.66 Favored Glycine 0 C--N 1.353 1.484 0 N-CA-C 109.145 -1.582 . . . . 0.0 109.145 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 23.6 p -91.13 179.65 5.67 Favored 'General case' 0 N--CA 1.419 -1.992 0 C-N-CA 126.497 1.919 . . . . 0.0 108.551 -178.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.297 0 N-CA-C 105.318 -2.104 . . . . 0.0 105.318 169.034 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.7 m . . . . . 0 CA--C 1.503 -0.832 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.4 m -132.56 -168.13 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 104.21 -2.515 . . . . 0.0 104.21 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.5 t-105 -139.77 143.75 37.07 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 175.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.12 54.36 3.05 Favored Glycine 0 C--N 1.355 1.623 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.38 172.96 22.22 Favored Glycine 0 C--N 1.353 1.495 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 -177.001 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 -93.45 -41.02 10.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 123.831 0.853 . . . . 0.0 109.77 -170.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.4 p -110.88 -140.12 0.38 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -169.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.6 m -141.85 145.52 34.75 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 -170.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.66 -99.56 0.09 Allowed 'General case' 0 C--N 1.365 1.251 0 N-CA-C 104.382 -2.451 . . . . 0.0 104.382 165.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -88.43 148.81 24.02 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.031 1.732 . . . . 0.0 106.496 169.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.1 tt -83.84 117.93 23.62 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 -177.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.57 38.62 6.15 Favored Glycine 0 C--N 1.353 1.491 0 N-CA-C 108.94 -1.664 . . . . 0.0 108.94 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.5 t -138.54 -68.44 0.45 Allowed 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.46 -165.72 30.71 Favored Glycine 0 CA--C 1.492 -1.384 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.77 -172.32 3.67 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.214 1.805 . . . . 0.0 108.812 -178.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.211 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 169.357 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.4 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.4 m -133.66 -168.75 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 N-CA-C 103.422 -2.807 . . . . 0.0 103.422 167.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 59.0 t-105 -139.26 145.32 39.04 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.09 53.59 3.27 Favored Glycine 0 C--N 1.355 1.621 0 N-CA-C 108.989 -1.644 . . . . 0.0 108.989 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.71 172.64 21.55 Favored Glycine 0 CA--C 1.49 -1.489 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -176.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -91.49 -40.03 11.62 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 124.838 1.255 . . . . 0.0 109.964 -171.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 11.1 p -114.18 -144.78 0.39 Allowed 'General case' 0 C--N 1.354 0.761 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 -170.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 35.0 m -139.76 144.69 37.55 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 105.864 -1.902 . . . . 0.0 105.864 -169.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.96 -98.79 0.09 Allowed 'General case' 0 C--N 1.368 1.375 0 N-CA-C 104.14 -2.541 . . . . 0.0 104.14 165.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -92.93 148.1 22.29 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 167.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.42 124.7 32.3 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -22.73 29.14 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.5 t -84.77 -67.14 0.82 Allowed 'General case' 0 N--CA 1.443 -0.811 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 -177.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.14 -163.9 29.47 Favored Glycine 0 CA--C 1.492 -1.395 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.4 p -88.81 -178.64 5.81 Favored 'General case' 0 N--CA 1.416 -2.16 0 C-N-CA 125.893 1.677 . . . . 0.0 108.656 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.336 0 N-CA-C 103.946 -2.613 . . . . 0.0 103.946 165.386 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.499 -0.988 0 CA-C-O 121.881 0.848 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.2 m -124.17 -167.45 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 N-CA-C 102.211 -3.255 . . . . 0.0 102.211 164.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.0 t-105 -137.63 148.77 46.08 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 175.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.77 45.26 5.8 Favored Glycine 0 C--N 1.355 1.588 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -178.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -125.16 166.81 17.72 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -175.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -92.58 -39.19 11.48 Favored 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 124.775 1.23 . . . . 0.0 109.025 -174.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.8 p -109.49 -145.44 0.4 Allowed 'General case' 0 C--N 1.355 0.829 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 -169.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.0 m -140.66 142.54 34.94 Favored 'General case' 0 C--N 1.356 0.853 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -170.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.02 -98.63 0.09 Allowed 'General case' 0 C--N 1.365 1.266 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 165.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -90.64 143.7 26.48 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 168.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.1 tp -84.53 123.15 29.97 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -177.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.61 -30.68 7.07 Favored Glycine 0 C--N 1.353 1.507 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -177.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.5 t -83.55 -63.86 1.27 Allowed 'General case' 0 C--N 1.357 0.919 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -175.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.49 -164.43 28.7 Favored Glycine 0 C--N 1.352 1.435 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.2 p -91.66 178.07 6.03 Favored 'General case' 0 N--CA 1.418 -2.061 0 C-N-CA 126.63 1.972 . . . . 0.0 108.252 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.313 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 168.686 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 N--CA 1.44 -0.973 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.3 m -126.73 -168.03 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 N-CA-C 104.128 -2.545 . . . . 0.0 104.128 168.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 35.5 t90 -128.42 141.1 51.51 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 177.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.09 56.14 2.95 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 110.066 -1.213 . . . . 0.0 110.066 173.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.15 170.34 22.95 Favored Glycine 0 CA--C 1.491 -1.437 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -178.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -95.12 -37.96 10.83 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.562 1.145 . . . . 0.0 108.696 -174.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.3 p -105.72 -153.22 0.49 Allowed 'General case' 0 C--N 1.353 0.744 0 N-CA-C 106.938 -1.505 . . . . 0.0 106.938 -168.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.8 m -140.91 143.31 34.55 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -169.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p30 -89.13 -100.26 0.09 Allowed 'General case' 0 C--N 1.365 1.248 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 168.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -87.04 155.28 20.21 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 126.789 2.036 . . . . 0.0 107.179 171.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.7 mt -81.55 123.33 28.56 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -176.039 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.91 -17.4 59.33 Favored Glycine 0 C--N 1.354 1.549 0 C-N-CA 123.519 0.581 . . . . 0.0 111.73 176.323 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.6 t -84.74 -65.95 0.95 Allowed 'General case' 0 C--N 1.358 0.978 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -171.65 -163.22 25.23 Favored Glycine 0 C--N 1.353 1.493 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 33.1 p -89.74 -175.69 4.72 Favored 'General case' 0 N--CA 1.42 -1.967 0 C-N-CA 126.363 1.865 . . . . 0.0 109.026 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.261 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 170.99 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.9 m . . . . . 0 CA--C 1.502 -0.895 0 CA-C-O 119.506 -0.283 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.7 m -84.96 166.88 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.844 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 -179.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 44.1 t-105 -121.12 149.67 42.42 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -174.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.23 41.56 5.17 Favored Glycine 0 C--N 1.354 1.559 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -178.195 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -126.7 172.59 18.3 Favored Glycine 0 C--N 1.353 1.5 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -176.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -102.18 -39.61 7.17 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.469 1.107 . . . . 0.0 108.196 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.2 p -98.69 -143.75 0.32 Allowed 'General case' 0 C--N 1.353 0.753 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 -168.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.04 143.29 31.11 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 -170.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.6 p30 -88.82 -100.94 0.09 Allowed 'General case' 0 C--N 1.364 1.215 0 N-CA-C 104.688 -2.338 . . . . 0.0 104.688 167.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -90.53 160.18 16.1 Favored 'General case' 0 N--CA 1.436 -1.15 0 C-N-CA 126.741 2.016 . . . . 0.0 107.038 171.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 74.8 mt -81.89 121.55 26.61 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -176.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.07 -6.89 79.02 Favored Glycine 0 C--N 1.354 1.553 0 C-N-CA 123.641 0.639 . . . . 0.0 111.67 177.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -88.85 -62.87 1.39 Allowed 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 -176.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.05 -164.17 30.38 Favored Glycine 0 C--N 1.35 1.358 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 178.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.9 p -88.92 -173.52 4.12 Favored 'General case' 0 N--CA 1.418 -2.04 0 C-N-CA 126.608 1.963 . . . . 0.0 108.087 178.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.305 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 175.536 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.3 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.4 m -134.7 -167.59 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 N-CA-C 103.8 -2.667 . . . . 0.0 103.8 168.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.9 t-105 -140.74 141.62 34.87 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 176.256 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.45 59.93 2.18 Favored Glycine 0 C--N 1.356 1.646 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -137.97 177.62 19.84 Favored Glycine 0 CA--C 1.488 -1.615 0 N-CA-C 108.926 -1.669 . . . . 0.0 108.926 -174.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -88.77 -44.53 10.47 Favored 'General case' 0 N--CA 1.44 -0.949 0 C-N-CA 124.226 1.011 . . . . 0.0 110.322 -170.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 71.9 m -119.79 -131.77 0.3 Allowed 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 -168.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 m -144.34 145.15 31.81 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 105.139 -2.171 . . . . 0.0 105.139 -169.302 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -88.78 -98.95 0.09 Allowed 'General case' 0 C--N 1.366 1.289 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 165.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -90.25 148.71 22.74 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 167.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.26 125.2 32.02 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 -176.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.0 -19.86 42.51 Favored Glycine 0 C--N 1.356 1.642 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -177.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.2 t -86.48 -68.16 0.76 Allowed 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -176.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.61 -164.41 29.43 Favored Glycine 0 CA--C 1.492 -1.393 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.539 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 40.5 p -88.69 -172.94 3.93 Favored 'General case' 0 N--CA 1.421 -1.912 0 C-N-CA 126.204 1.802 . . . . 0.0 109.062 -177.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.206 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 169.077 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 CA--C 1.506 -0.748 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.68 -166.27 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.772 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 167.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.7 t-105 -140.28 145.16 36.93 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 87.35 53.76 2.71 Favored Glycine 0 C--N 1.354 1.548 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.43 168.93 24.75 Favored Glycine 0 C--N 1.352 1.452 0 N-CA-C 107.513 -2.235 . . . . 0.0 107.513 -179.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -94.32 -32.97 13.38 Favored 'General case' 0 CA--C 1.501 -0.937 0 C-N-CA 124.138 0.975 . . . . 0.0 109.156 -175.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.3 m -101.3 -155.51 0.52 Allowed 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -170.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.8 m -140.86 144.86 35.55 Favored 'General case' 0 C--N 1.358 0.963 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 -171.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -88.61 -98.74 0.09 Allowed 'General case' 0 C--N 1.366 1.315 0 N-CA-C 104.138 -2.542 . . . . 0.0 104.138 165.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.8 m-85 -91.91 148.75 21.98 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 167.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -84.8 124.97 32.17 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -176.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.56 -21.74 34.02 Favored Glycine 0 C--N 1.353 1.492 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -177.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -85.29 -67.61 0.79 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -176.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -175.44 -164.59 30.21 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 44.4 p -88.92 -176.81 5.31 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.103 1.761 . . . . 0.0 108.852 -177.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.246 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 166.678 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.5 m . . . . . 0 CA--C 1.506 -0.718 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.65 -168.09 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 N-CA-C 103.495 -2.78 . . . . 0.0 103.495 167.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.4 t-105 -140.0 144.29 36.9 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 174.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.88 55.05 2.48 Favored Glycine 0 C--N 1.354 1.536 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.04 170.69 23.95 Favored Glycine 0 C--N 1.352 1.453 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -93.81 -38.06 11.44 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.393 1.077 . . . . 0.0 108.868 -174.101 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.5 p -105.86 -154.55 0.52 Allowed 'General case' 0 C--N 1.354 0.784 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 -169.318 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 37.8 m -139.39 144.53 38.19 Favored 'General case' 0 CA--C 1.504 -0.802 0 N-CA-C 105.913 -1.884 . . . . 0.0 105.913 -168.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.1 p30 -88.21 -99.17 0.09 Allowed 'General case' 0 C--N 1.366 1.323 0 N-CA-C 104.295 -2.483 . . . . 0.0 104.295 166.122 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -92.23 151.76 20.18 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 169.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.0 mp -85.11 126.36 33.54 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 -176.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.64 -19.63 49.51 Favored Glycine 0 C--N 1.354 1.575 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -178.19 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 15.7 t -86.0 -69.0 0.7 Allowed 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 -176.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.97 -164.13 29.21 Favored Glycine 0 CA--C 1.491 -1.444 0 N-CA-C 107.896 -2.082 . . . . 0.0 107.896 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.6 -173.47 4.16 Favored 'General case' 0 N--CA 1.418 -2.028 0 C-N-CA 126.108 1.763 . . . . 0.0 108.676 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.193 0 N-CA-C 105.817 -1.919 . . . . 0.0 105.817 170.886 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.1 m . . . . . 0 CA--C 1.506 -0.725 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.24 -171.95 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 N-CA-C 104.825 -2.287 . . . . 0.0 104.825 170.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 34.0 t90 -128.07 144.77 51.12 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.1 -1.815 . . . . 0.0 106.1 176.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.38 56.02 3.53 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 174.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.64 171.01 22.15 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -176.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -91.1 -39.34 12.22 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 124.953 1.301 . . . . 0.0 109.939 -172.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -115.2 -143.88 0.38 Allowed 'General case' 0 C--N 1.355 0.813 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 -169.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.4 m -140.55 144.62 36.01 Favored 'General case' 0 C--N 1.354 0.804 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 -169.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -88.03 -98.55 0.09 Allowed 'General case' 0 C--N 1.367 1.346 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 166.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -92.41 148.49 22.07 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 105.732 -1.951 . . . . 0.0 105.732 167.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.3 tp -84.77 125.01 32.19 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 -176.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.99 -20.9 37.29 Favored Glycine 0 C--N 1.353 1.476 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.9 t -85.61 -67.51 0.8 Allowed 'General case' 0 C--N 1.356 0.859 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -177.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.32 -164.67 29.65 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.7 p -89.08 -177.48 5.45 Favored 'General case' 0 N--CA 1.418 -2.044 0 C-N-CA 125.93 1.692 . . . . 0.0 108.593 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.402 0 N-CA-C 104.395 -2.446 . . . . 0.0 104.395 167.079 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.6 t . . . . . 0 CA--C 1.498 -1.052 0 CA-C-O 121.743 0.783 . . . . 0.0 109.138 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.2 m -127.66 -164.86 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 103.039 -2.948 . . . . 0.0 103.039 167.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.9 t-105 -139.55 143.85 37.56 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.66 51.45 3.64 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.58 170.44 22.36 Favored Glycine 0 C--N 1.353 1.48 0 N-CA-C 107.707 -2.157 . . . . 0.0 107.707 -177.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -91.74 -42.43 10.14 Favored 'General case' 0 N--CA 1.441 -0.919 0 C-N-CA 124.142 0.977 . . . . 0.0 109.119 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.6 p -107.44 -141.6 0.38 Allowed 'General case' 0 C--N 1.354 0.8 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 -167.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 54.1 m -143.16 144.06 32.05 Favored 'General case' 0 C--N 1.356 0.85 0 N-CA-C 105.445 -2.057 . . . . 0.0 105.445 -170.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 p30 -88.9 -99.8 0.09 Allowed 'General case' 0 C--N 1.364 1.238 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 167.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -82.76 149.33 27.31 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 127.029 2.131 . . . . 0.0 106.994 173.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.5 mt -79.1 109.46 13.43 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 -178.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 52.46 2.76 Favored Glycine 0 C--N 1.354 1.539 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -145.93 -72.03 0.24 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 173.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -164.09 -163.07 16.21 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.1 p -89.67 -174.5 4.33 Favored 'General case' 0 N--CA 1.418 -2.029 0 C-N-CA 126.424 1.889 . . . . 0.0 109.129 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.246 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 169.475 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.3 m . . . . . 0 CA--C 1.505 -0.755 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.6 m -133.23 -166.84 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 103.533 -2.765 . . . . 0.0 103.533 167.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.5 t-105 -141.64 143.75 33.79 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 106.692 -1.595 . . . . 0.0 106.692 176.141 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.79 55.09 2.48 Favored Glycine 0 C--N 1.353 1.511 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.19 172.06 23.37 Favored Glycine 0 C--N 1.352 1.432 0 N-CA-C 107.999 -2.04 . . . . 0.0 107.999 -178.287 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -94.34 -37.95 11.23 Favored 'General case' 0 N--CA 1.44 -0.947 0 C-N-CA 124.446 1.098 . . . . 0.0 108.784 -174.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -104.14 -156.6 0.57 Allowed 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -169.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.1 m -139.55 144.19 37.72 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 -168.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.04 -98.62 0.09 Allowed 'General case' 0 C--N 1.368 1.372 0 N-CA-C 104.189 -2.523 . . . . 0.0 104.189 166.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -92.55 147.86 22.55 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 167.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.23 124.57 32.02 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 -177.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.27 -22.79 28.45 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -176.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.3 t -84.79 -67.19 0.82 Allowed 'General case' 0 C--N 1.357 0.905 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 -177.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.13 -163.73 29.18 Favored Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 107.86 -2.096 . . . . 0.0 107.86 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.4 p -88.62 -173.35 4.11 Favored 'General case' 0 N--CA 1.416 -2.126 0 C-N-CA 126.028 1.731 . . . . 0.0 108.706 -178.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.21 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 170.154 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.0 m . . . . . 0 N--CA 1.444 -0.753 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -134.33 -168.17 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.752 0 N-CA-C 103.938 -2.616 . . . . 0.0 103.938 169.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.3 t-105 -139.66 143.58 37.21 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 106.379 -1.712 . . . . 0.0 106.379 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.21 53.44 3.12 Favored Glycine 0 C--N 1.355 1.625 0 N-CA-C 108.789 -1.724 . . . . 0.0 108.789 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.16 168.61 23.99 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.99 -2.044 . . . . 0.0 107.99 -176.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -92.89 -34.22 13.89 Favored 'General case' 0 N--CA 1.442 -0.846 0 C-N-CA 124.278 1.031 . . . . 0.0 111.455 -170.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.1 m -115.8 -137.5 0.36 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 -174.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.24 145.97 32.37 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 105.392 -2.077 . . . . 0.0 105.392 -169.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -89.38 -100.82 0.09 Allowed 'General case' 0 C--N 1.365 1.273 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 166.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -88.23 155.98 19.46 Favored 'General case' 0 N--CA 1.435 -1.195 0 C-N-CA 126.515 1.926 . . . . 0.0 107.119 172.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.3 mt -80.68 122.49 27.18 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 123.669 0.788 . . . . 0.0 109.048 -174.467 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.84 -3.94 81.41 Favored Glycine 0 C--N 1.354 1.579 0 C-N-CA 123.74 0.686 . . . . 0.0 111.663 178.159 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.8 t -90.91 -70.79 0.66 Allowed 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 -176.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -170.33 -165.29 27.45 Favored Glycine 0 CA--C 1.491 -1.419 0 N-CA-C 108.102 -1.999 . . . . 0.0 108.102 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.7 p -88.63 -173.17 4.04 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.036 1.734 . . . . 0.0 109.027 -177.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.237 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 169.587 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.5 -0.97 0 CA-C-O 121.763 0.792 . . . . 0.0 109.189 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.6 m -126.57 -164.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.855 0 N-CA-C 102.983 -2.969 . . . . 0.0 102.983 166.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.8 t-105 -139.4 142.15 37.5 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.91 58.16 2.55 Favored Glycine 0 C--N 1.354 1.565 0 N-CA-C 108.816 -1.713 . . . . 0.0 108.816 -179.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.93 174.83 20.94 Favored Glycine 0 CA--C 1.49 -1.479 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -174.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -90.17 -42.94 10.76 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 124.415 1.086 . . . . 0.0 110.136 -170.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.8 m -119.32 -133.94 0.32 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -168.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.4 m -145.3 143.63 30.3 Favored 'General case' 0 C--N 1.356 0.883 0 N-CA-C 105.331 -2.1 . . . . 0.0 105.331 -168.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.05 -98.86 0.09 Allowed 'General case' 0 C--N 1.364 1.204 0 N-CA-C 104.554 -2.388 . . . . 0.0 104.554 166.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.97 144.55 26.48 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 167.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.62 123.89 30.25 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.01 -28.62 9.62 Favored Glycine 0 C--N 1.353 1.483 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.26 -65.14 1.04 Allowed 'General case' 0 C--N 1.358 0.937 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -174.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.98 -163.66 27.1 Favored Glycine 0 C--N 1.353 1.497 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 36.9 p -89.91 -174.85 4.41 Favored 'General case' 0 N--CA 1.42 -1.931 0 C-N-CA 126.667 1.987 . . . . 0.0 109.361 -176.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.253 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 169.4 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.1 m . . . . . 0 CA--C 1.504 -0.796 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.8 m -132.92 -168.51 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.6 t-105 -139.19 143.57 38.15 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 174.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.43 58.69 2.25 Favored Glycine 0 C--N 1.356 1.68 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.84 172.79 22.93 Favored Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 -177.178 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -90.62 -40.13 12.1 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 124.765 1.226 . . . . 0.0 110.023 -171.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -114.32 -144.61 0.39 Allowed 'General case' 0 C--N 1.354 0.772 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -170.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 45.2 m -140.95 144.4 35.11 Favored 'General case' 0 C--N 1.355 0.845 0 N-CA-C 105.739 -1.948 . . . . 0.0 105.739 -169.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.81 -98.46 0.08 Allowed 'General case' 0 C--N 1.367 1.343 0 N-CA-C 104.238 -2.504 . . . . 0.0 104.238 165.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.02 147.96 22.4 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.5 tp -85.44 124.78 32.42 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.48 -23.33 26.82 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -176.329 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.77 -67.03 0.83 Allowed 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.51 -164.07 29.93 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 107.902 -2.079 . . . . 0.0 107.902 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 35.8 p -88.61 -176.4 5.26 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 126.047 1.739 . . . . 0.0 108.809 -178.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.85 162.83 34.43 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 167.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.7 m0 -91.67 -74.44 0.51 Allowed 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 -173.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.4 128.14 45.89 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 95.5 m -127.33 163.69 23.43 Favored 'General case' 0 CA--C 1.499 -0.992 0 N-CA-C 105.563 -2.014 . . . . 0.0 105.563 170.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.262 1.718 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.081 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 16.8 m -127.07 -174.05 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.787 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 169.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 40.8 t90 -119.45 139.5 51.95 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 176.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.78 59.1 2.7 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.47 171.55 22.22 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -178.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -92.84 -43.51 8.96 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 124.17 0.988 . . . . 0.0 109.147 -173.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.9 p -106.88 -137.78 0.37 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -167.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.1 m -144.51 142.69 30.41 Favored 'General case' 0 C--N 1.356 0.858 0 N-CA-C 105.518 -2.031 . . . . 0.0 105.518 -170.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.15 -98.71 0.09 Allowed 'General case' 0 C--N 1.364 1.208 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 166.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.51 144.81 26.53 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 166.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.49 124.06 30.35 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 -177.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.67 -28.72 9.71 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.9 t -84.27 -65.69 0.98 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.7 -163.28 26.24 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 p -90.36 -175.35 4.46 Favored 'General case' 0 N--CA 1.421 -1.917 0 C-N-CA 126.566 1.946 . . . . 0.0 109.458 -175.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.21 153.38 42.77 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 171.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 23.0 m0 -89.68 -48.92 6.96 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 -177.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.4 mm -82.45 118.42 30.13 Favored 'Isoleucine or valine' 0 C--N 1.357 0.897 0 N-CA-C 106.233 -1.766 . . . . 0.0 106.233 178.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 69.9 m -124.0 166.21 16.12 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 -173.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--O 1.261 1.668 0 N-CA-C 107.348 -1.352 . . . . 0.0 107.348 -179.739 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 CA--C 1.507 -0.709 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.0 m -132.97 -170.55 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.811 0 N-CA-C 103.368 -2.827 . . . . 0.0 103.368 168.087 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.3 t-105 -137.97 147.46 44.29 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.24 47.92 5.02 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -127.81 171.57 19.11 Favored Glycine 0 C--N 1.352 1.455 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -175.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.4 m-20 -93.28 -39.49 10.94 Favored 'General case' 0 N--CA 1.44 -0.932 0 C-N-CA 124.994 1.318 . . . . 0.0 109.852 -172.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.0 p -113.54 -145.19 0.4 Allowed 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -170.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -139.3 144.78 38.48 Favored 'General case' 0 C--N 1.357 0.892 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 -170.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p30 -88.49 -100.7 0.09 Allowed 'General case' 0 C--N 1.368 1.385 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 165.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -92.05 158.72 16.07 Favored 'General case' 0 N--CA 1.436 -1.138 0 C-N-CA 126.234 1.814 . . . . 0.0 107.323 174.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.1 mt -82.49 123.29 29.03 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.74 -6.56 79.79 Favored Glycine 0 C--N 1.354 1.553 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 178.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 18.1 t -89.7 -69.81 0.7 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -176.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.69 -164.62 29.15 Favored Glycine 0 CA--C 1.489 -1.533 0 N-CA-C 107.612 -2.195 . . . . 0.0 107.612 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.9 p -88.48 179.45 6.3 Favored 'General case' 0 N--CA 1.417 -2.105 0 C-N-CA 125.862 1.665 . . . . 0.0 108.515 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.58 161.94 34.51 Favored 'General case' 0 CA--C 1.49 -1.341 0 N-CA-C 104.247 -2.501 . . . . 0.0 104.247 166.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.3 m0 -86.82 -73.26 0.47 Allowed 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -172.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.9 pt -97.5 148.92 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.964 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 174.008 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 65.7 m -141.53 163.61 32.47 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 175.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.26 1.64 0 CA-C-O 117.511 -1.233 . . . . 0.0 108.637 178.956 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 92.9 m . . . . . 0 CA--C 1.504 -0.793 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 m -133.39 -167.23 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 103.824 -2.658 . . . . 0.0 103.824 167.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.5 t-105 -140.35 143.7 35.9 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 175.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.5 55.4 2.59 Favored Glycine 0 C--N 1.354 1.56 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.7 168.27 24.79 Favored Glycine 0 CA--C 1.49 -1.484 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -176.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -91.35 -34.84 14.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 124.771 1.228 . . . . 0.0 110.434 -173.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -111.12 -153.93 0.53 Allowed 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -169.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.8 m -139.59 144.5 37.79 Favored 'General case' 0 C--N 1.355 0.832 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -169.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -88.12 -98.36 0.09 Allowed 'General case' 0 C--N 1.365 1.269 0 N-CA-C 104.206 -2.516 . . . . 0.0 104.206 166.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.05 147.78 22.56 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 167.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.4 tp -85.19 124.58 32.01 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 -177.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.7 -23.61 25.71 Favored Glycine 0 C--N 1.354 1.556 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.61 -67.0 0.83 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 -177.318 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.02 -164.13 29.77 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.0 p -88.95 -173.05 3.93 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.075 1.75 . . . . 0.0 108.692 -177.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.42 159.22 42.66 Favored 'General case' 0 CA--C 1.492 -1.269 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 171.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 29.7 m0 -104.01 -66.46 0.95 Allowed 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.099 -2.185 . . . . 0.0 105.099 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.9 mt -89.47 125.17 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 N-CA-C 105.137 -2.172 . . . . 0.0 105.137 174.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 2.0 p -150.23 -49.87 0.13 Allowed 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 106.319 -1.734 . . . . 0.0 106.319 -174.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 9.9 m . . . . . 0 C--O 1.26 1.621 0 C-N-CA 124.58 1.152 . . . . 0.0 108.21 179.794 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 CA--C 1.499 -1.016 0 CA-C-O 121.759 0.79 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -124.89 -165.19 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.812 -3.033 . . . . 0.0 102.812 165.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.9 t-105 -138.7 143.94 39.35 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.25 55.88 2.81 Favored Glycine 0 C--N 1.355 1.589 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.46 170.55 22.63 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -176.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -91.27 -39.5 12.04 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 124.944 1.298 . . . . 0.0 109.957 -171.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.9 p -114.59 -145.47 0.4 Allowed 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -169.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 40.8 m -141.33 143.64 34.14 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 -170.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -88.78 -100.21 0.09 Allowed 'General case' 0 C--N 1.364 1.226 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 167.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -88.17 155.75 19.6 Favored 'General case' 0 N--CA 1.436 -1.17 0 C-N-CA 126.842 2.057 . . . . 0.0 107.268 172.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 72.8 mt -81.78 123.68 28.99 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -176.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -17.83 58.59 Favored Glycine 0 C--N 1.355 1.598 0 C-N-CA 123.517 0.58 . . . . 0.0 111.669 176.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.4 t -84.69 -65.43 1.01 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.288 -1.005 . . . . 0.0 108.288 -175.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.18 -164.14 27.21 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.2 p -89.78 -177.83 5.35 Favored 'General case' 0 N--CA 1.418 -2.038 0 C-N-CA 126.354 1.862 . . . . 0.0 108.945 -177.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.64 162.46 35.41 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 167.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.9 m0 -89.95 -75.84 0.44 Allowed 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 -173.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.53 128.41 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 178.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 94.1 m -126.34 163.33 23.49 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 105.589 -2.004 . . . . 0.0 105.589 170.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.9 m . . . . . 0 C--O 1.261 1.682 0 CA-C-O 117.27 -1.348 . . . . 0.0 110.301 179.939 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.4 m . . . . . 0 CA--C 1.504 -0.791 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 17.6 m -133.71 -172.66 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 36.9 t90 -125.97 141.85 51.78 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 176.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.52 60.85 2.72 Favored Glycine 0 C--N 1.354 1.581 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 174.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.43 173.41 22.02 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 -176.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -88.09 -42.13 12.59 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 124.442 1.097 . . . . 0.0 110.184 -171.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 81.4 m -117.57 -133.37 0.33 Allowed 'General case' 0 C--N 1.357 0.893 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -168.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.7 m -145.43 144.67 30.76 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.932 -2.247 . . . . 0.0 104.932 -169.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.71 -98.25 0.09 Allowed 'General case' 0 C--N 1.364 1.227 0 N-CA-C 104.281 -2.488 . . . . 0.0 104.281 166.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -90.81 149.39 21.99 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 166.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.1 tp -84.52 125.32 32.29 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.55 -19.56 44.63 Favored Glycine 0 C--N 1.354 1.537 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -177.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -86.5 -68.16 0.76 Allowed 'General case' 0 C--N 1.357 0.907 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -176.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.36 -165.07 29.67 Favored Glycine 0 C--N 1.351 1.391 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.5 p -88.97 -173.29 4.02 Favored 'General case' 0 N--CA 1.42 -1.947 0 C-N-CA 126.268 1.827 . . . . 0.0 108.854 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -148.6 150.8 33.93 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.4 m0 -87.38 -55.82 3.63 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 -175.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.5 mt -85.48 126.76 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 N-CA-C 104.076 -2.564 . . . . 0.0 104.076 169.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 96.5 m -86.46 151.9 23.12 Favored 'General case' 0 CA--C 1.499 -0.998 0 CA-C-O 121.399 0.619 . . . . 0.0 109.998 -167.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 29.7 m . . . . . 0 C--O 1.261 1.693 0 CA-C-O 117.286 -1.34 . . . . 0.0 110.274 -176.842 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.5 -0.972 0 CA-C-O 121.839 0.828 . . . . 0.0 109.418 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.7 m -125.1 -167.08 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 102.307 -3.22 . . . . 0.0 102.307 164.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.5 t-105 -137.74 147.57 44.86 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 175.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.6 47.96 4.92 Favored Glycine 0 C--N 1.353 1.52 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -128.42 166.88 20.81 Favored Glycine 0 C--N 1.353 1.506 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -91.86 -39.5 11.71 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 124.794 1.238 . . . . 0.0 109.128 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.1 p -109.38 -145.49 0.4 Allowed 'General case' 0 C--N 1.354 0.796 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 -169.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.4 m -141.19 142.92 33.97 Favored 'General case' 0 C--N 1.356 0.855 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 -170.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -88.24 -99.02 0.09 Allowed 'General case' 0 C--N 1.365 1.249 0 N-CA-C 104.613 -2.366 . . . . 0.0 104.613 166.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -89.77 149.11 22.86 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 126.056 1.742 . . . . 0.0 106.319 169.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.1 mp -84.32 125.73 32.55 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.62 -28.4 13.48 Favored Glycine 0 C--N 1.354 1.58 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.0 t -83.3 -65.04 1.06 Allowed 'General case' 0 C--N 1.358 0.97 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -174.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.09 -164.56 28.66 Favored Glycine 0 C--N 1.353 1.484 0 N-CA-C 109.145 -1.582 . . . . 0.0 109.145 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 23.6 p -91.13 179.65 5.67 Favored 'General case' 0 N--CA 1.419 -1.992 0 C-N-CA 126.497 1.919 . . . . 0.0 108.551 -178.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.8 162.88 34.09 Favored 'General case' 0 CA--C 1.491 -1.297 0 N-CA-C 105.318 -2.104 . . . . 0.0 105.318 169.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.4 m0 -88.81 -75.07 0.44 Allowed 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -174.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.5 mt -96.59 125.49 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 N-CA-C 105.944 -1.873 . . . . 0.0 105.944 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 91.8 m -123.5 -52.01 1.83 Allowed 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 104.87 -2.27 . . . . 0.0 104.87 170.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.2 t . . . . . 0 C--O 1.259 1.587 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 177.723 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.7 m . . . . . 0 CA--C 1.503 -0.832 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.4 m -132.56 -168.13 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 104.21 -2.515 . . . . 0.0 104.21 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.5 t-105 -139.77 143.75 37.07 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 175.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.12 54.36 3.05 Favored Glycine 0 C--N 1.355 1.623 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.38 172.96 22.22 Favored Glycine 0 C--N 1.353 1.495 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 -177.001 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 -93.45 -41.02 10.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 123.831 0.853 . . . . 0.0 109.77 -170.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.4 p -110.88 -140.12 0.38 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -169.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.6 m -141.85 145.52 34.75 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 -170.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.66 -99.56 0.09 Allowed 'General case' 0 C--N 1.365 1.251 0 N-CA-C 104.382 -2.451 . . . . 0.0 104.382 165.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -88.43 148.81 24.02 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.031 1.732 . . . . 0.0 106.496 169.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.1 tt -83.84 117.93 23.62 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 -177.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.57 38.62 6.15 Favored Glycine 0 C--N 1.353 1.491 0 N-CA-C 108.94 -1.664 . . . . 0.0 108.94 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.5 t -138.54 -68.44 0.45 Allowed 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.46 -165.72 30.71 Favored Glycine 0 CA--C 1.492 -1.384 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.77 -172.32 3.67 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.214 1.805 . . . . 0.0 108.812 -178.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.78 150.48 38.63 Favored 'General case' 0 CA--C 1.494 -1.211 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 169.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 22.1 m0 -89.19 -50.29 6.23 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -175.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.5 mt -82.28 119.39 31.73 Favored 'Isoleucine or valine' 0 C--N 1.356 0.881 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 177.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 75.6 m -124.19 -49.89 1.81 Allowed 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 -174.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.26 1.658 0 CA-C-O 117.518 -1.229 . . . . 0.0 108.193 176.886 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.4 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.4 m -133.66 -168.75 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 N-CA-C 103.422 -2.807 . . . . 0.0 103.422 167.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 59.0 t-105 -139.26 145.32 39.04 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.09 53.59 3.27 Favored Glycine 0 C--N 1.355 1.621 0 N-CA-C 108.989 -1.644 . . . . 0.0 108.989 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.71 172.64 21.55 Favored Glycine 0 CA--C 1.49 -1.489 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -176.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -91.49 -40.03 11.62 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 124.838 1.255 . . . . 0.0 109.964 -171.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 11.1 p -114.18 -144.78 0.39 Allowed 'General case' 0 C--N 1.354 0.761 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 -170.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 35.0 m -139.76 144.69 37.55 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 105.864 -1.902 . . . . 0.0 105.864 -169.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.96 -98.79 0.09 Allowed 'General case' 0 C--N 1.368 1.375 0 N-CA-C 104.14 -2.541 . . . . 0.0 104.14 165.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -92.93 148.1 22.29 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 167.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.42 124.7 32.3 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -22.73 29.14 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.5 t -84.77 -67.14 0.82 Allowed 'General case' 0 N--CA 1.443 -0.811 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 -177.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.14 -163.9 29.47 Favored Glycine 0 CA--C 1.492 -1.395 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.4 p -88.81 -178.64 5.81 Favored 'General case' 0 N--CA 1.416 -2.16 0 C-N-CA 125.893 1.677 . . . . 0.0 108.656 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -137.93 161.7 35.98 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 103.946 -2.613 . . . . 0.0 103.946 165.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.9 m0 -87.58 -72.68 0.51 Allowed 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 -172.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.4 pt -96.23 148.91 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 173.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.4 m -140.72 -52.89 0.48 Allowed 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 104.297 -2.483 . . . . 0.0 104.297 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 C--O 1.26 1.646 0 C-N-CA 123.981 0.913 . . . . 0.0 109.915 177.568 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.499 -0.988 0 CA-C-O 121.881 0.848 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.2 m -124.17 -167.45 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 N-CA-C 102.211 -3.255 . . . . 0.0 102.211 164.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.0 t-105 -137.63 148.77 46.08 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 175.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.77 45.26 5.8 Favored Glycine 0 C--N 1.355 1.588 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -178.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -125.16 166.81 17.72 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -175.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -92.58 -39.19 11.48 Favored 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 124.775 1.23 . . . . 0.0 109.025 -174.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.8 p -109.49 -145.44 0.4 Allowed 'General case' 0 C--N 1.355 0.829 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 -169.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.0 m -140.66 142.54 34.94 Favored 'General case' 0 C--N 1.356 0.853 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -170.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.02 -98.63 0.09 Allowed 'General case' 0 C--N 1.365 1.266 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 165.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -90.64 143.7 26.48 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 168.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.1 tp -84.53 123.15 29.97 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -177.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.61 -30.68 7.07 Favored Glycine 0 C--N 1.353 1.507 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -177.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.5 t -83.55 -63.86 1.27 Allowed 'General case' 0 C--N 1.357 0.919 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -175.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.49 -164.43 28.7 Favored Glycine 0 C--N 1.352 1.435 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.2 p -91.66 178.07 6.03 Favored 'General case' 0 N--CA 1.418 -2.061 0 C-N-CA 126.63 1.972 . . . . 0.0 108.252 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -137.42 163.03 32.06 Favored 'General case' 0 CA--C 1.491 -1.313 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 168.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.6 m0 -88.04 -74.38 0.45 Allowed 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -173.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 42.0 mm -98.3 127.39 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 91.0 m -124.47 -52.16 1.72 Allowed 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 171.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.0 t . . . . . 0 C--O 1.261 1.668 0 N-CA-C 106.492 -1.669 . . . . 0.0 106.492 177.734 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 N--CA 1.44 -0.973 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.3 m -126.73 -168.03 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 N-CA-C 104.128 -2.545 . . . . 0.0 104.128 168.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 35.5 t90 -128.42 141.1 51.51 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 177.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.09 56.14 2.95 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 110.066 -1.213 . . . . 0.0 110.066 173.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.15 170.34 22.95 Favored Glycine 0 CA--C 1.491 -1.437 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -178.281 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -95.12 -37.96 10.83 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.562 1.145 . . . . 0.0 108.696 -174.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.3 p -105.72 -153.22 0.49 Allowed 'General case' 0 C--N 1.353 0.744 0 N-CA-C 106.938 -1.505 . . . . 0.0 106.938 -168.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.8 m -140.91 143.31 34.55 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -169.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p30 -89.13 -100.26 0.09 Allowed 'General case' 0 C--N 1.365 1.248 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 168.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -87.04 155.28 20.21 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 126.789 2.036 . . . . 0.0 107.179 171.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.7 mt -81.55 123.33 28.56 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -176.039 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.91 -17.4 59.33 Favored Glycine 0 C--N 1.354 1.549 0 C-N-CA 123.519 0.581 . . . . 0.0 111.73 176.323 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.6 t -84.74 -65.95 0.95 Allowed 'General case' 0 C--N 1.358 0.978 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -171.65 -163.22 25.23 Favored Glycine 0 C--N 1.353 1.493 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 33.1 p -89.74 -175.69 4.72 Favored 'General case' 0 N--CA 1.42 -1.967 0 C-N-CA 126.363 1.865 . . . . 0.0 109.026 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -138.94 162.5 34.7 Favored 'General case' 0 CA--C 1.492 -1.261 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 170.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 29.0 m0 -106.19 -65.73 1.05 Allowed 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 105.089 -2.189 . . . . 0.0 105.089 177.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.7 mt -88.71 124.09 41.4 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 N-CA-C 105.13 -2.174 . . . . 0.0 105.13 175.011 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.7 p -150.11 -60.09 0.2 Allowed 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 105.4 -2.074 . . . . 0.0 105.4 -174.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--O 1.261 1.685 0 CA-C-O 117.232 -1.366 . . . . 0.0 109.712 177.394 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.9 m . . . . . 0 CA--C 1.502 -0.895 0 CA-C-O 119.506 -0.283 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.7 m -84.96 166.88 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.844 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 -179.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 44.1 t-105 -121.12 149.67 42.42 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -174.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.23 41.56 5.17 Favored Glycine 0 C--N 1.354 1.559 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -178.195 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -126.7 172.59 18.3 Favored Glycine 0 C--N 1.353 1.5 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -176.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -102.18 -39.61 7.17 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.469 1.107 . . . . 0.0 108.196 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.2 p -98.69 -143.75 0.32 Allowed 'General case' 0 C--N 1.353 0.753 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 -168.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.04 143.29 31.11 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 -170.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.6 p30 -88.82 -100.94 0.09 Allowed 'General case' 0 C--N 1.364 1.215 0 N-CA-C 104.688 -2.338 . . . . 0.0 104.688 167.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -90.53 160.18 16.1 Favored 'General case' 0 N--CA 1.436 -1.15 0 C-N-CA 126.741 2.016 . . . . 0.0 107.038 171.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 74.8 mt -81.89 121.55 26.61 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -176.017 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.07 -6.89 79.02 Favored Glycine 0 C--N 1.354 1.553 0 C-N-CA 123.641 0.639 . . . . 0.0 111.67 177.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -88.85 -62.87 1.39 Allowed 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 -176.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.05 -164.17 30.38 Favored Glycine 0 C--N 1.35 1.358 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 178.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.9 p -88.92 -173.52 4.12 Favored 'General case' 0 N--CA 1.418 -2.04 0 C-N-CA 126.608 1.963 . . . . 0.0 108.087 178.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.61 162.16 37.32 Favored 'General case' 0 CA--C 1.491 -1.305 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 175.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -101.13 -67.45 0.86 Allowed 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 177.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.5 mt -89.33 121.05 39.01 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.877 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 176.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.4 p -151.22 168.5 24.51 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 -175.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.259 1.563 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 177.836 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.3 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.4 m -134.7 -167.59 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 N-CA-C 103.8 -2.667 . . . . 0.0 103.8 168.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.9 t-105 -140.74 141.62 34.87 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 176.256 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.45 59.93 2.18 Favored Glycine 0 C--N 1.356 1.646 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -137.97 177.62 19.84 Favored Glycine 0 CA--C 1.488 -1.615 0 N-CA-C 108.926 -1.669 . . . . 0.0 108.926 -174.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -88.77 -44.53 10.47 Favored 'General case' 0 N--CA 1.44 -0.949 0 C-N-CA 124.226 1.011 . . . . 0.0 110.322 -170.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 71.9 m -119.79 -131.77 0.3 Allowed 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 -168.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 m -144.34 145.15 31.81 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 105.139 -2.171 . . . . 0.0 105.139 -169.302 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -88.78 -98.95 0.09 Allowed 'General case' 0 C--N 1.366 1.289 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 165.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -90.25 148.71 22.74 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 167.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.26 125.2 32.02 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 -176.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.0 -19.86 42.51 Favored Glycine 0 C--N 1.356 1.642 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -177.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.2 t -86.48 -68.16 0.76 Allowed 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -176.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.61 -164.41 29.43 Favored Glycine 0 CA--C 1.492 -1.393 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.539 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 40.5 p -88.69 -172.94 3.93 Favored 'General case' 0 N--CA 1.421 -1.912 0 C-N-CA 126.204 1.802 . . . . 0.0 109.062 -177.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.88 146.94 36.36 Favored 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 169.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 26.9 m0 -87.54 -49.83 6.93 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -176.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 57.2 mt -82.45 117.55 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.834 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 177.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -145.63 -52.15 0.26 Allowed 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.261 1.683 0 CA-C-O 117.534 -1.222 . . . . 0.0 108.248 177.595 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 CA--C 1.506 -0.748 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.68 -166.27 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.772 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 167.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.7 t-105 -140.28 145.16 36.93 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 87.35 53.76 2.71 Favored Glycine 0 C--N 1.354 1.548 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.43 168.93 24.75 Favored Glycine 0 C--N 1.352 1.452 0 N-CA-C 107.513 -2.235 . . . . 0.0 107.513 -179.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -94.32 -32.97 13.38 Favored 'General case' 0 CA--C 1.501 -0.937 0 C-N-CA 124.138 0.975 . . . . 0.0 109.156 -175.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.3 m -101.3 -155.51 0.52 Allowed 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -170.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.8 m -140.86 144.86 35.55 Favored 'General case' 0 C--N 1.358 0.963 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 -171.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -88.61 -98.74 0.09 Allowed 'General case' 0 C--N 1.366 1.315 0 N-CA-C 104.138 -2.542 . . . . 0.0 104.138 165.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.8 m-85 -91.91 148.75 21.98 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 167.546 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -84.8 124.97 32.17 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -176.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.56 -21.74 34.02 Favored Glycine 0 C--N 1.353 1.492 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -177.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -85.29 -67.61 0.79 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -176.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -175.44 -164.59 30.21 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 44.4 p -88.92 -176.81 5.31 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.103 1.761 . . . . 0.0 108.852 -177.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.21 151.96 41.2 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 166.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 17.8 m0 -91.27 -56.38 3.17 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -173.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 54.8 mt -83.02 113.34 22.05 Favored 'Isoleucine or valine' 0 C--N 1.355 0.841 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 -176.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.3 p -152.16 165.38 34.99 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 105.794 -1.928 . . . . 0.0 105.794 177.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 40.7 t . . . . . 0 C--O 1.26 1.616 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.057 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.5 m . . . . . 0 CA--C 1.506 -0.718 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.65 -168.09 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 N-CA-C 103.495 -2.78 . . . . 0.0 103.495 167.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.4 t-105 -140.0 144.29 36.9 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 174.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.88 55.05 2.48 Favored Glycine 0 C--N 1.354 1.536 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.04 170.69 23.95 Favored Glycine 0 C--N 1.352 1.453 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -93.81 -38.06 11.44 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.393 1.077 . . . . 0.0 108.868 -174.101 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.5 p -105.86 -154.55 0.52 Allowed 'General case' 0 C--N 1.354 0.784 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 -169.318 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 37.8 m -139.39 144.53 38.19 Favored 'General case' 0 CA--C 1.504 -0.802 0 N-CA-C 105.913 -1.884 . . . . 0.0 105.913 -168.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.1 p30 -88.21 -99.17 0.09 Allowed 'General case' 0 C--N 1.366 1.323 0 N-CA-C 104.295 -2.483 . . . . 0.0 104.295 166.122 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -92.23 151.76 20.18 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 169.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.0 mp -85.11 126.36 33.54 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 -176.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.64 -19.63 49.51 Favored Glycine 0 C--N 1.354 1.575 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -178.19 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 15.7 t -86.0 -69.0 0.7 Allowed 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 -176.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.97 -164.13 29.21 Favored Glycine 0 CA--C 1.491 -1.444 0 N-CA-C 107.896 -2.082 . . . . 0.0 107.896 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.6 -173.47 4.16 Favored 'General case' 0 N--CA 1.418 -2.028 0 C-N-CA 126.108 1.763 . . . . 0.0 108.676 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -138.61 158.41 44.3 Favored 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 105.817 -1.919 . . . . 0.0 105.817 170.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 30.8 m0 -100.36 -70.09 0.75 Allowed 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 105.26 -2.126 . . . . 0.0 105.26 178.521 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.1 tp -87.15 133.63 29.6 Favored 'Isoleucine or valine' 0 C--N 1.356 0.85 0 N-CA-C 106.127 -1.805 . . . . 0.0 106.127 171.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.4 p -151.58 -65.3 0.18 Allowed 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 105.189 -2.152 . . . . 0.0 105.189 -174.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 40.3 t . . . . . 0 C--O 1.26 1.606 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 177.646 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.1 m . . . . . 0 CA--C 1.506 -0.725 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.24 -171.95 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 N-CA-C 104.825 -2.287 . . . . 0.0 104.825 170.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 34.0 t90 -128.07 144.77 51.12 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.1 -1.815 . . . . 0.0 106.1 176.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.38 56.02 3.53 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 174.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.64 171.01 22.15 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -176.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -91.1 -39.34 12.22 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 124.953 1.301 . . . . 0.0 109.939 -172.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -115.2 -143.88 0.38 Allowed 'General case' 0 C--N 1.355 0.813 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 -169.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.4 m -140.55 144.62 36.01 Favored 'General case' 0 C--N 1.354 0.804 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 -169.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -88.03 -98.55 0.09 Allowed 'General case' 0 C--N 1.367 1.346 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 166.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -92.41 148.49 22.07 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 105.732 -1.951 . . . . 0.0 105.732 167.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.3 tp -84.77 125.01 32.19 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 -176.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.99 -20.9 37.29 Favored Glycine 0 C--N 1.353 1.476 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.9 t -85.61 -67.51 0.8 Allowed 'General case' 0 C--N 1.356 0.859 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -177.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.32 -164.67 29.65 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.7 p -89.08 -177.48 5.45 Favored 'General case' 0 N--CA 1.418 -2.044 0 C-N-CA 125.93 1.692 . . . . 0.0 108.593 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.58 162.19 36.11 Favored 'General case' 0 CA--C 1.489 -1.402 0 N-CA-C 104.395 -2.446 . . . . 0.0 104.395 167.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 14.9 m0 -89.25 -72.97 0.53 Allowed 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -172.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 mm -98.94 129.35 49.45 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 91.9 m -127.93 163.65 24.02 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 105.442 -2.058 . . . . 0.0 105.442 171.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 31.5 m . . . . . 0 C--O 1.261 1.687 0 CA-C-O 117.22 -1.371 . . . . 0.0 110.3 179.603 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.6 t . . . . . 0 CA--C 1.498 -1.052 0 CA-C-O 121.743 0.783 . . . . 0.0 109.138 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.2 m -127.66 -164.86 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 103.039 -2.948 . . . . 0.0 103.039 167.683 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.9 t-105 -139.55 143.85 37.56 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.66 51.45 3.64 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.58 170.44 22.36 Favored Glycine 0 C--N 1.353 1.48 0 N-CA-C 107.707 -2.157 . . . . 0.0 107.707 -177.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -91.74 -42.43 10.14 Favored 'General case' 0 N--CA 1.441 -0.919 0 C-N-CA 124.142 0.977 . . . . 0.0 109.119 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.6 p -107.44 -141.6 0.38 Allowed 'General case' 0 C--N 1.354 0.8 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 -167.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 54.1 m -143.16 144.06 32.05 Favored 'General case' 0 C--N 1.356 0.85 0 N-CA-C 105.445 -2.057 . . . . 0.0 105.445 -170.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 p30 -88.9 -99.8 0.09 Allowed 'General case' 0 C--N 1.364 1.238 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 167.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -82.76 149.33 27.31 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 127.029 2.131 . . . . 0.0 106.994 173.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.5 mt -79.1 109.46 13.43 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 -178.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 52.46 2.76 Favored Glycine 0 C--N 1.354 1.539 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -145.93 -72.03 0.24 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 173.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -164.09 -163.07 16.21 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.1 p -89.67 -174.5 4.33 Favored 'General case' 0 N--CA 1.418 -2.029 0 C-N-CA 126.424 1.889 . . . . 0.0 109.129 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.02 151.99 42.98 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 169.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 24.1 m0 -89.72 -48.91 6.96 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 -176.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.9 mt -82.27 118.81 30.65 Favored 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 105.851 -1.907 . . . . 0.0 105.851 177.309 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 84.8 m -123.83 165.9 16.53 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -173.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.0 m . . . . . 0 C--O 1.258 1.548 0 C-N-CA 123.787 0.835 . . . . 0.0 110.327 -179.739 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.3 m . . . . . 0 CA--C 1.505 -0.755 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.6 m -133.23 -166.84 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 103.533 -2.765 . . . . 0.0 103.533 167.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.5 t-105 -141.64 143.75 33.79 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 106.692 -1.595 . . . . 0.0 106.692 176.141 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.79 55.09 2.48 Favored Glycine 0 C--N 1.353 1.511 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.19 172.06 23.37 Favored Glycine 0 C--N 1.352 1.432 0 N-CA-C 107.999 -2.04 . . . . 0.0 107.999 -178.287 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -94.34 -37.95 11.23 Favored 'General case' 0 N--CA 1.44 -0.947 0 C-N-CA 124.446 1.098 . . . . 0.0 108.784 -174.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -104.14 -156.6 0.57 Allowed 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -169.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.1 m -139.55 144.19 37.72 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 -168.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.04 -98.62 0.09 Allowed 'General case' 0 C--N 1.368 1.372 0 N-CA-C 104.189 -2.523 . . . . 0.0 104.189 166.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -92.55 147.86 22.55 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 167.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.23 124.57 32.02 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 -177.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.27 -22.79 28.45 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -176.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.3 t -84.79 -67.19 0.82 Allowed 'General case' 0 C--N 1.357 0.905 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 -177.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.13 -163.73 29.18 Favored Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 107.86 -2.096 . . . . 0.0 107.86 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.4 p -88.62 -173.35 4.11 Favored 'General case' 0 N--CA 1.416 -2.126 0 C-N-CA 126.028 1.731 . . . . 0.0 108.706 -178.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.82 161.13 36.82 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 170.154 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -107.77 -65.27 1.13 Allowed 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 104.993 -2.225 . . . . 0.0 104.993 177.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.8 mt -87.9 118.39 33.52 Favored 'Isoleucine or valine' 0 C--N 1.356 0.864 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 175.5 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.0 p -151.47 168.72 23.99 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 -175.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.262 1.716 0 CA-C-O 117.427 -1.273 . . . . 0.0 108.499 177.437 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.0 m . . . . . 0 N--CA 1.444 -0.753 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -134.33 -168.17 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.752 0 N-CA-C 103.938 -2.616 . . . . 0.0 103.938 169.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.3 t-105 -139.66 143.58 37.21 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 106.379 -1.712 . . . . 0.0 106.379 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.21 53.44 3.12 Favored Glycine 0 C--N 1.355 1.625 0 N-CA-C 108.789 -1.724 . . . . 0.0 108.789 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.16 168.61 23.99 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.99 -2.044 . . . . 0.0 107.99 -176.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -92.89 -34.22 13.89 Favored 'General case' 0 N--CA 1.442 -0.846 0 C-N-CA 124.278 1.031 . . . . 0.0 111.455 -170.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.1 m -115.8 -137.5 0.36 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 -174.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.24 145.97 32.37 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 105.392 -2.077 . . . . 0.0 105.392 -169.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -89.38 -100.82 0.09 Allowed 'General case' 0 C--N 1.365 1.273 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 166.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -88.23 155.98 19.46 Favored 'General case' 0 N--CA 1.435 -1.195 0 C-N-CA 126.515 1.926 . . . . 0.0 107.119 172.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.3 mt -80.68 122.49 27.18 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 123.669 0.788 . . . . 0.0 109.048 -174.467 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.84 -3.94 81.41 Favored Glycine 0 C--N 1.354 1.579 0 C-N-CA 123.74 0.686 . . . . 0.0 111.663 178.159 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.8 t -90.91 -70.79 0.66 Allowed 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 -176.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -170.33 -165.29 27.45 Favored Glycine 0 CA--C 1.491 -1.419 0 N-CA-C 108.102 -1.999 . . . . 0.0 108.102 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.7 p -88.63 -173.17 4.04 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.036 1.734 . . . . 0.0 109.027 -177.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.08 148.53 36.8 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 169.587 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 24.0 m0 -88.54 -49.18 7.06 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 -176.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.2 mm -82.5 119.48 32.11 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 178.328 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.2 t -150.5 -52.42 0.14 Allowed 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 105.172 -2.158 . . . . 0.0 105.172 -176.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.4 t . . . . . 0 C--O 1.259 1.574 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 -178.781 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.5 -0.97 0 CA-C-O 121.763 0.792 . . . . 0.0 109.189 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.6 m -126.57 -164.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.855 0 N-CA-C 102.983 -2.969 . . . . 0.0 102.983 166.494 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.8 t-105 -139.4 142.15 37.5 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.91 58.16 2.55 Favored Glycine 0 C--N 1.354 1.565 0 N-CA-C 108.816 -1.713 . . . . 0.0 108.816 -179.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.93 174.83 20.94 Favored Glycine 0 CA--C 1.49 -1.479 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -174.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -90.17 -42.94 10.76 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 124.415 1.086 . . . . 0.0 110.136 -170.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.8 m -119.32 -133.94 0.32 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -168.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.4 m -145.3 143.63 30.3 Favored 'General case' 0 C--N 1.356 0.883 0 N-CA-C 105.331 -2.1 . . . . 0.0 105.331 -168.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.05 -98.86 0.09 Allowed 'General case' 0 C--N 1.364 1.204 0 N-CA-C 104.554 -2.388 . . . . 0.0 104.554 166.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.97 144.55 26.48 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 167.126 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.62 123.89 30.25 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.01 -28.62 9.62 Favored Glycine 0 C--N 1.353 1.483 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.26 -65.14 1.04 Allowed 'General case' 0 C--N 1.358 0.937 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -174.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.98 -163.66 27.1 Favored Glycine 0 C--N 1.353 1.497 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 36.9 p -89.91 -174.85 4.41 Favored 'General case' 0 N--CA 1.42 -1.931 0 C-N-CA 126.667 1.987 . . . . 0.0 109.361 -176.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.18 149.39 39.65 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 169.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 25.1 m0 -87.33 -50.61 6.46 Favored 'General case' 0 CA--C 1.5 -0.98 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -176.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.5 tt -79.18 134.14 28.44 Favored 'Isoleucine or valine' 0 C--N 1.354 0.776 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 175.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.1 t -150.81 155.42 39.18 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 105.587 -2.005 . . . . 0.0 105.587 -175.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.259 1.58 0 C-N-CA 124.036 0.934 . . . . 0.0 108.574 178.238 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.1 m . . . . . 0 CA--C 1.504 -0.796 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.8 m -132.92 -168.51 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.286 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.6 t-105 -139.19 143.57 38.15 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 174.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.43 58.69 2.25 Favored Glycine 0 C--N 1.356 1.68 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.84 172.79 22.93 Favored Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 -177.178 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -90.62 -40.13 12.1 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 124.765 1.226 . . . . 0.0 110.023 -171.122 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -114.32 -144.61 0.39 Allowed 'General case' 0 C--N 1.354 0.772 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -170.1 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 45.2 m -140.95 144.4 35.11 Favored 'General case' 0 C--N 1.355 0.845 0 N-CA-C 105.739 -1.948 . . . . 0.0 105.739 -169.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.81 -98.46 0.08 Allowed 'General case' 0 C--N 1.367 1.343 0 N-CA-C 104.238 -2.504 . . . . 0.0 104.238 165.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.02 147.96 22.4 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.5 tp -85.44 124.78 32.42 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.48 -23.33 26.82 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -176.329 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.77 -67.03 0.83 Allowed 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.282 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.51 -164.07 29.93 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 107.902 -2.079 . . . . 0.0 107.902 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 35.8 p -88.61 -176.4 5.26 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 126.047 1.739 . . . . 0.0 108.809 -178.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.272 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 167.083 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 16.8 m -127.07 -174.05 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.787 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 169.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 40.8 t90 -119.45 139.5 51.95 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 176.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.78 59.1 2.7 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.47 171.55 22.22 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -178.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -92.84 -43.51 8.96 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 124.17 0.988 . . . . 0.0 109.147 -173.232 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.9 p -106.88 -137.78 0.37 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -167.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.1 m -144.51 142.69 30.41 Favored 'General case' 0 C--N 1.356 0.858 0 N-CA-C 105.518 -2.031 . . . . 0.0 105.518 -170.02 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.15 -98.71 0.09 Allowed 'General case' 0 C--N 1.364 1.208 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 166.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.51 144.81 26.53 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 166.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.49 124.06 30.35 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 -177.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.67 -28.72 9.71 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.9 t -84.27 -65.69 0.98 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.7 -163.28 26.24 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 p -90.36 -175.35 4.46 Favored 'General case' 0 N--CA 1.421 -1.917 0 C-N-CA 126.566 1.946 . . . . 0.0 109.458 -175.515 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.223 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 171.043 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 CA--C 1.507 -0.709 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.0 m -132.97 -170.55 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.811 0 N-CA-C 103.368 -2.827 . . . . 0.0 103.368 168.087 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.3 t-105 -137.97 147.46 44.29 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.24 47.92 5.02 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -127.81 171.57 19.11 Favored Glycine 0 C--N 1.352 1.455 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -175.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.4 m-20 -93.28 -39.49 10.94 Favored 'General case' 0 N--CA 1.44 -0.932 0 C-N-CA 124.994 1.318 . . . . 0.0 109.852 -172.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.0 p -113.54 -145.19 0.4 Allowed 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -170.535 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -139.3 144.78 38.48 Favored 'General case' 0 C--N 1.357 0.892 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 -170.5 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p30 -88.49 -100.7 0.09 Allowed 'General case' 0 C--N 1.368 1.385 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 165.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -92.05 158.72 16.07 Favored 'General case' 0 N--CA 1.436 -1.138 0 C-N-CA 126.234 1.814 . . . . 0.0 107.323 174.683 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.1 mt -82.49 123.29 29.03 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.74 -6.56 79.79 Favored Glycine 0 C--N 1.354 1.553 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 178.191 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 18.1 t -89.7 -69.81 0.7 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -176.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.69 -164.62 29.15 Favored Glycine 0 CA--C 1.489 -1.533 0 N-CA-C 107.612 -2.195 . . . . 0.0 107.612 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.9 p -88.48 179.45 6.3 Favored 'General case' 0 N--CA 1.417 -2.105 0 C-N-CA 125.862 1.665 . . . . 0.0 108.515 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.341 0 N-CA-C 104.247 -2.501 . . . . 0.0 104.247 166.806 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 92.9 m . . . . . 0 CA--C 1.504 -0.793 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 m -133.39 -167.23 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 103.824 -2.658 . . . . 0.0 103.824 167.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.5 t-105 -140.35 143.7 35.9 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 175.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.5 55.4 2.59 Favored Glycine 0 C--N 1.354 1.56 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.7 168.27 24.79 Favored Glycine 0 CA--C 1.49 -1.484 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -176.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -91.35 -34.84 14.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 124.771 1.228 . . . . 0.0 110.434 -173.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -111.12 -153.93 0.53 Allowed 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -169.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.8 m -139.59 144.5 37.79 Favored 'General case' 0 C--N 1.355 0.832 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -169.095 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -88.12 -98.36 0.09 Allowed 'General case' 0 C--N 1.365 1.269 0 N-CA-C 104.206 -2.516 . . . . 0.0 104.206 166.612 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.05 147.78 22.56 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 167.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.4 tp -85.19 124.58 32.01 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 -177.363 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.7 -23.61 25.71 Favored Glycine 0 C--N 1.354 1.556 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.61 -67.0 0.83 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 -177.318 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.02 -164.13 29.77 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.0 p -88.95 -173.05 3.93 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.075 1.75 . . . . 0.0 108.692 -177.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.269 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 171.06 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 CA--C 1.499 -1.016 0 CA-C-O 121.759 0.79 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -124.89 -165.19 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.812 -3.033 . . . . 0.0 102.812 165.447 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.9 t-105 -138.7 143.94 39.35 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.046 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.25 55.88 2.81 Favored Glycine 0 C--N 1.355 1.589 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.46 170.55 22.63 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -176.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -91.27 -39.5 12.04 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 124.944 1.298 . . . . 0.0 109.957 -171.768 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.9 p -114.59 -145.47 0.4 Allowed 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -169.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 40.8 m -141.33 143.64 34.14 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 -170.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -88.78 -100.21 0.09 Allowed 'General case' 0 C--N 1.364 1.226 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 167.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -88.17 155.75 19.6 Favored 'General case' 0 N--CA 1.436 -1.17 0 C-N-CA 126.842 2.057 . . . . 0.0 107.268 172.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 72.8 mt -81.78 123.68 28.99 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -176.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -17.83 58.59 Favored Glycine 0 C--N 1.355 1.598 0 C-N-CA 123.517 0.58 . . . . 0.0 111.669 176.362 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.4 t -84.69 -65.43 1.01 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.288 -1.005 . . . . 0.0 108.288 -175.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.18 -164.14 27.21 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.2 p -89.78 -177.83 5.35 Favored 'General case' 0 N--CA 1.418 -2.038 0 C-N-CA 126.354 1.862 . . . . 0.0 108.945 -177.391 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.332 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 167.785 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.4 m . . . . . 0 CA--C 1.504 -0.791 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 17.6 m -133.71 -172.66 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 36.9 t90 -125.97 141.85 51.78 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 176.212 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.52 60.85 2.72 Favored Glycine 0 C--N 1.354 1.581 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 174.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.43 173.41 22.02 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 -176.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -88.09 -42.13 12.59 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 124.442 1.097 . . . . 0.0 110.184 -171.024 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 81.4 m -117.57 -133.37 0.33 Allowed 'General case' 0 C--N 1.357 0.893 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -168.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.7 m -145.43 144.67 30.76 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.932 -2.247 . . . . 0.0 104.932 -169.352 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.71 -98.25 0.09 Allowed 'General case' 0 C--N 1.364 1.227 0 N-CA-C 104.281 -2.488 . . . . 0.0 104.281 166.356 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -90.81 149.39 21.99 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 166.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.1 tp -84.52 125.32 32.29 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.19 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.55 -19.56 44.63 Favored Glycine 0 C--N 1.354 1.537 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -177.567 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -86.5 -68.16 0.76 Allowed 'General case' 0 C--N 1.357 0.907 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -176.488 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.36 -165.07 29.67 Favored Glycine 0 C--N 1.351 1.391 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.5 p -88.97 -173.29 4.02 Favored 'General case' 0 N--CA 1.42 -1.947 0 C-N-CA 126.268 1.827 . . . . 0.0 108.854 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.24 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.278 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.5 -0.972 0 CA-C-O 121.839 0.828 . . . . 0.0 109.418 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.7 m -125.1 -167.08 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 102.307 -3.22 . . . . 0.0 102.307 164.51 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.5 t-105 -137.74 147.57 44.86 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 175.229 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.6 47.96 4.92 Favored Glycine 0 C--N 1.353 1.52 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -128.42 166.88 20.81 Favored Glycine 0 C--N 1.353 1.506 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -91.86 -39.5 11.71 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 124.794 1.238 . . . . 0.0 109.128 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.1 p -109.38 -145.49 0.4 Allowed 'General case' 0 C--N 1.354 0.796 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 -169.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.4 m -141.19 142.92 33.97 Favored 'General case' 0 C--N 1.356 0.855 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 -170.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -88.24 -99.02 0.09 Allowed 'General case' 0 C--N 1.365 1.249 0 N-CA-C 104.613 -2.366 . . . . 0.0 104.613 166.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -89.77 149.11 22.86 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 126.056 1.742 . . . . 0.0 106.319 169.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.1 mp -84.32 125.73 32.55 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.62 -28.4 13.48 Favored Glycine 0 C--N 1.354 1.58 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.0 t -83.3 -65.04 1.06 Allowed 'General case' 0 C--N 1.358 0.97 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -174.664 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.09 -164.56 28.66 Favored Glycine 0 C--N 1.353 1.484 0 N-CA-C 109.145 -1.582 . . . . 0.0 109.145 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 23.6 p -91.13 179.65 5.67 Favored 'General case' 0 N--CA 1.419 -1.992 0 C-N-CA 126.497 1.919 . . . . 0.0 108.551 -178.43 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.297 0 N-CA-C 105.318 -2.104 . . . . 0.0 105.318 169.034 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.7 m . . . . . 0 CA--C 1.503 -0.832 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.4 m -132.56 -168.13 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 104.21 -2.515 . . . . 0.0 104.21 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.5 t-105 -139.77 143.75 37.07 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 175.731 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.12 54.36 3.05 Favored Glycine 0 C--N 1.355 1.623 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.38 172.96 22.22 Favored Glycine 0 C--N 1.353 1.495 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 -177.001 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 -93.45 -41.02 10.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 123.831 0.853 . . . . 0.0 109.77 -170.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.4 p -110.88 -140.12 0.38 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -169.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.6 m -141.85 145.52 34.75 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 -170.056 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.66 -99.56 0.09 Allowed 'General case' 0 C--N 1.365 1.251 0 N-CA-C 104.382 -2.451 . . . . 0.0 104.382 165.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -88.43 148.81 24.02 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.031 1.732 . . . . 0.0 106.496 169.164 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.1 tt -83.84 117.93 23.62 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 -177.015 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.57 38.62 6.15 Favored Glycine 0 C--N 1.353 1.491 0 N-CA-C 108.94 -1.664 . . . . 0.0 108.94 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.5 t -138.54 -68.44 0.45 Allowed 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.428 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.46 -165.72 30.71 Favored Glycine 0 CA--C 1.492 -1.384 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.77 -172.32 3.67 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.214 1.805 . . . . 0.0 108.812 -178.121 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.211 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 169.357 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.4 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.4 m -133.66 -168.75 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 N-CA-C 103.422 -2.807 . . . . 0.0 103.422 167.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 59.0 t-105 -139.26 145.32 39.04 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.09 53.59 3.27 Favored Glycine 0 C--N 1.355 1.621 0 N-CA-C 108.989 -1.644 . . . . 0.0 108.989 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.71 172.64 21.55 Favored Glycine 0 CA--C 1.49 -1.489 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -176.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -91.49 -40.03 11.62 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 124.838 1.255 . . . . 0.0 109.964 -171.704 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 11.1 p -114.18 -144.78 0.39 Allowed 'General case' 0 C--N 1.354 0.761 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 -170.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 35.0 m -139.76 144.69 37.55 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 105.864 -1.902 . . . . 0.0 105.864 -169.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.96 -98.79 0.09 Allowed 'General case' 0 C--N 1.368 1.375 0 N-CA-C 104.14 -2.541 . . . . 0.0 104.14 165.464 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -92.93 148.1 22.29 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 167.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.42 124.7 32.3 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -22.73 29.14 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.5 t -84.77 -67.14 0.82 Allowed 'General case' 0 N--CA 1.443 -0.811 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 -177.402 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.14 -163.9 29.47 Favored Glycine 0 CA--C 1.492 -1.395 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.4 p -88.81 -178.64 5.81 Favored 'General case' 0 N--CA 1.416 -2.16 0 C-N-CA 125.893 1.677 . . . . 0.0 108.656 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.336 0 N-CA-C 103.946 -2.613 . . . . 0.0 103.946 165.386 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.499 -0.988 0 CA-C-O 121.881 0.848 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.2 m -124.17 -167.45 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 N-CA-C 102.211 -3.255 . . . . 0.0 102.211 164.205 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.0 t-105 -137.63 148.77 46.08 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 175.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.77 45.26 5.8 Favored Glycine 0 C--N 1.355 1.588 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -178.319 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -125.16 166.81 17.72 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -175.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -92.58 -39.19 11.48 Favored 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 124.775 1.23 . . . . 0.0 109.025 -174.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.8 p -109.49 -145.44 0.4 Allowed 'General case' 0 C--N 1.355 0.829 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 -169.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.0 m -140.66 142.54 34.94 Favored 'General case' 0 C--N 1.356 0.853 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -170.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.02 -98.63 0.09 Allowed 'General case' 0 C--N 1.365 1.266 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 165.728 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -90.64 143.7 26.48 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 168.456 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.1 tp -84.53 123.15 29.97 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -177.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.61 -30.68 7.07 Favored Glycine 0 C--N 1.353 1.507 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -177.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.5 t -83.55 -63.86 1.27 Allowed 'General case' 0 C--N 1.357 0.919 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -175.607 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.49 -164.43 28.7 Favored Glycine 0 C--N 1.352 1.435 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.2 p -91.66 178.07 6.03 Favored 'General case' 0 N--CA 1.418 -2.061 0 C-N-CA 126.63 1.972 . . . . 0.0 108.252 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.313 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 168.686 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 N--CA 1.44 -0.973 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.3 m -126.73 -168.03 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 N-CA-C 104.128 -2.545 . . . . 0.0 104.128 168.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 35.5 t90 -128.42 141.1 51.51 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 177.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.09 56.14 2.95 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 110.066 -1.213 . . . . 0.0 110.066 173.163 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.15 170.34 22.95 Favored Glycine 0 CA--C 1.491 -1.437 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -178.281 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -95.12 -37.96 10.83 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.562 1.145 . . . . 0.0 108.696 -174.217 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.3 p -105.72 -153.22 0.49 Allowed 'General case' 0 C--N 1.353 0.744 0 N-CA-C 106.938 -1.505 . . . . 0.0 106.938 -168.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.8 m -140.91 143.31 34.55 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -169.057 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p30 -89.13 -100.26 0.09 Allowed 'General case' 0 C--N 1.365 1.248 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 168.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -87.04 155.28 20.21 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 126.789 2.036 . . . . 0.0 107.179 171.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.7 mt -81.55 123.33 28.56 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -176.039 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.91 -17.4 59.33 Favored Glycine 0 C--N 1.354 1.549 0 C-N-CA 123.519 0.581 . . . . 0.0 111.73 176.323 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.6 t -84.74 -65.95 0.95 Allowed 'General case' 0 C--N 1.358 0.978 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -171.65 -163.22 25.23 Favored Glycine 0 C--N 1.353 1.493 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 33.1 p -89.74 -175.69 4.72 Favored 'General case' 0 N--CA 1.42 -1.967 0 C-N-CA 126.363 1.865 . . . . 0.0 109.026 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.261 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 170.99 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.9 m . . . . . 0 CA--C 1.502 -0.895 0 CA-C-O 119.506 -0.283 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.7 m -84.96 166.88 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.844 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 -179.022 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 44.1 t-105 -121.12 149.67 42.42 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -174.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.23 41.56 5.17 Favored Glycine 0 C--N 1.354 1.559 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -178.195 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -126.7 172.59 18.3 Favored Glycine 0 C--N 1.353 1.5 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -176.486 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -102.18 -39.61 7.17 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.469 1.107 . . . . 0.0 108.196 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.2 p -98.69 -143.75 0.32 Allowed 'General case' 0 C--N 1.353 0.753 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 -168.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.04 143.29 31.11 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 -170.234 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.6 p30 -88.82 -100.94 0.09 Allowed 'General case' 0 C--N 1.364 1.215 0 N-CA-C 104.688 -2.338 . . . . 0.0 104.688 167.3 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -90.53 160.18 16.1 Favored 'General case' 0 N--CA 1.436 -1.15 0 C-N-CA 126.741 2.016 . . . . 0.0 107.038 171.877 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 74.8 mt -81.89 121.55 26.61 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -176.017 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.07 -6.89 79.02 Favored Glycine 0 C--N 1.354 1.553 0 C-N-CA 123.641 0.639 . . . . 0.0 111.67 177.273 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -88.85 -62.87 1.39 Allowed 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 -176.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.05 -164.17 30.38 Favored Glycine 0 C--N 1.35 1.358 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 178.322 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.9 p -88.92 -173.52 4.12 Favored 'General case' 0 N--CA 1.418 -2.04 0 C-N-CA 126.608 1.963 . . . . 0.0 108.087 178.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.305 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 175.536 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.3 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.4 m -134.7 -167.59 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 N-CA-C 103.8 -2.667 . . . . 0.0 103.8 168.554 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.9 t-105 -140.74 141.62 34.87 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 176.256 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.45 59.93 2.18 Favored Glycine 0 C--N 1.356 1.646 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -137.97 177.62 19.84 Favored Glycine 0 CA--C 1.488 -1.615 0 N-CA-C 108.926 -1.669 . . . . 0.0 108.926 -174.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -88.77 -44.53 10.47 Favored 'General case' 0 N--CA 1.44 -0.949 0 C-N-CA 124.226 1.011 . . . . 0.0 110.322 -170.693 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 71.9 m -119.79 -131.77 0.3 Allowed 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 -168.764 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 m -144.34 145.15 31.81 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 105.139 -2.171 . . . . 0.0 105.139 -169.302 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -88.78 -98.95 0.09 Allowed 'General case' 0 C--N 1.366 1.289 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 165.419 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -90.25 148.71 22.74 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 167.212 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.26 125.2 32.02 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 -176.303 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.0 -19.86 42.51 Favored Glycine 0 C--N 1.356 1.642 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -177.375 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.2 t -86.48 -68.16 0.76 Allowed 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -176.609 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.61 -164.41 29.43 Favored Glycine 0 CA--C 1.492 -1.393 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.539 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 40.5 p -88.69 -172.94 3.93 Favored 'General case' 0 N--CA 1.421 -1.912 0 C-N-CA 126.204 1.802 . . . . 0.0 109.062 -177.281 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.206 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 169.077 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 CA--C 1.506 -0.748 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.68 -166.27 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.772 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 167.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.7 t-105 -140.28 145.16 36.93 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 87.35 53.76 2.71 Favored Glycine 0 C--N 1.354 1.548 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.43 168.93 24.75 Favored Glycine 0 C--N 1.352 1.452 0 N-CA-C 107.513 -2.235 . . . . 0.0 107.513 -179.19 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -94.32 -32.97 13.38 Favored 'General case' 0 CA--C 1.501 -0.937 0 C-N-CA 124.138 0.975 . . . . 0.0 109.156 -175.824 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.3 m -101.3 -155.51 0.52 Allowed 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -170.422 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.8 m -140.86 144.86 35.55 Favored 'General case' 0 C--N 1.358 0.963 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 -171.096 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -88.61 -98.74 0.09 Allowed 'General case' 0 C--N 1.366 1.315 0 N-CA-C 104.138 -2.542 . . . . 0.0 104.138 165.454 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.8 m-85 -91.91 148.75 21.98 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 167.546 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -84.8 124.97 32.17 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -176.816 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.56 -21.74 34.02 Favored Glycine 0 C--N 1.353 1.492 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -177.104 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -85.29 -67.61 0.79 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -176.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -175.44 -164.59 30.21 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 44.4 p -88.92 -176.81 5.31 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.103 1.761 . . . . 0.0 108.852 -177.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.246 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 166.678 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.5 m . . . . . 0 CA--C 1.506 -0.718 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.65 -168.09 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 N-CA-C 103.495 -2.78 . . . . 0.0 103.495 167.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.4 t-105 -140.0 144.29 36.9 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 174.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.88 55.05 2.48 Favored Glycine 0 C--N 1.354 1.536 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.04 170.69 23.95 Favored Glycine 0 C--N 1.352 1.453 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -93.81 -38.06 11.44 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.393 1.077 . . . . 0.0 108.868 -174.101 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.5 p -105.86 -154.55 0.52 Allowed 'General case' 0 C--N 1.354 0.784 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 -169.318 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 37.8 m -139.39 144.53 38.19 Favored 'General case' 0 CA--C 1.504 -0.802 0 N-CA-C 105.913 -1.884 . . . . 0.0 105.913 -168.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.1 p30 -88.21 -99.17 0.09 Allowed 'General case' 0 C--N 1.366 1.323 0 N-CA-C 104.295 -2.483 . . . . 0.0 104.295 166.122 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -92.23 151.76 20.18 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 169.689 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.0 mp -85.11 126.36 33.54 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 -176.649 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.64 -19.63 49.51 Favored Glycine 0 C--N 1.354 1.575 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -178.19 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 15.7 t -86.0 -69.0 0.7 Allowed 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 -176.497 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.97 -164.13 29.21 Favored Glycine 0 CA--C 1.491 -1.444 0 N-CA-C 107.896 -2.082 . . . . 0.0 107.896 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.6 -173.47 4.16 Favored 'General case' 0 N--CA 1.418 -2.028 0 C-N-CA 126.108 1.763 . . . . 0.0 108.676 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.193 0 N-CA-C 105.817 -1.919 . . . . 0.0 105.817 170.886 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.1 m . . . . . 0 CA--C 1.506 -0.725 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.24 -171.95 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 N-CA-C 104.825 -2.287 . . . . 0.0 104.825 170.367 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 34.0 t90 -128.07 144.77 51.12 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.1 -1.815 . . . . 0.0 106.1 176.694 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.38 56.02 3.53 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 174.519 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.64 171.01 22.15 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -176.477 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -91.1 -39.34 12.22 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 124.953 1.301 . . . . 0.0 109.939 -172.16 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -115.2 -143.88 0.38 Allowed 'General case' 0 C--N 1.355 0.813 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 -169.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.4 m -140.55 144.62 36.01 Favored 'General case' 0 C--N 1.354 0.804 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 -169.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -88.03 -98.55 0.09 Allowed 'General case' 0 C--N 1.367 1.346 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 166.34 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -92.41 148.49 22.07 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 105.732 -1.951 . . . . 0.0 105.732 167.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.3 tp -84.77 125.01 32.19 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 -176.623 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.99 -20.9 37.29 Favored Glycine 0 C--N 1.353 1.476 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.109 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.9 t -85.61 -67.51 0.8 Allowed 'General case' 0 C--N 1.356 0.859 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -177.112 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.32 -164.67 29.65 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.7 p -89.08 -177.48 5.45 Favored 'General case' 0 N--CA 1.418 -2.044 0 C-N-CA 125.93 1.692 . . . . 0.0 108.593 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.402 0 N-CA-C 104.395 -2.446 . . . . 0.0 104.395 167.079 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.6 t . . . . . 0 CA--C 1.498 -1.052 0 CA-C-O 121.743 0.783 . . . . 0.0 109.138 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.2 m -127.66 -164.86 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 103.039 -2.948 . . . . 0.0 103.039 167.683 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.9 t-105 -139.55 143.85 37.56 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.261 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.66 51.45 3.64 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.58 170.44 22.36 Favored Glycine 0 C--N 1.353 1.48 0 N-CA-C 107.707 -2.157 . . . . 0.0 107.707 -177.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -91.74 -42.43 10.14 Favored 'General case' 0 N--CA 1.441 -0.919 0 C-N-CA 124.142 0.977 . . . . 0.0 109.119 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.6 p -107.44 -141.6 0.38 Allowed 'General case' 0 C--N 1.354 0.8 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 -167.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 54.1 m -143.16 144.06 32.05 Favored 'General case' 0 C--N 1.356 0.85 0 N-CA-C 105.445 -2.057 . . . . 0.0 105.445 -170.201 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 p30 -88.9 -99.8 0.09 Allowed 'General case' 0 C--N 1.364 1.238 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 167.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -82.76 149.33 27.31 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 127.029 2.131 . . . . 0.0 106.994 173.763 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.5 mt -79.1 109.46 13.43 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 -178.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 52.46 2.76 Favored Glycine 0 C--N 1.354 1.539 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -145.93 -72.03 0.24 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 173.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -164.09 -163.07 16.21 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.1 p -89.67 -174.5 4.33 Favored 'General case' 0 N--CA 1.418 -2.029 0 C-N-CA 126.424 1.889 . . . . 0.0 109.129 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.246 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 169.475 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.3 m . . . . . 0 CA--C 1.505 -0.755 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.6 m -133.23 -166.84 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 103.533 -2.765 . . . . 0.0 103.533 167.337 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.5 t-105 -141.64 143.75 33.79 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 106.692 -1.595 . . . . 0.0 106.692 176.141 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.79 55.09 2.48 Favored Glycine 0 C--N 1.353 1.511 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.19 172.06 23.37 Favored Glycine 0 C--N 1.352 1.432 0 N-CA-C 107.999 -2.04 . . . . 0.0 107.999 -178.287 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -94.34 -37.95 11.23 Favored 'General case' 0 N--CA 1.44 -0.947 0 C-N-CA 124.446 1.098 . . . . 0.0 108.784 -174.419 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -104.14 -156.6 0.57 Allowed 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -169.565 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.1 m -139.55 144.19 37.72 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 -168.53 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.04 -98.62 0.09 Allowed 'General case' 0 C--N 1.368 1.372 0 N-CA-C 104.189 -2.523 . . . . 0.0 104.189 166.121 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -92.55 147.86 22.55 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 167.671 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.23 124.57 32.02 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 -177.12 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.27 -22.79 28.45 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -176.605 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.3 t -84.79 -67.19 0.82 Allowed 'General case' 0 C--N 1.357 0.905 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 -177.407 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.13 -163.73 29.18 Favored Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 107.86 -2.096 . . . . 0.0 107.86 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.4 p -88.62 -173.35 4.11 Favored 'General case' 0 N--CA 1.416 -2.126 0 C-N-CA 126.028 1.731 . . . . 0.0 108.706 -178.003 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.21 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 170.154 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.0 m . . . . . 0 N--CA 1.444 -0.753 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -134.33 -168.17 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.752 0 N-CA-C 103.938 -2.616 . . . . 0.0 103.938 169.398 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.3 t-105 -139.66 143.58 37.21 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 106.379 -1.712 . . . . 0.0 106.379 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.21 53.44 3.12 Favored Glycine 0 C--N 1.355 1.625 0 N-CA-C 108.789 -1.724 . . . . 0.0 108.789 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.16 168.61 23.99 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.99 -2.044 . . . . 0.0 107.99 -176.004 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -92.89 -34.22 13.89 Favored 'General case' 0 N--CA 1.442 -0.846 0 C-N-CA 124.278 1.031 . . . . 0.0 111.455 -170.062 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.1 m -115.8 -137.5 0.36 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 -174.794 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.24 145.97 32.37 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 105.392 -2.077 . . . . 0.0 105.392 -169.198 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -89.38 -100.82 0.09 Allowed 'General case' 0 C--N 1.365 1.273 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 166.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -88.23 155.98 19.46 Favored 'General case' 0 N--CA 1.435 -1.195 0 C-N-CA 126.515 1.926 . . . . 0.0 107.119 172.484 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.3 mt -80.68 122.49 27.18 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 123.669 0.788 . . . . 0.0 109.048 -174.467 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.84 -3.94 81.41 Favored Glycine 0 C--N 1.354 1.579 0 C-N-CA 123.74 0.686 . . . . 0.0 111.663 178.159 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.8 t -90.91 -70.79 0.66 Allowed 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 -176.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -170.33 -165.29 27.45 Favored Glycine 0 CA--C 1.491 -1.419 0 N-CA-C 108.102 -1.999 . . . . 0.0 108.102 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.7 p -88.63 -173.17 4.04 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.036 1.734 . . . . 0.0 109.027 -177.212 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.237 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 169.587 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.5 -0.97 0 CA-C-O 121.763 0.792 . . . . 0.0 109.189 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.6 m -126.57 -164.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.855 0 N-CA-C 102.983 -2.969 . . . . 0.0 102.983 166.494 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.8 t-105 -139.4 142.15 37.5 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.132 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.91 58.16 2.55 Favored Glycine 0 C--N 1.354 1.565 0 N-CA-C 108.816 -1.713 . . . . 0.0 108.816 -179.622 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.93 174.83 20.94 Favored Glycine 0 CA--C 1.49 -1.479 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -174.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -90.17 -42.94 10.76 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 124.415 1.086 . . . . 0.0 110.136 -170.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.8 m -119.32 -133.94 0.32 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -168.622 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.4 m -145.3 143.63 30.3 Favored 'General case' 0 C--N 1.356 0.883 0 N-CA-C 105.331 -2.1 . . . . 0.0 105.331 -168.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.05 -98.86 0.09 Allowed 'General case' 0 C--N 1.364 1.204 0 N-CA-C 104.554 -2.388 . . . . 0.0 104.554 166.561 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.97 144.55 26.48 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 167.126 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.62 123.89 30.25 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.245 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.01 -28.62 9.62 Favored Glycine 0 C--N 1.353 1.483 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.26 -65.14 1.04 Allowed 'General case' 0 C--N 1.358 0.937 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -174.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.98 -163.66 27.1 Favored Glycine 0 C--N 1.353 1.497 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 36.9 p -89.91 -174.85 4.41 Favored 'General case' 0 N--CA 1.42 -1.931 0 C-N-CA 126.667 1.987 . . . . 0.0 109.361 -176.127 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.253 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 169.4 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.1 m . . . . . 0 CA--C 1.504 -0.796 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.8 m -132.92 -168.51 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.6 t-105 -139.19 143.57 38.15 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 174.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.43 58.69 2.25 Favored Glycine 0 C--N 1.356 1.68 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.84 172.79 22.93 Favored Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 -177.178 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -90.62 -40.13 12.1 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 124.765 1.226 . . . . 0.0 110.023 -171.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -114.32 -144.61 0.39 Allowed 'General case' 0 C--N 1.354 0.772 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -170.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 45.2 m -140.95 144.4 35.11 Favored 'General case' 0 C--N 1.355 0.845 0 N-CA-C 105.739 -1.948 . . . . 0.0 105.739 -169.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.81 -98.46 0.08 Allowed 'General case' 0 C--N 1.367 1.343 0 N-CA-C 104.238 -2.504 . . . . 0.0 104.238 165.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.02 147.96 22.4 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.5 tp -85.44 124.78 32.42 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.48 -23.33 26.82 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -176.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.77 -67.03 0.83 Allowed 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.51 -164.07 29.93 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 107.902 -2.079 . . . . 0.0 107.902 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 35.8 p -88.61 -176.4 5.26 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 126.047 1.739 . . . . 0.0 108.809 -178.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.85 162.83 34.43 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 167.083 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.7 m0 -91.67 -74.44 0.51 Allowed 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 -173.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.4 128.14 45.89 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 95.5 m -127.33 163.69 23.43 Favored 'General case' 0 CA--C 1.499 -0.992 0 N-CA-C 105.563 -2.014 . . . . 0.0 105.563 170.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.262 1.718 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.081 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 16.8 m -127.07 -174.05 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.787 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 169.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 40.8 t90 -119.45 139.5 51.95 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 176.235 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.78 59.1 2.7 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.47 171.55 22.22 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -178.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -92.84 -43.51 8.96 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 124.17 0.988 . . . . 0.0 109.147 -173.232 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.9 p -106.88 -137.78 0.37 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -167.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.1 m -144.51 142.69 30.41 Favored 'General case' 0 C--N 1.356 0.858 0 N-CA-C 105.518 -2.031 . . . . 0.0 105.518 -170.02 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.15 -98.71 0.09 Allowed 'General case' 0 C--N 1.364 1.208 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 166.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.51 144.81 26.53 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 166.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.49 124.06 30.35 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 -177.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.67 -28.72 9.71 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.9 t -84.27 -65.69 0.98 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.7 -163.28 26.24 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 p -90.36 -175.35 4.46 Favored 'General case' 0 N--CA 1.421 -1.917 0 C-N-CA 126.566 1.946 . . . . 0.0 109.458 -175.515 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.21 153.38 42.77 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 171.043 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 23.0 m0 -89.68 -48.92 6.96 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 -177.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.4 mm -82.45 118.42 30.13 Favored 'Isoleucine or valine' 0 C--N 1.357 0.897 0 N-CA-C 106.233 -1.766 . . . . 0.0 106.233 178.344 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 69.9 m -124.0 166.21 16.12 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 -173.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--O 1.261 1.668 0 N-CA-C 107.348 -1.352 . . . . 0.0 107.348 -179.739 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 CA--C 1.507 -0.709 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.0 m -132.97 -170.55 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.811 0 N-CA-C 103.368 -2.827 . . . . 0.0 103.368 168.087 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.3 t-105 -137.97 147.46 44.29 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.24 47.92 5.02 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -127.81 171.57 19.11 Favored Glycine 0 C--N 1.352 1.455 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -175.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.4 m-20 -93.28 -39.49 10.94 Favored 'General case' 0 N--CA 1.44 -0.932 0 C-N-CA 124.994 1.318 . . . . 0.0 109.852 -172.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.0 p -113.54 -145.19 0.4 Allowed 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -170.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -139.3 144.78 38.48 Favored 'General case' 0 C--N 1.357 0.892 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 -170.5 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p30 -88.49 -100.7 0.09 Allowed 'General case' 0 C--N 1.368 1.385 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 165.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -92.05 158.72 16.07 Favored 'General case' 0 N--CA 1.436 -1.138 0 C-N-CA 126.234 1.814 . . . . 0.0 107.323 174.683 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.1 mt -82.49 123.29 29.03 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.74 -6.56 79.79 Favored Glycine 0 C--N 1.354 1.553 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 178.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 18.1 t -89.7 -69.81 0.7 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -176.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.69 -164.62 29.15 Favored Glycine 0 CA--C 1.489 -1.533 0 N-CA-C 107.612 -2.195 . . . . 0.0 107.612 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.9 p -88.48 179.45 6.3 Favored 'General case' 0 N--CA 1.417 -2.105 0 C-N-CA 125.862 1.665 . . . . 0.0 108.515 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.58 161.94 34.51 Favored 'General case' 0 CA--C 1.49 -1.341 0 N-CA-C 104.247 -2.501 . . . . 0.0 104.247 166.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.3 m0 -86.82 -73.26 0.47 Allowed 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -172.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.9 pt -97.5 148.92 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.964 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 174.008 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 65.7 m -141.53 163.61 32.47 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 175.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.26 1.64 0 CA-C-O 117.511 -1.233 . . . . 0.0 108.637 178.956 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 92.9 m . . . . . 0 CA--C 1.504 -0.793 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 m -133.39 -167.23 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 103.824 -2.658 . . . . 0.0 103.824 167.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.5 t-105 -140.35 143.7 35.9 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 175.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.5 55.4 2.59 Favored Glycine 0 C--N 1.354 1.56 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.7 168.27 24.79 Favored Glycine 0 CA--C 1.49 -1.484 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -176.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -91.35 -34.84 14.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 124.771 1.228 . . . . 0.0 110.434 -173.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -111.12 -153.93 0.53 Allowed 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -169.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.8 m -139.59 144.5 37.79 Favored 'General case' 0 C--N 1.355 0.832 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -169.095 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -88.12 -98.36 0.09 Allowed 'General case' 0 C--N 1.365 1.269 0 N-CA-C 104.206 -2.516 . . . . 0.0 104.206 166.612 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.05 147.78 22.56 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 167.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.4 tp -85.19 124.58 32.01 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 -177.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.7 -23.61 25.71 Favored Glycine 0 C--N 1.354 1.556 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.61 -67.0 0.83 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 -177.318 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.02 -164.13 29.77 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.0 p -88.95 -173.05 3.93 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.075 1.75 . . . . 0.0 108.692 -177.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.42 159.22 42.66 Favored 'General case' 0 CA--C 1.492 -1.269 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 171.06 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 29.7 m0 -104.01 -66.46 0.95 Allowed 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.099 -2.185 . . . . 0.0 105.099 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.9 mt -89.47 125.17 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 N-CA-C 105.137 -2.172 . . . . 0.0 105.137 174.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 2.0 p -150.23 -49.87 0.13 Allowed 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 106.319 -1.734 . . . . 0.0 106.319 -174.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 9.9 m . . . . . 0 C--O 1.26 1.621 0 C-N-CA 124.58 1.152 . . . . 0.0 108.21 179.794 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 CA--C 1.499 -1.016 0 CA-C-O 121.759 0.79 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -124.89 -165.19 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.812 -3.033 . . . . 0.0 102.812 165.447 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.9 t-105 -138.7 143.94 39.35 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.046 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.25 55.88 2.81 Favored Glycine 0 C--N 1.355 1.589 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.46 170.55 22.63 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -176.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -91.27 -39.5 12.04 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 124.944 1.298 . . . . 0.0 109.957 -171.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.9 p -114.59 -145.47 0.4 Allowed 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -169.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 40.8 m -141.33 143.64 34.14 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 -170.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -88.78 -100.21 0.09 Allowed 'General case' 0 C--N 1.364 1.226 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 167.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -88.17 155.75 19.6 Favored 'General case' 0 N--CA 1.436 -1.17 0 C-N-CA 126.842 2.057 . . . . 0.0 107.268 172.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 72.8 mt -81.78 123.68 28.99 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -176.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -17.83 58.59 Favored Glycine 0 C--N 1.355 1.598 0 C-N-CA 123.517 0.58 . . . . 0.0 111.669 176.362 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.4 t -84.69 -65.43 1.01 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.288 -1.005 . . . . 0.0 108.288 -175.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.18 -164.14 27.21 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.2 p -89.78 -177.83 5.35 Favored 'General case' 0 N--CA 1.418 -2.038 0 C-N-CA 126.354 1.862 . . . . 0.0 108.945 -177.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.64 162.46 35.41 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 167.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.9 m0 -89.95 -75.84 0.44 Allowed 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 -173.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.53 128.41 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 178.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 94.1 m -126.34 163.33 23.49 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 105.589 -2.004 . . . . 0.0 105.589 170.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.9 m . . . . . 0 C--O 1.261 1.682 0 CA-C-O 117.27 -1.348 . . . . 0.0 110.301 179.939 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.4 m . . . . . 0 CA--C 1.504 -0.791 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 17.6 m -133.71 -172.66 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 36.9 t90 -125.97 141.85 51.78 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 176.212 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.52 60.85 2.72 Favored Glycine 0 C--N 1.354 1.581 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 174.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.43 173.41 22.02 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 -176.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -88.09 -42.13 12.59 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 124.442 1.097 . . . . 0.0 110.184 -171.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 81.4 m -117.57 -133.37 0.33 Allowed 'General case' 0 C--N 1.357 0.893 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -168.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.7 m -145.43 144.67 30.76 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.932 -2.247 . . . . 0.0 104.932 -169.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.71 -98.25 0.09 Allowed 'General case' 0 C--N 1.364 1.227 0 N-CA-C 104.281 -2.488 . . . . 0.0 104.281 166.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -90.81 149.39 21.99 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 166.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.1 tp -84.52 125.32 32.29 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.19 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.55 -19.56 44.63 Favored Glycine 0 C--N 1.354 1.537 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -177.567 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -86.5 -68.16 0.76 Allowed 'General case' 0 C--N 1.357 0.907 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -176.488 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.36 -165.07 29.67 Favored Glycine 0 C--N 1.351 1.391 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.5 p -88.97 -173.29 4.02 Favored 'General case' 0 N--CA 1.42 -1.947 0 C-N-CA 126.268 1.827 . . . . 0.0 108.854 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -148.6 150.8 33.93 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.278 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.4 m0 -87.38 -55.82 3.63 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 -175.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.5 mt -85.48 126.76 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 N-CA-C 104.076 -2.564 . . . . 0.0 104.076 169.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 96.5 m -86.46 151.9 23.12 Favored 'General case' 0 CA--C 1.499 -0.998 0 CA-C-O 121.399 0.619 . . . . 0.0 109.998 -167.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 29.7 m . . . . . 0 C--O 1.261 1.693 0 CA-C-O 117.286 -1.34 . . . . 0.0 110.274 -176.842 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.5 -0.972 0 CA-C-O 121.839 0.828 . . . . 0.0 109.418 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.7 m -125.1 -167.08 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 102.307 -3.22 . . . . 0.0 102.307 164.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.5 t-105 -137.74 147.57 44.86 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 175.229 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.6 47.96 4.92 Favored Glycine 0 C--N 1.353 1.52 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -128.42 166.88 20.81 Favored Glycine 0 C--N 1.353 1.506 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -91.86 -39.5 11.71 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 124.794 1.238 . . . . 0.0 109.128 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.1 p -109.38 -145.49 0.4 Allowed 'General case' 0 C--N 1.354 0.796 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 -169.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.4 m -141.19 142.92 33.97 Favored 'General case' 0 C--N 1.356 0.855 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 -170.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -88.24 -99.02 0.09 Allowed 'General case' 0 C--N 1.365 1.249 0 N-CA-C 104.613 -2.366 . . . . 0.0 104.613 166.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -89.77 149.11 22.86 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 126.056 1.742 . . . . 0.0 106.319 169.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.1 mp -84.32 125.73 32.55 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.62 -28.4 13.48 Favored Glycine 0 C--N 1.354 1.58 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.0 t -83.3 -65.04 1.06 Allowed 'General case' 0 C--N 1.358 0.97 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -174.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.09 -164.56 28.66 Favored Glycine 0 C--N 1.353 1.484 0 N-CA-C 109.145 -1.582 . . . . 0.0 109.145 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 23.6 p -91.13 179.65 5.67 Favored 'General case' 0 N--CA 1.419 -1.992 0 C-N-CA 126.497 1.919 . . . . 0.0 108.551 -178.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.8 162.88 34.09 Favored 'General case' 0 CA--C 1.491 -1.297 0 N-CA-C 105.318 -2.104 . . . . 0.0 105.318 169.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.4 m0 -88.81 -75.07 0.44 Allowed 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -174.153 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.5 mt -96.59 125.49 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 N-CA-C 105.944 -1.873 . . . . 0.0 105.944 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 91.8 m -123.5 -52.01 1.83 Allowed 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 104.87 -2.27 . . . . 0.0 104.87 170.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.2 t . . . . . 0 C--O 1.259 1.587 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 177.723 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.7 m . . . . . 0 CA--C 1.503 -0.832 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.4 m -132.56 -168.13 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 104.21 -2.515 . . . . 0.0 104.21 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.5 t-105 -139.77 143.75 37.07 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 175.731 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.12 54.36 3.05 Favored Glycine 0 C--N 1.355 1.623 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.38 172.96 22.22 Favored Glycine 0 C--N 1.353 1.495 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 -177.001 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 -93.45 -41.02 10.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 123.831 0.853 . . . . 0.0 109.77 -170.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.4 p -110.88 -140.12 0.38 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -169.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.6 m -141.85 145.52 34.75 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 -170.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.66 -99.56 0.09 Allowed 'General case' 0 C--N 1.365 1.251 0 N-CA-C 104.382 -2.451 . . . . 0.0 104.382 165.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -88.43 148.81 24.02 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.031 1.732 . . . . 0.0 106.496 169.164 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.1 tt -83.84 117.93 23.62 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 -177.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.57 38.62 6.15 Favored Glycine 0 C--N 1.353 1.491 0 N-CA-C 108.94 -1.664 . . . . 0.0 108.94 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.5 t -138.54 -68.44 0.45 Allowed 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.428 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.46 -165.72 30.71 Favored Glycine 0 CA--C 1.492 -1.384 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.77 -172.32 3.67 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.214 1.805 . . . . 0.0 108.812 -178.121 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.78 150.48 38.63 Favored 'General case' 0 CA--C 1.494 -1.211 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 169.357 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 22.1 m0 -89.19 -50.29 6.23 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -175.693 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.5 mt -82.28 119.39 31.73 Favored 'Isoleucine or valine' 0 C--N 1.356 0.881 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 177.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 75.6 m -124.19 -49.89 1.81 Allowed 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 -174.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.26 1.658 0 CA-C-O 117.518 -1.229 . . . . 0.0 108.193 176.886 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.4 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.4 m -133.66 -168.75 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 N-CA-C 103.422 -2.807 . . . . 0.0 103.422 167.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 59.0 t-105 -139.26 145.32 39.04 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.09 53.59 3.27 Favored Glycine 0 C--N 1.355 1.621 0 N-CA-C 108.989 -1.644 . . . . 0.0 108.989 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.71 172.64 21.55 Favored Glycine 0 CA--C 1.49 -1.489 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -176.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -91.49 -40.03 11.62 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 124.838 1.255 . . . . 0.0 109.964 -171.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 11.1 p -114.18 -144.78 0.39 Allowed 'General case' 0 C--N 1.354 0.761 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 -170.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 35.0 m -139.76 144.69 37.55 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 105.864 -1.902 . . . . 0.0 105.864 -169.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.96 -98.79 0.09 Allowed 'General case' 0 C--N 1.368 1.375 0 N-CA-C 104.14 -2.541 . . . . 0.0 104.14 165.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -92.93 148.1 22.29 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 167.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.42 124.7 32.3 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -22.73 29.14 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.5 t -84.77 -67.14 0.82 Allowed 'General case' 0 N--CA 1.443 -0.811 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 -177.402 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.14 -163.9 29.47 Favored Glycine 0 CA--C 1.492 -1.395 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.4 p -88.81 -178.64 5.81 Favored 'General case' 0 N--CA 1.416 -2.16 0 C-N-CA 125.893 1.677 . . . . 0.0 108.656 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -137.93 161.7 35.98 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 103.946 -2.613 . . . . 0.0 103.946 165.386 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.9 m0 -87.58 -72.68 0.51 Allowed 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 -172.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.4 pt -96.23 148.91 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 173.426 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.4 m -140.72 -52.89 0.48 Allowed 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 104.297 -2.483 . . . . 0.0 104.297 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 C--O 1.26 1.646 0 C-N-CA 123.981 0.913 . . . . 0.0 109.915 177.568 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.499 -0.988 0 CA-C-O 121.881 0.848 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.2 m -124.17 -167.45 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 N-CA-C 102.211 -3.255 . . . . 0.0 102.211 164.205 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.0 t-105 -137.63 148.77 46.08 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 175.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.77 45.26 5.8 Favored Glycine 0 C--N 1.355 1.588 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -178.319 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -125.16 166.81 17.72 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -175.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -92.58 -39.19 11.48 Favored 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 124.775 1.23 . . . . 0.0 109.025 -174.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.8 p -109.49 -145.44 0.4 Allowed 'General case' 0 C--N 1.355 0.829 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 -169.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.0 m -140.66 142.54 34.94 Favored 'General case' 0 C--N 1.356 0.853 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -170.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.02 -98.63 0.09 Allowed 'General case' 0 C--N 1.365 1.266 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 165.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -90.64 143.7 26.48 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 168.456 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.1 tp -84.53 123.15 29.97 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -177.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.61 -30.68 7.07 Favored Glycine 0 C--N 1.353 1.507 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -177.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.5 t -83.55 -63.86 1.27 Allowed 'General case' 0 C--N 1.357 0.919 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -175.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.49 -164.43 28.7 Favored Glycine 0 C--N 1.352 1.435 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.2 p -91.66 178.07 6.03 Favored 'General case' 0 N--CA 1.418 -2.061 0 C-N-CA 126.63 1.972 . . . . 0.0 108.252 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -137.42 163.03 32.06 Favored 'General case' 0 CA--C 1.491 -1.313 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 168.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.6 m0 -88.04 -74.38 0.45 Allowed 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -173.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 42.0 mm -98.3 127.39 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 91.0 m -124.47 -52.16 1.72 Allowed 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 171.292 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.0 t . . . . . 0 C--O 1.261 1.668 0 N-CA-C 106.492 -1.669 . . . . 0.0 106.492 177.734 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 N--CA 1.44 -0.973 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.3 m -126.73 -168.03 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 N-CA-C 104.128 -2.545 . . . . 0.0 104.128 168.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 35.5 t90 -128.42 141.1 51.51 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 177.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.09 56.14 2.95 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 110.066 -1.213 . . . . 0.0 110.066 173.163 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.15 170.34 22.95 Favored Glycine 0 CA--C 1.491 -1.437 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -178.281 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -95.12 -37.96 10.83 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.562 1.145 . . . . 0.0 108.696 -174.217 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.3 p -105.72 -153.22 0.49 Allowed 'General case' 0 C--N 1.353 0.744 0 N-CA-C 106.938 -1.505 . . . . 0.0 106.938 -168.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.8 m -140.91 143.31 34.55 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -169.057 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p30 -89.13 -100.26 0.09 Allowed 'General case' 0 C--N 1.365 1.248 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 168.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -87.04 155.28 20.21 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 126.789 2.036 . . . . 0.0 107.179 171.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.7 mt -81.55 123.33 28.56 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -176.039 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.91 -17.4 59.33 Favored Glycine 0 C--N 1.354 1.549 0 C-N-CA 123.519 0.581 . . . . 0.0 111.73 176.323 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.6 t -84.74 -65.95 0.95 Allowed 'General case' 0 C--N 1.358 0.978 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -171.65 -163.22 25.23 Favored Glycine 0 C--N 1.353 1.493 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 33.1 p -89.74 -175.69 4.72 Favored 'General case' 0 N--CA 1.42 -1.967 0 C-N-CA 126.363 1.865 . . . . 0.0 109.026 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -138.94 162.5 34.7 Favored 'General case' 0 CA--C 1.492 -1.261 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 170.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 29.0 m0 -106.19 -65.73 1.05 Allowed 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 105.089 -2.189 . . . . 0.0 105.089 177.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.7 mt -88.71 124.09 41.4 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 N-CA-C 105.13 -2.174 . . . . 0.0 105.13 175.011 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.7 p -150.11 -60.09 0.2 Allowed 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 105.4 -2.074 . . . . 0.0 105.4 -174.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--O 1.261 1.685 0 CA-C-O 117.232 -1.366 . . . . 0.0 109.712 177.394 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.9 m . . . . . 0 CA--C 1.502 -0.895 0 CA-C-O 119.506 -0.283 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.7 m -84.96 166.88 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.844 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 -179.022 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 44.1 t-105 -121.12 149.67 42.42 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -174.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.23 41.56 5.17 Favored Glycine 0 C--N 1.354 1.559 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -178.195 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -126.7 172.59 18.3 Favored Glycine 0 C--N 1.353 1.5 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -176.486 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -102.18 -39.61 7.17 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.469 1.107 . . . . 0.0 108.196 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.2 p -98.69 -143.75 0.32 Allowed 'General case' 0 C--N 1.353 0.753 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 -168.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.04 143.29 31.11 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 -170.234 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.6 p30 -88.82 -100.94 0.09 Allowed 'General case' 0 C--N 1.364 1.215 0 N-CA-C 104.688 -2.338 . . . . 0.0 104.688 167.3 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -90.53 160.18 16.1 Favored 'General case' 0 N--CA 1.436 -1.15 0 C-N-CA 126.741 2.016 . . . . 0.0 107.038 171.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 74.8 mt -81.89 121.55 26.61 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -176.017 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.07 -6.89 79.02 Favored Glycine 0 C--N 1.354 1.553 0 C-N-CA 123.641 0.639 . . . . 0.0 111.67 177.273 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -88.85 -62.87 1.39 Allowed 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 -176.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.05 -164.17 30.38 Favored Glycine 0 C--N 1.35 1.358 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 178.322 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.9 p -88.92 -173.52 4.12 Favored 'General case' 0 N--CA 1.418 -2.04 0 C-N-CA 126.608 1.963 . . . . 0.0 108.087 178.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.61 162.16 37.32 Favored 'General case' 0 CA--C 1.491 -1.305 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 175.536 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -101.13 -67.45 0.86 Allowed 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 177.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.5 mt -89.33 121.05 39.01 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.877 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 176.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.4 p -151.22 168.5 24.51 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 -175.655 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.259 1.563 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 177.836 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.3 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.4 m -134.7 -167.59 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 N-CA-C 103.8 -2.667 . . . . 0.0 103.8 168.554 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.9 t-105 -140.74 141.62 34.87 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 176.256 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.45 59.93 2.18 Favored Glycine 0 C--N 1.356 1.646 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -137.97 177.62 19.84 Favored Glycine 0 CA--C 1.488 -1.615 0 N-CA-C 108.926 -1.669 . . . . 0.0 108.926 -174.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -88.77 -44.53 10.47 Favored 'General case' 0 N--CA 1.44 -0.949 0 C-N-CA 124.226 1.011 . . . . 0.0 110.322 -170.693 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 71.9 m -119.79 -131.77 0.3 Allowed 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 -168.764 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 m -144.34 145.15 31.81 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 105.139 -2.171 . . . . 0.0 105.139 -169.302 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -88.78 -98.95 0.09 Allowed 'General case' 0 C--N 1.366 1.289 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 165.419 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -90.25 148.71 22.74 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 167.212 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.26 125.2 32.02 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 -176.303 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.0 -19.86 42.51 Favored Glycine 0 C--N 1.356 1.642 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -177.375 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.2 t -86.48 -68.16 0.76 Allowed 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -176.609 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.61 -164.41 29.43 Favored Glycine 0 CA--C 1.492 -1.393 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.539 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 40.5 p -88.69 -172.94 3.93 Favored 'General case' 0 N--CA 1.421 -1.912 0 C-N-CA 126.204 1.802 . . . . 0.0 109.062 -177.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.88 146.94 36.36 Favored 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 169.077 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 26.9 m0 -87.54 -49.83 6.93 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -176.137 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 57.2 mt -82.45 117.55 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.834 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 177.506 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -145.63 -52.15 0.26 Allowed 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.261 1.683 0 CA-C-O 117.534 -1.222 . . . . 0.0 108.248 177.595 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 CA--C 1.506 -0.748 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.68 -166.27 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.772 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 167.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.7 t-105 -140.28 145.16 36.93 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 87.35 53.76 2.71 Favored Glycine 0 C--N 1.354 1.548 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.43 168.93 24.75 Favored Glycine 0 C--N 1.352 1.452 0 N-CA-C 107.513 -2.235 . . . . 0.0 107.513 -179.19 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -94.32 -32.97 13.38 Favored 'General case' 0 CA--C 1.501 -0.937 0 C-N-CA 124.138 0.975 . . . . 0.0 109.156 -175.824 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.3 m -101.3 -155.51 0.52 Allowed 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -170.422 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.8 m -140.86 144.86 35.55 Favored 'General case' 0 C--N 1.358 0.963 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 -171.096 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -88.61 -98.74 0.09 Allowed 'General case' 0 C--N 1.366 1.315 0 N-CA-C 104.138 -2.542 . . . . 0.0 104.138 165.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.8 m-85 -91.91 148.75 21.98 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 167.546 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -84.8 124.97 32.17 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -176.816 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.56 -21.74 34.02 Favored Glycine 0 C--N 1.353 1.492 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -177.104 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -85.29 -67.61 0.79 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -176.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -175.44 -164.59 30.21 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 44.4 p -88.92 -176.81 5.31 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.103 1.761 . . . . 0.0 108.852 -177.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.21 151.96 41.2 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 166.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 17.8 m0 -91.27 -56.38 3.17 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -173.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 54.8 mt -83.02 113.34 22.05 Favored 'Isoleucine or valine' 0 C--N 1.355 0.841 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 -176.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.3 p -152.16 165.38 34.99 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 105.794 -1.928 . . . . 0.0 105.794 177.714 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 40.7 t . . . . . 0 C--O 1.26 1.616 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.057 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.5 m . . . . . 0 CA--C 1.506 -0.718 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.65 -168.09 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 N-CA-C 103.495 -2.78 . . . . 0.0 103.495 167.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.4 t-105 -140.0 144.29 36.9 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 174.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.88 55.05 2.48 Favored Glycine 0 C--N 1.354 1.536 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.04 170.69 23.95 Favored Glycine 0 C--N 1.352 1.453 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -93.81 -38.06 11.44 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.393 1.077 . . . . 0.0 108.868 -174.101 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.5 p -105.86 -154.55 0.52 Allowed 'General case' 0 C--N 1.354 0.784 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 -169.318 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 37.8 m -139.39 144.53 38.19 Favored 'General case' 0 CA--C 1.504 -0.802 0 N-CA-C 105.913 -1.884 . . . . 0.0 105.913 -168.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.1 p30 -88.21 -99.17 0.09 Allowed 'General case' 0 C--N 1.366 1.323 0 N-CA-C 104.295 -2.483 . . . . 0.0 104.295 166.122 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -92.23 151.76 20.18 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 169.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.0 mp -85.11 126.36 33.54 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 -176.649 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.64 -19.63 49.51 Favored Glycine 0 C--N 1.354 1.575 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -178.19 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 15.7 t -86.0 -69.0 0.7 Allowed 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 -176.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.97 -164.13 29.21 Favored Glycine 0 CA--C 1.491 -1.444 0 N-CA-C 107.896 -2.082 . . . . 0.0 107.896 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.6 -173.47 4.16 Favored 'General case' 0 N--CA 1.418 -2.028 0 C-N-CA 126.108 1.763 . . . . 0.0 108.676 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -138.61 158.41 44.3 Favored 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 105.817 -1.919 . . . . 0.0 105.817 170.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 30.8 m0 -100.36 -70.09 0.75 Allowed 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 105.26 -2.126 . . . . 0.0 105.26 178.521 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.1 tp -87.15 133.63 29.6 Favored 'Isoleucine or valine' 0 C--N 1.356 0.85 0 N-CA-C 106.127 -1.805 . . . . 0.0 106.127 171.255 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.4 p -151.58 -65.3 0.18 Allowed 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 105.189 -2.152 . . . . 0.0 105.189 -174.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 40.3 t . . . . . 0 C--O 1.26 1.606 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 177.646 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.1 m . . . . . 0 CA--C 1.506 -0.725 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.24 -171.95 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 N-CA-C 104.825 -2.287 . . . . 0.0 104.825 170.367 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 34.0 t90 -128.07 144.77 51.12 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.1 -1.815 . . . . 0.0 106.1 176.694 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.38 56.02 3.53 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 174.519 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.64 171.01 22.15 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -176.477 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -91.1 -39.34 12.22 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 124.953 1.301 . . . . 0.0 109.939 -172.16 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -115.2 -143.88 0.38 Allowed 'General case' 0 C--N 1.355 0.813 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 -169.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.4 m -140.55 144.62 36.01 Favored 'General case' 0 C--N 1.354 0.804 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 -169.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -88.03 -98.55 0.09 Allowed 'General case' 0 C--N 1.367 1.346 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 166.34 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -92.41 148.49 22.07 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 105.732 -1.951 . . . . 0.0 105.732 167.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.3 tp -84.77 125.01 32.19 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 -176.623 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.99 -20.9 37.29 Favored Glycine 0 C--N 1.353 1.476 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.109 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.9 t -85.61 -67.51 0.8 Allowed 'General case' 0 C--N 1.356 0.859 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -177.112 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.32 -164.67 29.65 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.7 p -89.08 -177.48 5.45 Favored 'General case' 0 N--CA 1.418 -2.044 0 C-N-CA 125.93 1.692 . . . . 0.0 108.593 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.58 162.19 36.11 Favored 'General case' 0 CA--C 1.489 -1.402 0 N-CA-C 104.395 -2.446 . . . . 0.0 104.395 167.079 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 14.9 m0 -89.25 -72.97 0.53 Allowed 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -172.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 mm -98.94 129.35 49.45 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 91.9 m -127.93 163.65 24.02 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 105.442 -2.058 . . . . 0.0 105.442 171.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 31.5 m . . . . . 0 C--O 1.261 1.687 0 CA-C-O 117.22 -1.371 . . . . 0.0 110.3 179.603 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.6 t . . . . . 0 CA--C 1.498 -1.052 0 CA-C-O 121.743 0.783 . . . . 0.0 109.138 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.2 m -127.66 -164.86 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 103.039 -2.948 . . . . 0.0 103.039 167.683 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.9 t-105 -139.55 143.85 37.56 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.261 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.66 51.45 3.64 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.58 170.44 22.36 Favored Glycine 0 C--N 1.353 1.48 0 N-CA-C 107.707 -2.157 . . . . 0.0 107.707 -177.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -91.74 -42.43 10.14 Favored 'General case' 0 N--CA 1.441 -0.919 0 C-N-CA 124.142 0.977 . . . . 0.0 109.119 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.6 p -107.44 -141.6 0.38 Allowed 'General case' 0 C--N 1.354 0.8 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 -167.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 54.1 m -143.16 144.06 32.05 Favored 'General case' 0 C--N 1.356 0.85 0 N-CA-C 105.445 -2.057 . . . . 0.0 105.445 -170.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 p30 -88.9 -99.8 0.09 Allowed 'General case' 0 C--N 1.364 1.238 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 167.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -82.76 149.33 27.31 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 127.029 2.131 . . . . 0.0 106.994 173.763 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.5 mt -79.1 109.46 13.43 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 -178.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 52.46 2.76 Favored Glycine 0 C--N 1.354 1.539 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -145.93 -72.03 0.24 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 173.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -164.09 -163.07 16.21 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.1 p -89.67 -174.5 4.33 Favored 'General case' 0 N--CA 1.418 -2.029 0 C-N-CA 126.424 1.889 . . . . 0.0 109.129 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.02 151.99 42.98 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 169.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 24.1 m0 -89.72 -48.91 6.96 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 -176.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.9 mt -82.27 118.81 30.65 Favored 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 105.851 -1.907 . . . . 0.0 105.851 177.309 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 84.8 m -123.83 165.9 16.53 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -173.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.0 m . . . . . 0 C--O 1.258 1.548 0 C-N-CA 123.787 0.835 . . . . 0.0 110.327 -179.739 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.3 m . . . . . 0 CA--C 1.505 -0.755 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.6 m -133.23 -166.84 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 103.533 -2.765 . . . . 0.0 103.533 167.337 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.5 t-105 -141.64 143.75 33.79 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 106.692 -1.595 . . . . 0.0 106.692 176.141 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.79 55.09 2.48 Favored Glycine 0 C--N 1.353 1.511 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.19 172.06 23.37 Favored Glycine 0 C--N 1.352 1.432 0 N-CA-C 107.999 -2.04 . . . . 0.0 107.999 -178.287 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -94.34 -37.95 11.23 Favored 'General case' 0 N--CA 1.44 -0.947 0 C-N-CA 124.446 1.098 . . . . 0.0 108.784 -174.419 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -104.14 -156.6 0.57 Allowed 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -169.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.1 m -139.55 144.19 37.72 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 -168.53 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.04 -98.62 0.09 Allowed 'General case' 0 C--N 1.368 1.372 0 N-CA-C 104.189 -2.523 . . . . 0.0 104.189 166.121 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -92.55 147.86 22.55 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 167.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.23 124.57 32.02 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 -177.12 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.27 -22.79 28.45 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -176.605 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.3 t -84.79 -67.19 0.82 Allowed 'General case' 0 C--N 1.357 0.905 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 -177.407 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.13 -163.73 29.18 Favored Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 107.86 -2.096 . . . . 0.0 107.86 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.4 p -88.62 -173.35 4.11 Favored 'General case' 0 N--CA 1.416 -2.126 0 C-N-CA 126.028 1.731 . . . . 0.0 108.706 -178.003 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.82 161.13 36.82 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 170.154 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -107.77 -65.27 1.13 Allowed 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 104.993 -2.225 . . . . 0.0 104.993 177.686 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.8 mt -87.9 118.39 33.52 Favored 'Isoleucine or valine' 0 C--N 1.356 0.864 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 175.5 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.0 p -151.47 168.72 23.99 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 -175.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.262 1.716 0 CA-C-O 117.427 -1.273 . . . . 0.0 108.499 177.437 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.0 m . . . . . 0 N--CA 1.444 -0.753 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -134.33 -168.17 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.752 0 N-CA-C 103.938 -2.616 . . . . 0.0 103.938 169.398 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.3 t-105 -139.66 143.58 37.21 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 106.379 -1.712 . . . . 0.0 106.379 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.21 53.44 3.12 Favored Glycine 0 C--N 1.355 1.625 0 N-CA-C 108.789 -1.724 . . . . 0.0 108.789 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.16 168.61 23.99 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.99 -2.044 . . . . 0.0 107.99 -176.004 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -92.89 -34.22 13.89 Favored 'General case' 0 N--CA 1.442 -0.846 0 C-N-CA 124.278 1.031 . . . . 0.0 111.455 -170.062 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.1 m -115.8 -137.5 0.36 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 -174.794 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.24 145.97 32.37 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 105.392 -2.077 . . . . 0.0 105.392 -169.198 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -89.38 -100.82 0.09 Allowed 'General case' 0 C--N 1.365 1.273 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 166.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -88.23 155.98 19.46 Favored 'General case' 0 N--CA 1.435 -1.195 0 C-N-CA 126.515 1.926 . . . . 0.0 107.119 172.484 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.3 mt -80.68 122.49 27.18 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 123.669 0.788 . . . . 0.0 109.048 -174.467 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.84 -3.94 81.41 Favored Glycine 0 C--N 1.354 1.579 0 C-N-CA 123.74 0.686 . . . . 0.0 111.663 178.159 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.8 t -90.91 -70.79 0.66 Allowed 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 -176.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -170.33 -165.29 27.45 Favored Glycine 0 CA--C 1.491 -1.419 0 N-CA-C 108.102 -1.999 . . . . 0.0 108.102 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.7 p -88.63 -173.17 4.04 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.036 1.734 . . . . 0.0 109.027 -177.212 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.08 148.53 36.8 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 169.587 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 24.0 m0 -88.54 -49.18 7.06 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 -176.551 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.2 mm -82.5 119.48 32.11 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 178.328 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.2 t -150.5 -52.42 0.14 Allowed 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 105.172 -2.158 . . . . 0.0 105.172 -176.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.4 t . . . . . 0 C--O 1.259 1.574 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 -178.781 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.5 -0.97 0 CA-C-O 121.763 0.792 . . . . 0.0 109.189 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.6 m -126.57 -164.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.855 0 N-CA-C 102.983 -2.969 . . . . 0.0 102.983 166.494 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.8 t-105 -139.4 142.15 37.5 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.132 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.91 58.16 2.55 Favored Glycine 0 C--N 1.354 1.565 0 N-CA-C 108.816 -1.713 . . . . 0.0 108.816 -179.622 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.93 174.83 20.94 Favored Glycine 0 CA--C 1.49 -1.479 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -174.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -90.17 -42.94 10.76 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 124.415 1.086 . . . . 0.0 110.136 -170.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.8 m -119.32 -133.94 0.32 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -168.622 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.4 m -145.3 143.63 30.3 Favored 'General case' 0 C--N 1.356 0.883 0 N-CA-C 105.331 -2.1 . . . . 0.0 105.331 -168.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.05 -98.86 0.09 Allowed 'General case' 0 C--N 1.364 1.204 0 N-CA-C 104.554 -2.388 . . . . 0.0 104.554 166.561 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.97 144.55 26.48 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 167.126 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.62 123.89 30.25 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.245 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.01 -28.62 9.62 Favored Glycine 0 C--N 1.353 1.483 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.26 -65.14 1.04 Allowed 'General case' 0 C--N 1.358 0.937 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -174.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.98 -163.66 27.1 Favored Glycine 0 C--N 1.353 1.497 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 36.9 p -89.91 -174.85 4.41 Favored 'General case' 0 N--CA 1.42 -1.931 0 C-N-CA 126.667 1.987 . . . . 0.0 109.361 -176.127 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.18 149.39 39.65 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 169.4 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 25.1 m0 -87.33 -50.61 6.46 Favored 'General case' 0 CA--C 1.5 -0.98 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -176.318 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.5 tt -79.18 134.14 28.44 Favored 'Isoleucine or valine' 0 C--N 1.354 0.776 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 175.301 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.1 t -150.81 155.42 39.18 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 105.587 -2.005 . . . . 0.0 105.587 -175.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.259 1.58 0 C-N-CA 124.036 0.934 . . . . 0.0 108.574 178.238 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.1 m . . . . . 0 CA--C 1.504 -0.796 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.8 m -132.92 -168.51 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.6 t-105 -139.19 143.57 38.15 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 174.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.43 58.69 2.25 Favored Glycine 0 C--N 1.356 1.68 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.84 172.79 22.93 Favored Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 -177.178 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -90.62 -40.13 12.1 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 124.765 1.226 . . . . 0.0 110.023 -171.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -114.32 -144.61 0.39 Allowed 'General case' 0 C--N 1.354 0.772 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -170.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 45.2 m -140.95 144.4 35.11 Favored 'General case' 0 C--N 1.355 0.845 0 N-CA-C 105.739 -1.948 . . . . 0.0 105.739 -169.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.81 -98.46 0.08 Allowed 'General case' 0 C--N 1.367 1.343 0 N-CA-C 104.238 -2.504 . . . . 0.0 104.238 165.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.02 147.96 22.4 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.5 tp -85.44 124.78 32.42 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.48 -23.33 26.82 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -176.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.77 -67.03 0.83 Allowed 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.51 -164.07 29.93 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 107.902 -2.079 . . . . 0.0 107.902 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 35.8 p -88.61 -176.4 5.26 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 126.047 1.739 . . . . 0.0 108.809 -178.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.272 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 167.083 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 16.8 m -127.07 -174.05 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.787 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 169.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 40.8 t90 -119.45 139.5 51.95 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 176.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.78 59.1 2.7 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.47 171.55 22.22 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -178.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -92.84 -43.51 8.96 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 124.17 0.988 . . . . 0.0 109.147 -173.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.9 p -106.88 -137.78 0.37 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -167.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.1 m -144.51 142.69 30.41 Favored 'General case' 0 C--N 1.356 0.858 0 N-CA-C 105.518 -2.031 . . . . 0.0 105.518 -170.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.15 -98.71 0.09 Allowed 'General case' 0 C--N 1.364 1.208 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 166.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.51 144.81 26.53 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 166.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.49 124.06 30.35 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 -177.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.67 -28.72 9.71 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.9 t -84.27 -65.69 0.98 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.7 -163.28 26.24 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 p -90.36 -175.35 4.46 Favored 'General case' 0 N--CA 1.421 -1.917 0 C-N-CA 126.566 1.946 . . . . 0.0 109.458 -175.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.223 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 171.043 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 CA--C 1.507 -0.709 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.0 m -132.97 -170.55 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.811 0 N-CA-C 103.368 -2.827 . . . . 0.0 103.368 168.087 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.3 t-105 -137.97 147.46 44.29 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.24 47.92 5.02 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -127.81 171.57 19.11 Favored Glycine 0 C--N 1.352 1.455 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -175.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.4 m-20 -93.28 -39.49 10.94 Favored 'General case' 0 N--CA 1.44 -0.932 0 C-N-CA 124.994 1.318 . . . . 0.0 109.852 -172.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.0 p -113.54 -145.19 0.4 Allowed 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -170.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -139.3 144.78 38.48 Favored 'General case' 0 C--N 1.357 0.892 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 -170.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p30 -88.49 -100.7 0.09 Allowed 'General case' 0 C--N 1.368 1.385 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 165.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -92.05 158.72 16.07 Favored 'General case' 0 N--CA 1.436 -1.138 0 C-N-CA 126.234 1.814 . . . . 0.0 107.323 174.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.1 mt -82.49 123.29 29.03 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.74 -6.56 79.79 Favored Glycine 0 C--N 1.354 1.553 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 178.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 18.1 t -89.7 -69.81 0.7 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -176.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.69 -164.62 29.15 Favored Glycine 0 CA--C 1.489 -1.533 0 N-CA-C 107.612 -2.195 . . . . 0.0 107.612 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.9 p -88.48 179.45 6.3 Favored 'General case' 0 N--CA 1.417 -2.105 0 C-N-CA 125.862 1.665 . . . . 0.0 108.515 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.341 0 N-CA-C 104.247 -2.501 . . . . 0.0 104.247 166.806 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 92.9 m . . . . . 0 CA--C 1.504 -0.793 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 m -133.39 -167.23 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 103.824 -2.658 . . . . 0.0 103.824 167.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.5 t-105 -140.35 143.7 35.9 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 175.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.5 55.4 2.59 Favored Glycine 0 C--N 1.354 1.56 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.7 168.27 24.79 Favored Glycine 0 CA--C 1.49 -1.484 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -176.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -91.35 -34.84 14.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 124.771 1.228 . . . . 0.0 110.434 -173.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -111.12 -153.93 0.53 Allowed 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -169.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.8 m -139.59 144.5 37.79 Favored 'General case' 0 C--N 1.355 0.832 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -169.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -88.12 -98.36 0.09 Allowed 'General case' 0 C--N 1.365 1.269 0 N-CA-C 104.206 -2.516 . . . . 0.0 104.206 166.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.05 147.78 22.56 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 167.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.4 tp -85.19 124.58 32.01 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 -177.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.7 -23.61 25.71 Favored Glycine 0 C--N 1.354 1.556 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.61 -67.0 0.83 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 -177.318 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.02 -164.13 29.77 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.0 p -88.95 -173.05 3.93 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.075 1.75 . . . . 0.0 108.692 -177.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.269 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 171.06 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 CA--C 1.499 -1.016 0 CA-C-O 121.759 0.79 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -124.89 -165.19 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.812 -3.033 . . . . 0.0 102.812 165.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.9 t-105 -138.7 143.94 39.35 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.25 55.88 2.81 Favored Glycine 0 C--N 1.355 1.589 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.46 170.55 22.63 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -176.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -91.27 -39.5 12.04 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 124.944 1.298 . . . . 0.0 109.957 -171.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.9 p -114.59 -145.47 0.4 Allowed 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -169.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 40.8 m -141.33 143.64 34.14 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 -170.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -88.78 -100.21 0.09 Allowed 'General case' 0 C--N 1.364 1.226 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 167.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -88.17 155.75 19.6 Favored 'General case' 0 N--CA 1.436 -1.17 0 C-N-CA 126.842 2.057 . . . . 0.0 107.268 172.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 72.8 mt -81.78 123.68 28.99 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -176.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -17.83 58.59 Favored Glycine 0 C--N 1.355 1.598 0 C-N-CA 123.517 0.58 . . . . 0.0 111.669 176.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.4 t -84.69 -65.43 1.01 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.288 -1.005 . . . . 0.0 108.288 -175.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.18 -164.14 27.21 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.2 p -89.78 -177.83 5.35 Favored 'General case' 0 N--CA 1.418 -2.038 0 C-N-CA 126.354 1.862 . . . . 0.0 108.945 -177.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.332 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 167.785 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.4 m . . . . . 0 CA--C 1.504 -0.791 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 17.6 m -133.71 -172.66 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 36.9 t90 -125.97 141.85 51.78 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 176.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.52 60.85 2.72 Favored Glycine 0 C--N 1.354 1.581 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 174.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.43 173.41 22.02 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 -176.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -88.09 -42.13 12.59 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 124.442 1.097 . . . . 0.0 110.184 -171.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 81.4 m -117.57 -133.37 0.33 Allowed 'General case' 0 C--N 1.357 0.893 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -168.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.7 m -145.43 144.67 30.76 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.932 -2.247 . . . . 0.0 104.932 -169.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.71 -98.25 0.09 Allowed 'General case' 0 C--N 1.364 1.227 0 N-CA-C 104.281 -2.488 . . . . 0.0 104.281 166.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -90.81 149.39 21.99 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 166.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.1 tp -84.52 125.32 32.29 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.55 -19.56 44.63 Favored Glycine 0 C--N 1.354 1.537 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -177.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -86.5 -68.16 0.76 Allowed 'General case' 0 C--N 1.357 0.907 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -176.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.36 -165.07 29.67 Favored Glycine 0 C--N 1.351 1.391 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.5 p -88.97 -173.29 4.02 Favored 'General case' 0 N--CA 1.42 -1.947 0 C-N-CA 126.268 1.827 . . . . 0.0 108.854 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.24 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.278 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.5 -0.972 0 CA-C-O 121.839 0.828 . . . . 0.0 109.418 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.7 m -125.1 -167.08 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 102.307 -3.22 . . . . 0.0 102.307 164.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.5 t-105 -137.74 147.57 44.86 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 175.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.6 47.96 4.92 Favored Glycine 0 C--N 1.353 1.52 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -128.42 166.88 20.81 Favored Glycine 0 C--N 1.353 1.506 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -91.86 -39.5 11.71 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 124.794 1.238 . . . . 0.0 109.128 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.1 p -109.38 -145.49 0.4 Allowed 'General case' 0 C--N 1.354 0.796 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 -169.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.4 m -141.19 142.92 33.97 Favored 'General case' 0 C--N 1.356 0.855 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 -170.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -88.24 -99.02 0.09 Allowed 'General case' 0 C--N 1.365 1.249 0 N-CA-C 104.613 -2.366 . . . . 0.0 104.613 166.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -89.77 149.11 22.86 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 126.056 1.742 . . . . 0.0 106.319 169.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.1 mp -84.32 125.73 32.55 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.62 -28.4 13.48 Favored Glycine 0 C--N 1.354 1.58 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.0 t -83.3 -65.04 1.06 Allowed 'General case' 0 C--N 1.358 0.97 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -174.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.09 -164.56 28.66 Favored Glycine 0 C--N 1.353 1.484 0 N-CA-C 109.145 -1.582 . . . . 0.0 109.145 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 23.6 p -91.13 179.65 5.67 Favored 'General case' 0 N--CA 1.419 -1.992 0 C-N-CA 126.497 1.919 . . . . 0.0 108.551 -178.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.297 0 N-CA-C 105.318 -2.104 . . . . 0.0 105.318 169.034 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.7 m . . . . . 0 CA--C 1.503 -0.832 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.4 m -132.56 -168.13 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 104.21 -2.515 . . . . 0.0 104.21 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.5 t-105 -139.77 143.75 37.07 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 175.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.12 54.36 3.05 Favored Glycine 0 C--N 1.355 1.623 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.38 172.96 22.22 Favored Glycine 0 C--N 1.353 1.495 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 -177.001 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 -93.45 -41.02 10.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 123.831 0.853 . . . . 0.0 109.77 -170.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.4 p -110.88 -140.12 0.38 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -169.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.6 m -141.85 145.52 34.75 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 -170.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.66 -99.56 0.09 Allowed 'General case' 0 C--N 1.365 1.251 0 N-CA-C 104.382 -2.451 . . . . 0.0 104.382 165.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -88.43 148.81 24.02 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.031 1.732 . . . . 0.0 106.496 169.164 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.1 tt -83.84 117.93 23.62 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 -177.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.57 38.62 6.15 Favored Glycine 0 C--N 1.353 1.491 0 N-CA-C 108.94 -1.664 . . . . 0.0 108.94 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.5 t -138.54 -68.44 0.45 Allowed 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.46 -165.72 30.71 Favored Glycine 0 CA--C 1.492 -1.384 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.77 -172.32 3.67 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.214 1.805 . . . . 0.0 108.812 -178.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.211 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 169.357 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.4 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.4 m -133.66 -168.75 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 N-CA-C 103.422 -2.807 . . . . 0.0 103.422 167.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 59.0 t-105 -139.26 145.32 39.04 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.09 53.59 3.27 Favored Glycine 0 C--N 1.355 1.621 0 N-CA-C 108.989 -1.644 . . . . 0.0 108.989 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.71 172.64 21.55 Favored Glycine 0 CA--C 1.49 -1.489 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -176.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -91.49 -40.03 11.62 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 124.838 1.255 . . . . 0.0 109.964 -171.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 11.1 p -114.18 -144.78 0.39 Allowed 'General case' 0 C--N 1.354 0.761 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 -170.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 35.0 m -139.76 144.69 37.55 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 105.864 -1.902 . . . . 0.0 105.864 -169.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.96 -98.79 0.09 Allowed 'General case' 0 C--N 1.368 1.375 0 N-CA-C 104.14 -2.541 . . . . 0.0 104.14 165.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -92.93 148.1 22.29 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 167.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.42 124.7 32.3 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -22.73 29.14 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.5 t -84.77 -67.14 0.82 Allowed 'General case' 0 N--CA 1.443 -0.811 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 -177.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.14 -163.9 29.47 Favored Glycine 0 CA--C 1.492 -1.395 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.4 p -88.81 -178.64 5.81 Favored 'General case' 0 N--CA 1.416 -2.16 0 C-N-CA 125.893 1.677 . . . . 0.0 108.656 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.49 -1.336 0 N-CA-C 103.946 -2.613 . . . . 0.0 103.946 165.386 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.499 -0.988 0 CA-C-O 121.881 0.848 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.2 m -124.17 -167.45 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 N-CA-C 102.211 -3.255 . . . . 0.0 102.211 164.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.0 t-105 -137.63 148.77 46.08 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 175.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.77 45.26 5.8 Favored Glycine 0 C--N 1.355 1.588 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -178.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -125.16 166.81 17.72 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -175.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -92.58 -39.19 11.48 Favored 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 124.775 1.23 . . . . 0.0 109.025 -174.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.8 p -109.49 -145.44 0.4 Allowed 'General case' 0 C--N 1.355 0.829 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 -169.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.0 m -140.66 142.54 34.94 Favored 'General case' 0 C--N 1.356 0.853 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -170.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.02 -98.63 0.09 Allowed 'General case' 0 C--N 1.365 1.266 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 165.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -90.64 143.7 26.48 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 168.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.1 tp -84.53 123.15 29.97 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -177.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.61 -30.68 7.07 Favored Glycine 0 C--N 1.353 1.507 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -177.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.5 t -83.55 -63.86 1.27 Allowed 'General case' 0 C--N 1.357 0.919 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -175.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.49 -164.43 28.7 Favored Glycine 0 C--N 1.352 1.435 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.2 p -91.66 178.07 6.03 Favored 'General case' 0 N--CA 1.418 -2.061 0 C-N-CA 126.63 1.972 . . . . 0.0 108.252 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.313 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 168.686 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 N--CA 1.44 -0.973 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.3 m -126.73 -168.03 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 N-CA-C 104.128 -2.545 . . . . 0.0 104.128 168.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 35.5 t90 -128.42 141.1 51.51 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 177.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.09 56.14 2.95 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 110.066 -1.213 . . . . 0.0 110.066 173.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.15 170.34 22.95 Favored Glycine 0 CA--C 1.491 -1.437 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -178.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -95.12 -37.96 10.83 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.562 1.145 . . . . 0.0 108.696 -174.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.3 p -105.72 -153.22 0.49 Allowed 'General case' 0 C--N 1.353 0.744 0 N-CA-C 106.938 -1.505 . . . . 0.0 106.938 -168.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.8 m -140.91 143.31 34.55 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -169.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p30 -89.13 -100.26 0.09 Allowed 'General case' 0 C--N 1.365 1.248 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 168.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -87.04 155.28 20.21 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 126.789 2.036 . . . . 0.0 107.179 171.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.7 mt -81.55 123.33 28.56 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -176.039 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.91 -17.4 59.33 Favored Glycine 0 C--N 1.354 1.549 0 C-N-CA 123.519 0.581 . . . . 0.0 111.73 176.323 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.6 t -84.74 -65.95 0.95 Allowed 'General case' 0 C--N 1.358 0.978 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -171.65 -163.22 25.23 Favored Glycine 0 C--N 1.353 1.493 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 33.1 p -89.74 -175.69 4.72 Favored 'General case' 0 N--CA 1.42 -1.967 0 C-N-CA 126.363 1.865 . . . . 0.0 109.026 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.261 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 170.99 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.9 m . . . . . 0 CA--C 1.502 -0.895 0 CA-C-O 119.506 -0.283 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.7 m -84.96 166.88 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.844 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 -179.022 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 44.1 t-105 -121.12 149.67 42.42 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -174.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.23 41.56 5.17 Favored Glycine 0 C--N 1.354 1.559 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -178.195 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -126.7 172.59 18.3 Favored Glycine 0 C--N 1.353 1.5 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -176.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -102.18 -39.61 7.17 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.469 1.107 . . . . 0.0 108.196 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.2 p -98.69 -143.75 0.32 Allowed 'General case' 0 C--N 1.353 0.753 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 -168.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.04 143.29 31.11 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 -170.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.6 p30 -88.82 -100.94 0.09 Allowed 'General case' 0 C--N 1.364 1.215 0 N-CA-C 104.688 -2.338 . . . . 0.0 104.688 167.3 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -90.53 160.18 16.1 Favored 'General case' 0 N--CA 1.436 -1.15 0 C-N-CA 126.741 2.016 . . . . 0.0 107.038 171.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 74.8 mt -81.89 121.55 26.61 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -176.017 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.07 -6.89 79.02 Favored Glycine 0 C--N 1.354 1.553 0 C-N-CA 123.641 0.639 . . . . 0.0 111.67 177.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -88.85 -62.87 1.39 Allowed 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 -176.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.05 -164.17 30.38 Favored Glycine 0 C--N 1.35 1.358 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 178.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.9 p -88.92 -173.52 4.12 Favored 'General case' 0 N--CA 1.418 -2.04 0 C-N-CA 126.608 1.963 . . . . 0.0 108.087 178.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.491 -1.305 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 175.536 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.3 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.4 m -134.7 -167.59 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 N-CA-C 103.8 -2.667 . . . . 0.0 103.8 168.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.9 t-105 -140.74 141.62 34.87 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 176.256 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.45 59.93 2.18 Favored Glycine 0 C--N 1.356 1.646 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -137.97 177.62 19.84 Favored Glycine 0 CA--C 1.488 -1.615 0 N-CA-C 108.926 -1.669 . . . . 0.0 108.926 -174.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -88.77 -44.53 10.47 Favored 'General case' 0 N--CA 1.44 -0.949 0 C-N-CA 124.226 1.011 . . . . 0.0 110.322 -170.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 71.9 m -119.79 -131.77 0.3 Allowed 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 -168.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 m -144.34 145.15 31.81 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 105.139 -2.171 . . . . 0.0 105.139 -169.302 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -88.78 -98.95 0.09 Allowed 'General case' 0 C--N 1.366 1.289 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 165.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -90.25 148.71 22.74 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 167.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.26 125.2 32.02 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 -176.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.0 -19.86 42.51 Favored Glycine 0 C--N 1.356 1.642 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -177.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.2 t -86.48 -68.16 0.76 Allowed 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -176.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.61 -164.41 29.43 Favored Glycine 0 CA--C 1.492 -1.393 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.539 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 40.5 p -88.69 -172.94 3.93 Favored 'General case' 0 N--CA 1.421 -1.912 0 C-N-CA 126.204 1.802 . . . . 0.0 109.062 -177.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.206 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 169.077 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 CA--C 1.506 -0.748 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.68 -166.27 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.772 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 167.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.7 t-105 -140.28 145.16 36.93 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 87.35 53.76 2.71 Favored Glycine 0 C--N 1.354 1.548 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.43 168.93 24.75 Favored Glycine 0 C--N 1.352 1.452 0 N-CA-C 107.513 -2.235 . . . . 0.0 107.513 -179.19 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -94.32 -32.97 13.38 Favored 'General case' 0 CA--C 1.501 -0.937 0 C-N-CA 124.138 0.975 . . . . 0.0 109.156 -175.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.3 m -101.3 -155.51 0.52 Allowed 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -170.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.8 m -140.86 144.86 35.55 Favored 'General case' 0 C--N 1.358 0.963 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 -171.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -88.61 -98.74 0.09 Allowed 'General case' 0 C--N 1.366 1.315 0 N-CA-C 104.138 -2.542 . . . . 0.0 104.138 165.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.8 m-85 -91.91 148.75 21.98 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 167.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -84.8 124.97 32.17 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -176.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.56 -21.74 34.02 Favored Glycine 0 C--N 1.353 1.492 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -177.104 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -85.29 -67.61 0.79 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -176.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -175.44 -164.59 30.21 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 44.4 p -88.92 -176.81 5.31 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.103 1.761 . . . . 0.0 108.852 -177.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.246 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 166.678 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.5 m . . . . . 0 CA--C 1.506 -0.718 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.65 -168.09 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 N-CA-C 103.495 -2.78 . . . . 0.0 103.495 167.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.4 t-105 -140.0 144.29 36.9 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 174.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.88 55.05 2.48 Favored Glycine 0 C--N 1.354 1.536 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.04 170.69 23.95 Favored Glycine 0 C--N 1.352 1.453 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -93.81 -38.06 11.44 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.393 1.077 . . . . 0.0 108.868 -174.101 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.5 p -105.86 -154.55 0.52 Allowed 'General case' 0 C--N 1.354 0.784 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 -169.318 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 37.8 m -139.39 144.53 38.19 Favored 'General case' 0 CA--C 1.504 -0.802 0 N-CA-C 105.913 -1.884 . . . . 0.0 105.913 -168.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.1 p30 -88.21 -99.17 0.09 Allowed 'General case' 0 C--N 1.366 1.323 0 N-CA-C 104.295 -2.483 . . . . 0.0 104.295 166.122 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -92.23 151.76 20.18 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 169.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.0 mp -85.11 126.36 33.54 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 -176.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.64 -19.63 49.51 Favored Glycine 0 C--N 1.354 1.575 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -178.19 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 15.7 t -86.0 -69.0 0.7 Allowed 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 -176.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.97 -164.13 29.21 Favored Glycine 0 CA--C 1.491 -1.444 0 N-CA-C 107.896 -2.082 . . . . 0.0 107.896 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.6 -173.47 4.16 Favored 'General case' 0 N--CA 1.418 -2.028 0 C-N-CA 126.108 1.763 . . . . 0.0 108.676 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.193 0 N-CA-C 105.817 -1.919 . . . . 0.0 105.817 170.886 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.1 m . . . . . 0 CA--C 1.506 -0.725 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.24 -171.95 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 N-CA-C 104.825 -2.287 . . . . 0.0 104.825 170.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 34.0 t90 -128.07 144.77 51.12 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.1 -1.815 . . . . 0.0 106.1 176.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.38 56.02 3.53 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 174.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.64 171.01 22.15 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -176.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -91.1 -39.34 12.22 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 124.953 1.301 . . . . 0.0 109.939 -172.16 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -115.2 -143.88 0.38 Allowed 'General case' 0 C--N 1.355 0.813 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 -169.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.4 m -140.55 144.62 36.01 Favored 'General case' 0 C--N 1.354 0.804 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 -169.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -88.03 -98.55 0.09 Allowed 'General case' 0 C--N 1.367 1.346 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 166.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -92.41 148.49 22.07 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 105.732 -1.951 . . . . 0.0 105.732 167.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.3 tp -84.77 125.01 32.19 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 -176.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.99 -20.9 37.29 Favored Glycine 0 C--N 1.353 1.476 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.9 t -85.61 -67.51 0.8 Allowed 'General case' 0 C--N 1.356 0.859 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -177.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.32 -164.67 29.65 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.7 p -89.08 -177.48 5.45 Favored 'General case' 0 N--CA 1.418 -2.044 0 C-N-CA 125.93 1.692 . . . . 0.0 108.593 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.402 0 N-CA-C 104.395 -2.446 . . . . 0.0 104.395 167.079 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.6 t . . . . . 0 CA--C 1.498 -1.052 0 CA-C-O 121.743 0.783 . . . . 0.0 109.138 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.2 m -127.66 -164.86 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 103.039 -2.948 . . . . 0.0 103.039 167.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.9 t-105 -139.55 143.85 37.56 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.66 51.45 3.64 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.58 170.44 22.36 Favored Glycine 0 C--N 1.353 1.48 0 N-CA-C 107.707 -2.157 . . . . 0.0 107.707 -177.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -91.74 -42.43 10.14 Favored 'General case' 0 N--CA 1.441 -0.919 0 C-N-CA 124.142 0.977 . . . . 0.0 109.119 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.6 p -107.44 -141.6 0.38 Allowed 'General case' 0 C--N 1.354 0.8 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 -167.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 54.1 m -143.16 144.06 32.05 Favored 'General case' 0 C--N 1.356 0.85 0 N-CA-C 105.445 -2.057 . . . . 0.0 105.445 -170.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 p30 -88.9 -99.8 0.09 Allowed 'General case' 0 C--N 1.364 1.238 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 167.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -82.76 149.33 27.31 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 127.029 2.131 . . . . 0.0 106.994 173.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.5 mt -79.1 109.46 13.43 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 -178.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 52.46 2.76 Favored Glycine 0 C--N 1.354 1.539 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -145.93 -72.03 0.24 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 173.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -164.09 -163.07 16.21 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.1 p -89.67 -174.5 4.33 Favored 'General case' 0 N--CA 1.418 -2.029 0 C-N-CA 126.424 1.889 . . . . 0.0 109.129 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.246 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 169.475 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.3 m . . . . . 0 CA--C 1.505 -0.755 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.6 m -133.23 -166.84 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 103.533 -2.765 . . . . 0.0 103.533 167.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.5 t-105 -141.64 143.75 33.79 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 106.692 -1.595 . . . . 0.0 106.692 176.141 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.79 55.09 2.48 Favored Glycine 0 C--N 1.353 1.511 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.19 172.06 23.37 Favored Glycine 0 C--N 1.352 1.432 0 N-CA-C 107.999 -2.04 . . . . 0.0 107.999 -178.287 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -94.34 -37.95 11.23 Favored 'General case' 0 N--CA 1.44 -0.947 0 C-N-CA 124.446 1.098 . . . . 0.0 108.784 -174.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -104.14 -156.6 0.57 Allowed 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -169.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.1 m -139.55 144.19 37.72 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 -168.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.04 -98.62 0.09 Allowed 'General case' 0 C--N 1.368 1.372 0 N-CA-C 104.189 -2.523 . . . . 0.0 104.189 166.121 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -92.55 147.86 22.55 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 167.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.23 124.57 32.02 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 -177.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.27 -22.79 28.45 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -176.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.3 t -84.79 -67.19 0.82 Allowed 'General case' 0 C--N 1.357 0.905 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 -177.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.13 -163.73 29.18 Favored Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 107.86 -2.096 . . . . 0.0 107.86 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.4 p -88.62 -173.35 4.11 Favored 'General case' 0 N--CA 1.416 -2.126 0 C-N-CA 126.028 1.731 . . . . 0.0 108.706 -178.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.494 -1.21 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 170.154 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.0 m . . . . . 0 N--CA 1.444 -0.753 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -134.33 -168.17 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.752 0 N-CA-C 103.938 -2.616 . . . . 0.0 103.938 169.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.3 t-105 -139.66 143.58 37.21 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 106.379 -1.712 . . . . 0.0 106.379 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.21 53.44 3.12 Favored Glycine 0 C--N 1.355 1.625 0 N-CA-C 108.789 -1.724 . . . . 0.0 108.789 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.16 168.61 23.99 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.99 -2.044 . . . . 0.0 107.99 -176.004 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -92.89 -34.22 13.89 Favored 'General case' 0 N--CA 1.442 -0.846 0 C-N-CA 124.278 1.031 . . . . 0.0 111.455 -170.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.1 m -115.8 -137.5 0.36 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 -174.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.24 145.97 32.37 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 105.392 -2.077 . . . . 0.0 105.392 -169.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -89.38 -100.82 0.09 Allowed 'General case' 0 C--N 1.365 1.273 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 166.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -88.23 155.98 19.46 Favored 'General case' 0 N--CA 1.435 -1.195 0 C-N-CA 126.515 1.926 . . . . 0.0 107.119 172.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.3 mt -80.68 122.49 27.18 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 123.669 0.788 . . . . 0.0 109.048 -174.467 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.84 -3.94 81.41 Favored Glycine 0 C--N 1.354 1.579 0 C-N-CA 123.74 0.686 . . . . 0.0 111.663 178.159 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.8 t -90.91 -70.79 0.66 Allowed 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 -176.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -170.33 -165.29 27.45 Favored Glycine 0 CA--C 1.491 -1.419 0 N-CA-C 108.102 -1.999 . . . . 0.0 108.102 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.7 p -88.63 -173.17 4.04 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.036 1.734 . . . . 0.0 109.027 -177.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.493 -1.237 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 169.587 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.5 -0.97 0 CA-C-O 121.763 0.792 . . . . 0.0 109.189 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.6 m -126.57 -164.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.855 0 N-CA-C 102.983 -2.969 . . . . 0.0 102.983 166.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.8 t-105 -139.4 142.15 37.5 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.91 58.16 2.55 Favored Glycine 0 C--N 1.354 1.565 0 N-CA-C 108.816 -1.713 . . . . 0.0 108.816 -179.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.93 174.83 20.94 Favored Glycine 0 CA--C 1.49 -1.479 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -174.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -90.17 -42.94 10.76 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 124.415 1.086 . . . . 0.0 110.136 -170.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.8 m -119.32 -133.94 0.32 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -168.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.4 m -145.3 143.63 30.3 Favored 'General case' 0 C--N 1.356 0.883 0 N-CA-C 105.331 -2.1 . . . . 0.0 105.331 -168.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.05 -98.86 0.09 Allowed 'General case' 0 C--N 1.364 1.204 0 N-CA-C 104.554 -2.388 . . . . 0.0 104.554 166.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.97 144.55 26.48 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 167.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.62 123.89 30.25 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.01 -28.62 9.62 Favored Glycine 0 C--N 1.353 1.483 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.26 -65.14 1.04 Allowed 'General case' 0 C--N 1.358 0.937 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -174.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.98 -163.66 27.1 Favored Glycine 0 C--N 1.353 1.497 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 36.9 p -89.91 -174.85 4.41 Favored 'General case' 0 N--CA 1.42 -1.931 0 C-N-CA 126.667 1.987 . . . . 0.0 109.361 -176.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.492 -1.253 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 169.4 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.1 m . . . . . 0 CA--C 1.504 -0.796 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.8 m -132.92 -168.51 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.777 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 167.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.6 t-105 -139.19 143.57 38.15 Favored 'General case' 0 N--CA 1.435 -1.206 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 174.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.43 58.69 2.25 Favored Glycine 0 C--N 1.356 1.68 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.84 172.79 22.93 Favored Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 -177.178 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -90.62 -40.13 12.1 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 124.765 1.226 . . . . 0.0 110.023 -171.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -114.32 -144.61 0.39 Allowed 'General case' 0 C--N 1.354 0.772 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -170.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 45.2 m -140.95 144.4 35.11 Favored 'General case' 0 C--N 1.355 0.845 0 N-CA-C 105.739 -1.948 . . . . 0.0 105.739 -169.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.81 -98.46 0.08 Allowed 'General case' 0 C--N 1.367 1.343 0 N-CA-C 104.238 -2.504 . . . . 0.0 104.238 165.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.02 147.96 22.4 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 167.567 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.5 tp -85.44 124.78 32.42 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 -177.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.48 -23.33 26.82 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -176.329 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.77 -67.03 0.83 Allowed 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.51 -164.07 29.93 Favored Glycine 0 CA--C 1.491 -1.427 0 N-CA-C 107.902 -2.079 . . . . 0.0 107.902 179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 35.8 p -88.61 -176.4 5.26 Favored 'General case' 0 N--CA 1.416 -2.167 0 C-N-CA 126.047 1.739 . . . . 0.0 108.809 -178.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.85 162.83 34.43 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 167.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.7 m0 -91.67 -74.44 0.51 Allowed 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 -173.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.4 128.14 45.89 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.765 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 95.5 m -127.33 163.69 23.43 Favored 'General case' 0 CA--C 1.499 -0.992 0 N-CA-C 105.563 -2.014 . . . . 0.0 105.563 170.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.262 1.718 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.081 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 16.8 m -127.07 -174.05 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.787 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 169.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 40.8 t90 -119.45 139.5 51.95 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.185 -1.783 . . . . 0.0 106.185 176.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.78 59.1 2.7 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 173.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.47 171.55 22.22 Favored Glycine 0 C--N 1.352 1.457 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 -178.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -92.84 -43.51 8.96 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 124.17 0.988 . . . . 0.0 109.147 -173.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 7.9 p -106.88 -137.78 0.37 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 -167.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 60.1 m -144.51 142.69 30.41 Favored 'General case' 0 C--N 1.356 0.858 0 N-CA-C 105.518 -2.031 . . . . 0.0 105.518 -170.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.15 -98.71 0.09 Allowed 'General case' 0 C--N 1.364 1.208 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 166.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.51 144.81 26.53 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 166.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.49 124.06 30.35 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 -177.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.67 -28.72 9.71 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -178.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.9 t -84.27 -65.69 0.98 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.7 -163.28 26.24 Favored Glycine 0 C--N 1.353 1.49 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 p -90.36 -175.35 4.46 Favored 'General case' 0 N--CA 1.421 -1.917 0 C-N-CA 126.566 1.946 . . . . 0.0 109.458 -175.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.21 153.38 42.77 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 171.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 23.0 m0 -89.68 -48.92 6.96 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 -177.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.4 mm -82.45 118.42 30.13 Favored 'Isoleucine or valine' 0 C--N 1.357 0.897 0 N-CA-C 106.233 -1.766 . . . . 0.0 106.233 178.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 69.9 m -124.0 166.21 16.12 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 -173.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--O 1.261 1.668 0 N-CA-C 107.348 -1.352 . . . . 0.0 107.348 -179.739 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 97.0 m . . . . . 0 CA--C 1.507 -0.709 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.0 m -132.97 -170.55 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.811 0 N-CA-C 103.368 -2.827 . . . . 0.0 103.368 168.087 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.3 t-105 -137.97 147.46 44.29 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.917 -1.512 . . . . 0.0 106.917 176.014 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.24 47.92 5.02 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -127.81 171.57 19.11 Favored Glycine 0 C--N 1.352 1.455 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -175.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.4 m-20 -93.28 -39.49 10.94 Favored 'General case' 0 N--CA 1.44 -0.932 0 C-N-CA 124.994 1.318 . . . . 0.0 109.852 -172.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.0 p -113.54 -145.19 0.4 Allowed 'General case' 0 C--N 1.355 0.844 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -170.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 27.3 m -139.3 144.78 38.48 Favored 'General case' 0 C--N 1.357 0.892 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 -170.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p30 -88.49 -100.7 0.09 Allowed 'General case' 0 C--N 1.368 1.385 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 165.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -92.05 158.72 16.07 Favored 'General case' 0 N--CA 1.436 -1.138 0 C-N-CA 126.234 1.814 . . . . 0.0 107.323 174.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.1 mt -82.49 123.29 29.03 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.74 -6.56 79.79 Favored Glycine 0 C--N 1.354 1.553 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 178.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 18.1 t -89.7 -69.81 0.7 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -176.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.69 -164.62 29.15 Favored Glycine 0 CA--C 1.489 -1.533 0 N-CA-C 107.612 -2.195 . . . . 0.0 107.612 179.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.9 p -88.48 179.45 6.3 Favored 'General case' 0 N--CA 1.417 -2.105 0 C-N-CA 125.862 1.665 . . . . 0.0 108.515 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.58 161.94 34.51 Favored 'General case' 0 CA--C 1.49 -1.341 0 N-CA-C 104.247 -2.501 . . . . 0.0 104.247 166.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.3 m0 -86.82 -73.26 0.47 Allowed 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -172.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 29.9 pt -97.5 148.92 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.964 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 174.008 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 65.7 m -141.53 163.61 32.47 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 105.247 -2.131 . . . . 0.0 105.247 175.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.26 1.64 0 CA-C-O 117.511 -1.233 . . . . 0.0 108.637 178.956 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 92.9 m . . . . . 0 CA--C 1.504 -0.793 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 m -133.39 -167.23 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 103.824 -2.658 . . . . 0.0 103.824 167.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.5 t-105 -140.35 143.7 35.9 Favored 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 175.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.5 55.4 2.59 Favored Glycine 0 C--N 1.354 1.56 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -138.7 168.27 24.79 Favored Glycine 0 CA--C 1.49 -1.484 0 N-CA-C 108.51 -1.836 . . . . 0.0 108.51 -176.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -91.35 -34.84 14.73 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 124.771 1.228 . . . . 0.0 110.434 -173.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -111.12 -153.93 0.53 Allowed 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 -169.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.8 m -139.59 144.5 37.79 Favored 'General case' 0 C--N 1.355 0.832 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 -169.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -88.12 -98.36 0.09 Allowed 'General case' 0 C--N 1.365 1.269 0 N-CA-C 104.206 -2.516 . . . . 0.0 104.206 166.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -93.05 147.78 22.56 Favored 'General case' 0 N--CA 1.438 -1.029 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 167.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.4 tp -85.19 124.58 32.01 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 -177.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.7 -23.61 25.71 Favored Glycine 0 C--N 1.354 1.556 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -176.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.1 t -84.61 -67.0 0.83 Allowed 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 -177.318 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.02 -164.13 29.77 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.001 -2.039 . . . . 0.0 108.001 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.0 p -88.95 -173.05 3.93 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.075 1.75 . . . . 0.0 108.692 -177.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.42 159.22 42.66 Favored 'General case' 0 CA--C 1.492 -1.269 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 171.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 29.7 m0 -104.01 -66.46 0.95 Allowed 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.099 -2.185 . . . . 0.0 105.099 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.9 mt -89.47 125.17 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 N-CA-C 105.137 -2.172 . . . . 0.0 105.137 174.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 2.0 p -150.23 -49.87 0.13 Allowed 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 106.319 -1.734 . . . . 0.0 106.319 -174.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 9.9 m . . . . . 0 C--O 1.26 1.621 0 C-N-CA 124.58 1.152 . . . . 0.0 108.21 179.794 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 CA--C 1.499 -1.016 0 CA-C-O 121.759 0.79 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -124.89 -165.19 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.812 -3.033 . . . . 0.0 102.812 165.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.9 t-105 -138.7 143.94 39.35 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 83.25 55.88 2.81 Favored Glycine 0 C--N 1.355 1.589 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 -179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.46 170.55 22.63 Favored Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 -176.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -91.27 -39.5 12.04 Favored 'General case' 0 N--CA 1.441 -0.91 0 C-N-CA 124.944 1.298 . . . . 0.0 109.957 -171.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.9 p -114.59 -145.47 0.4 Allowed 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -169.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 40.8 m -141.33 143.64 34.14 Favored 'General case' 0 C--N 1.356 0.871 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 -170.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.0 p30 -88.78 -100.21 0.09 Allowed 'General case' 0 C--N 1.364 1.226 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 167.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -88.17 155.75 19.6 Favored 'General case' 0 N--CA 1.436 -1.17 0 C-N-CA 126.842 2.057 . . . . 0.0 107.268 172.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 72.8 mt -81.78 123.68 28.99 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 -176.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.9 -17.83 58.59 Favored Glycine 0 C--N 1.355 1.598 0 C-N-CA 123.517 0.58 . . . . 0.0 111.669 176.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.4 t -84.69 -65.43 1.01 Allowed 'General case' 0 C--N 1.356 0.89 0 N-CA-C 108.288 -1.005 . . . . 0.0 108.288 -175.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.18 -164.14 27.21 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 32.2 p -89.78 -177.83 5.35 Favored 'General case' 0 N--CA 1.418 -2.038 0 C-N-CA 126.354 1.862 . . . . 0.0 108.945 -177.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.64 162.46 35.41 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 104.815 -2.291 . . . . 0.0 104.815 167.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.9 m0 -89.95 -75.84 0.44 Allowed 'General case' 0 CA--C 1.5 -0.967 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 -173.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 4.8 mp -94.53 128.41 45.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 N-CA-C 106.159 -1.793 . . . . 0.0 106.159 178.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 94.1 m -126.34 163.33 23.49 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 105.589 -2.004 . . . . 0.0 105.589 170.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.9 m . . . . . 0 C--O 1.261 1.682 0 CA-C-O 117.27 -1.348 . . . . 0.0 110.301 179.939 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 89.4 m . . . . . 0 CA--C 1.504 -0.791 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 17.6 m -133.71 -172.66 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 105.119 -2.178 . . . . 0.0 105.119 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 36.9 t90 -125.97 141.85 51.78 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 105.839 -1.912 . . . . 0.0 105.839 176.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 77.52 60.85 2.72 Favored Glycine 0 C--N 1.354 1.581 0 N-CA-C 110.059 -1.216 . . . . 0.0 110.059 174.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.43 173.41 22.02 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 -176.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -88.09 -42.13 12.59 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 124.442 1.097 . . . . 0.0 110.184 -171.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 81.4 m -117.57 -133.37 0.33 Allowed 'General case' 0 C--N 1.357 0.893 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -168.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.7 m -145.43 144.67 30.76 Favored 'General case' 0 N--CA 1.442 -0.853 0 N-CA-C 104.932 -2.247 . . . . 0.0 104.932 -169.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.71 -98.25 0.09 Allowed 'General case' 0 C--N 1.364 1.227 0 N-CA-C 104.281 -2.488 . . . . 0.0 104.281 166.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -90.81 149.39 21.99 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 166.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.1 tp -84.52 125.32 32.29 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -176.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.55 -19.56 44.63 Favored Glycine 0 C--N 1.354 1.537 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -177.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -86.5 -68.16 0.76 Allowed 'General case' 0 C--N 1.357 0.907 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -176.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.36 -165.07 29.67 Favored Glycine 0 C--N 1.351 1.391 0 N-CA-C 108.563 -1.815 . . . . 0.0 108.563 -179.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.5 p -88.97 -173.29 4.02 Favored 'General case' 0 N--CA 1.42 -1.947 0 C-N-CA 126.268 1.827 . . . . 0.0 108.854 -177.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -148.6 150.8 33.93 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.4 m0 -87.38 -55.82 3.63 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 -175.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 64.5 mt -85.48 126.76 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 N-CA-C 104.076 -2.564 . . . . 0.0 104.076 169.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 96.5 m -86.46 151.9 23.12 Favored 'General case' 0 CA--C 1.499 -0.998 0 CA-C-O 121.399 0.619 . . . . 0.0 109.998 -167.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 29.7 m . . . . . 0 C--O 1.261 1.693 0 CA-C-O 117.286 -1.34 . . . . 0.0 110.274 -176.842 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.5 -0.972 0 CA-C-O 121.839 0.828 . . . . 0.0 109.418 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.7 m -125.1 -167.08 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.921 0 N-CA-C 102.307 -3.22 . . . . 0.0 102.307 164.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.5 t-105 -137.74 147.57 44.86 Favored 'General case' 0 N--CA 1.437 -1.124 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 175.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.6 47.96 4.92 Favored Glycine 0 C--N 1.353 1.52 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -128.42 166.88 20.81 Favored Glycine 0 C--N 1.353 1.506 0 N-CA-C 108.894 -1.682 . . . . 0.0 108.894 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -91.86 -39.5 11.71 Favored 'General case' 0 N--CA 1.438 -1.04 0 C-N-CA 124.794 1.238 . . . . 0.0 109.128 -174.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.1 p -109.38 -145.49 0.4 Allowed 'General case' 0 C--N 1.354 0.796 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 -169.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 32.4 m -141.19 142.92 33.97 Favored 'General case' 0 C--N 1.356 0.855 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 -170.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -88.24 -99.02 0.09 Allowed 'General case' 0 C--N 1.365 1.249 0 N-CA-C 104.613 -2.366 . . . . 0.0 104.613 166.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -89.77 149.11 22.86 Favored 'General case' 0 N--CA 1.438 -1.066 0 C-N-CA 126.056 1.742 . . . . 0.0 106.319 169.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.1 mp -84.32 125.73 32.55 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -177.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.62 -28.4 13.48 Favored Glycine 0 C--N 1.354 1.58 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.0 t -83.3 -65.04 1.06 Allowed 'General case' 0 C--N 1.358 0.97 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -174.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.09 -164.56 28.66 Favored Glycine 0 C--N 1.353 1.484 0 N-CA-C 109.145 -1.582 . . . . 0.0 109.145 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 23.6 p -91.13 179.65 5.67 Favored 'General case' 0 N--CA 1.419 -1.992 0 C-N-CA 126.497 1.919 . . . . 0.0 108.551 -178.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.8 162.88 34.09 Favored 'General case' 0 CA--C 1.491 -1.297 0 N-CA-C 105.318 -2.104 . . . . 0.0 105.318 169.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.4 m0 -88.81 -75.07 0.44 Allowed 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -174.153 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.5 mt -96.59 125.49 49.51 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.927 0 N-CA-C 105.944 -1.873 . . . . 0.0 105.944 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 91.8 m -123.5 -52.01 1.83 Allowed 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 104.87 -2.27 . . . . 0.0 104.87 170.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.2 t . . . . . 0 C--O 1.259 1.587 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 177.723 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.7 m . . . . . 0 CA--C 1.503 -0.832 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.4 m -132.56 -168.13 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 104.21 -2.515 . . . . 0.0 104.21 170.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.5 t-105 -139.77 143.75 37.07 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 175.731 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.12 54.36 3.05 Favored Glycine 0 C--N 1.355 1.623 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.38 172.96 22.22 Favored Glycine 0 C--N 1.353 1.495 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 -177.001 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 -93.45 -41.02 10.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 123.831 0.853 . . . . 0.0 109.77 -170.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.4 p -110.88 -140.12 0.38 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -169.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.6 m -141.85 145.52 34.75 Favored 'General case' 0 C--N 1.355 0.846 0 N-CA-C 105.271 -2.122 . . . . 0.0 105.271 -170.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.66 -99.56 0.09 Allowed 'General case' 0 C--N 1.365 1.251 0 N-CA-C 104.382 -2.451 . . . . 0.0 104.382 165.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -88.43 148.81 24.02 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.031 1.732 . . . . 0.0 106.496 169.164 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.1 tt -83.84 117.93 23.62 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 -177.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.57 38.62 6.15 Favored Glycine 0 C--N 1.353 1.491 0 N-CA-C 108.94 -1.664 . . . . 0.0 108.94 -177.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 21.5 t -138.54 -68.44 0.45 Allowed 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.46 -165.72 30.71 Favored Glycine 0 CA--C 1.492 -1.384 0 N-CA-C 108.291 -1.923 . . . . 0.0 108.291 179.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.77 -172.32 3.67 Favored 'General case' 0 N--CA 1.418 -2.046 0 C-N-CA 126.214 1.805 . . . . 0.0 108.812 -178.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.78 150.48 38.63 Favored 'General case' 0 CA--C 1.494 -1.211 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 169.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 22.1 m0 -89.19 -50.29 6.23 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -175.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.5 mt -82.28 119.39 31.73 Favored 'Isoleucine or valine' 0 C--N 1.356 0.881 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 177.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 75.6 m -124.19 -49.89 1.81 Allowed 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 -174.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.26 1.658 0 CA-C-O 117.518 -1.229 . . . . 0.0 108.193 176.886 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.4 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.4 m -133.66 -168.75 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.824 0 N-CA-C 103.422 -2.807 . . . . 0.0 103.422 167.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 59.0 t-105 -139.26 145.32 39.04 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.09 53.59 3.27 Favored Glycine 0 C--N 1.355 1.621 0 N-CA-C 108.989 -1.644 . . . . 0.0 108.989 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.71 172.64 21.55 Favored Glycine 0 CA--C 1.49 -1.489 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -176.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -91.49 -40.03 11.62 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 124.838 1.255 . . . . 0.0 109.964 -171.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 11.1 p -114.18 -144.78 0.39 Allowed 'General case' 0 C--N 1.354 0.761 0 N-CA-C 107.17 -1.419 . . . . 0.0 107.17 -170.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 35.0 m -139.76 144.69 37.55 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 105.864 -1.902 . . . . 0.0 105.864 -169.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -87.96 -98.79 0.09 Allowed 'General case' 0 C--N 1.368 1.375 0 N-CA-C 104.14 -2.541 . . . . 0.0 104.14 165.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -92.93 148.1 22.29 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 105.707 -1.96 . . . . 0.0 105.707 167.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.42 124.7 32.3 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -177.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 106.99 -22.73 29.14 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 -176.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.5 t -84.77 -67.14 0.82 Allowed 'General case' 0 N--CA 1.443 -0.811 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 -177.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.14 -163.9 29.47 Favored Glycine 0 CA--C 1.492 -1.395 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 34.4 p -88.81 -178.64 5.81 Favored 'General case' 0 N--CA 1.416 -2.16 0 C-N-CA 125.893 1.677 . . . . 0.0 108.656 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -137.93 161.7 35.98 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 103.946 -2.613 . . . . 0.0 103.946 165.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.9 m0 -87.58 -72.68 0.51 Allowed 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 -172.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 30.4 pt -96.23 148.91 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 173.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 61.4 m -140.72 -52.89 0.48 Allowed 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 104.297 -2.483 . . . . 0.0 104.297 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 C--O 1.26 1.646 0 C-N-CA 123.981 0.913 . . . . 0.0 109.915 177.568 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.2 t . . . . . 0 CA--C 1.499 -0.988 0 CA-C-O 121.881 0.848 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.2 m -124.17 -167.45 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.931 0 N-CA-C 102.211 -3.255 . . . . 0.0 102.211 164.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 56.0 t-105 -137.63 148.77 46.08 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 175.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.77 45.26 5.8 Favored Glycine 0 C--N 1.355 1.588 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -178.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -125.16 166.81 17.72 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 -175.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -92.58 -39.19 11.48 Favored 'General case' 0 N--CA 1.439 -1.016 0 C-N-CA 124.775 1.23 . . . . 0.0 109.025 -174.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 14.8 p -109.49 -145.44 0.4 Allowed 'General case' 0 C--N 1.355 0.829 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 -169.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.0 m -140.66 142.54 34.94 Favored 'General case' 0 C--N 1.356 0.853 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -170.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -88.02 -98.63 0.09 Allowed 'General case' 0 C--N 1.365 1.266 0 N-CA-C 104.515 -2.402 . . . . 0.0 104.515 165.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -90.64 143.7 26.48 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 105.686 -1.968 . . . . 0.0 105.686 168.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.1 tp -84.53 123.15 29.97 Favored 'General case' 0 N--CA 1.441 -0.896 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -177.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 113.61 -30.68 7.07 Favored Glycine 0 C--N 1.353 1.507 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 -177.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.5 t -83.55 -63.86 1.27 Allowed 'General case' 0 C--N 1.357 0.919 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -175.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -173.49 -164.43 28.7 Favored Glycine 0 C--N 1.352 1.435 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.2 p -91.66 178.07 6.03 Favored 'General case' 0 N--CA 1.418 -2.061 0 C-N-CA 126.63 1.972 . . . . 0.0 108.252 -178.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -137.42 163.03 32.06 Favored 'General case' 0 CA--C 1.491 -1.313 0 N-CA-C 105.185 -2.154 . . . . 0.0 105.185 168.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 16.6 m0 -88.04 -74.38 0.45 Allowed 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 -173.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 42.0 mm -98.3 127.39 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.905 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 91.0 m -124.47 -52.16 1.72 Allowed 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 104.823 -2.288 . . . . 0.0 104.823 171.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.0 t . . . . . 0 C--O 1.261 1.668 0 N-CA-C 106.492 -1.669 . . . . 0.0 106.492 177.734 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 t . . . . . 0 N--CA 1.44 -0.973 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.3 m -126.73 -168.03 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 N-CA-C 104.128 -2.545 . . . . 0.0 104.128 168.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 35.5 t90 -128.42 141.1 51.51 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 106.439 -1.689 . . . . 0.0 106.439 177.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.09 56.14 2.95 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 110.066 -1.213 . . . . 0.0 110.066 173.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -135.15 170.34 22.95 Favored Glycine 0 CA--C 1.491 -1.437 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -178.281 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -95.12 -37.96 10.83 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 124.562 1.145 . . . . 0.0 108.696 -174.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.3 p -105.72 -153.22 0.49 Allowed 'General case' 0 C--N 1.353 0.744 0 N-CA-C 106.938 -1.505 . . . . 0.0 106.938 -168.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.8 m -140.91 143.31 34.55 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 -169.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 7.5 p30 -89.13 -100.26 0.09 Allowed 'General case' 0 C--N 1.365 1.248 0 N-CA-C 105.07 -2.196 . . . . 0.0 105.07 168.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -87.04 155.28 20.21 Favored 'General case' 0 N--CA 1.437 -1.104 0 C-N-CA 126.789 2.036 . . . . 0.0 107.179 171.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.7 mt -81.55 123.33 28.56 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -176.039 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.91 -17.4 59.33 Favored Glycine 0 C--N 1.354 1.549 0 C-N-CA 123.519 0.581 . . . . 0.0 111.73 176.323 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 8.6 t -84.74 -65.95 0.95 Allowed 'General case' 0 C--N 1.358 0.978 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -171.65 -163.22 25.23 Favored Glycine 0 C--N 1.353 1.493 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 33.1 p -89.74 -175.69 4.72 Favored 'General case' 0 N--CA 1.42 -1.967 0 C-N-CA 126.363 1.865 . . . . 0.0 109.026 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -138.94 162.5 34.7 Favored 'General case' 0 CA--C 1.492 -1.261 0 N-CA-C 106.128 -1.804 . . . . 0.0 106.128 170.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 29.0 m0 -106.19 -65.73 1.05 Allowed 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 105.089 -2.189 . . . . 0.0 105.089 177.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.7 mt -88.71 124.09 41.4 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 N-CA-C 105.13 -2.174 . . . . 0.0 105.13 175.011 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.7 p -150.11 -60.09 0.2 Allowed 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 105.4 -2.074 . . . . 0.0 105.4 -174.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--O 1.261 1.685 0 CA-C-O 117.232 -1.366 . . . . 0.0 109.712 177.394 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 46.9 m . . . . . 0 CA--C 1.502 -0.895 0 CA-C-O 119.506 -0.283 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 19.7 m -84.96 166.88 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.844 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 -179.022 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 44.1 t-105 -121.12 149.67 42.42 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -174.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.23 41.56 5.17 Favored Glycine 0 C--N 1.354 1.559 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -178.195 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -126.7 172.59 18.3 Favored Glycine 0 C--N 1.353 1.5 0 N-CA-C 108.492 -1.843 . . . . 0.0 108.492 -176.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -102.18 -39.61 7.17 Favored 'General case' 0 N--CA 1.44 -0.931 0 C-N-CA 124.469 1.107 . . . . 0.0 108.196 -175.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 3.2 p -98.69 -143.75 0.32 Allowed 'General case' 0 C--N 1.353 0.753 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 -168.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.04 143.29 31.11 Favored 'General case' 0 CA--C 1.503 -0.865 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 -170.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.6 p30 -88.82 -100.94 0.09 Allowed 'General case' 0 C--N 1.364 1.215 0 N-CA-C 104.688 -2.338 . . . . 0.0 104.688 167.3 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -90.53 160.18 16.1 Favored 'General case' 0 N--CA 1.436 -1.15 0 C-N-CA 126.741 2.016 . . . . 0.0 107.038 171.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 74.8 mt -81.89 121.55 26.61 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -176.017 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.07 -6.89 79.02 Favored Glycine 0 C--N 1.354 1.553 0 C-N-CA 123.641 0.639 . . . . 0.0 111.67 177.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -88.85 -62.87 1.39 Allowed 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 -176.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -177.05 -164.17 30.38 Favored Glycine 0 C--N 1.35 1.358 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 178.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 18.9 p -88.92 -173.52 4.12 Favored 'General case' 0 N--CA 1.418 -2.04 0 C-N-CA 126.608 1.963 . . . . 0.0 108.087 178.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -144.61 162.16 37.32 Favored 'General case' 0 CA--C 1.491 -1.305 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 175.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -101.13 -67.45 0.86 Allowed 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 177.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.5 mt -89.33 121.05 39.01 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.877 0 N-CA-C 105.549 -2.019 . . . . 0.0 105.549 176.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 5.4 p -151.22 168.5 24.51 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 -175.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.259 1.563 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 177.836 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 99.3 m . . . . . 0 CA--C 1.506 -0.747 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.4 m -134.7 -167.59 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 N-CA-C 103.8 -2.667 . . . . 0.0 103.8 168.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.9 t-105 -140.74 141.62 34.87 Favored 'General case' 0 N--CA 1.438 -1.051 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 176.256 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 82.45 59.93 2.18 Favored Glycine 0 C--N 1.356 1.646 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -137.97 177.62 19.84 Favored Glycine 0 CA--C 1.488 -1.615 0 N-CA-C 108.926 -1.669 . . . . 0.0 108.926 -174.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -88.77 -44.53 10.47 Favored 'General case' 0 N--CA 1.44 -0.949 0 C-N-CA 124.226 1.011 . . . . 0.0 110.322 -170.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 71.9 m -119.79 -131.77 0.3 Allowed 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 -168.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 51.1 m -144.34 145.15 31.81 Favored 'General case' 0 C--N 1.356 0.872 0 N-CA-C 105.139 -2.171 . . . . 0.0 105.139 -169.302 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -88.78 -98.95 0.09 Allowed 'General case' 0 C--N 1.366 1.289 0 N-CA-C 104.124 -2.547 . . . . 0.0 104.124 165.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -90.25 148.71 22.74 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 106.0 -1.852 . . . . 0.0 106.0 167.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.4 tp -84.26 125.2 32.02 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 -176.303 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.0 -19.86 42.51 Favored Glycine 0 C--N 1.356 1.642 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -177.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.2 t -86.48 -68.16 0.76 Allowed 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -176.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.61 -164.41 29.43 Favored Glycine 0 CA--C 1.492 -1.393 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.539 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 40.5 p -88.69 -172.94 3.93 Favored 'General case' 0 N--CA 1.421 -1.912 0 C-N-CA 126.204 1.802 . . . . 0.0 109.062 -177.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -141.88 146.94 36.36 Favored 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 169.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 26.9 m0 -87.54 -49.83 6.93 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 -176.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 57.2 mt -82.45 117.55 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.834 0 N-CA-C 106.067 -1.827 . . . . 0.0 106.067 177.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 41.8 t -145.63 -52.15 0.26 Allowed 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.261 1.683 0 CA-C-O 117.534 -1.222 . . . . 0.0 108.248 177.595 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 94.4 m . . . . . 0 CA--C 1.506 -0.748 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.9 m -133.68 -166.27 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.772 0 N-CA-C 103.666 -2.716 . . . . 0.0 103.666 167.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.7 t-105 -140.28 145.16 36.93 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 87.35 53.76 2.71 Favored Glycine 0 C--N 1.354 1.548 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.43 168.93 24.75 Favored Glycine 0 C--N 1.352 1.452 0 N-CA-C 107.513 -2.235 . . . . 0.0 107.513 -179.19 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -94.32 -32.97 13.38 Favored 'General case' 0 CA--C 1.501 -0.937 0 C-N-CA 124.138 0.975 . . . . 0.0 109.156 -175.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 75.3 m -101.3 -155.51 0.52 Allowed 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -170.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 39.8 m -140.86 144.86 35.55 Favored 'General case' 0 C--N 1.358 0.963 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 -171.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -88.61 -98.74 0.09 Allowed 'General case' 0 C--N 1.366 1.315 0 N-CA-C 104.138 -2.542 . . . . 0.0 104.138 165.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.8 m-85 -91.91 148.75 21.98 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 105.855 -1.906 . . . . 0.0 105.855 167.546 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.3 tp -84.8 124.97 32.17 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -176.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 105.56 -21.74 34.02 Favored Glycine 0 C--N 1.353 1.492 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -177.104 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.6 t -85.29 -67.61 0.79 Allowed 'General case' 0 C--N 1.357 0.899 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -176.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -175.44 -164.59 30.21 Favored Glycine 0 CA--C 1.491 -1.456 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 44.4 p -88.92 -176.81 5.31 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.103 1.761 . . . . 0.0 108.852 -177.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.21 151.96 41.2 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 166.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 17.8 m0 -91.27 -56.38 3.17 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -173.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 54.8 mt -83.02 113.34 22.05 Favored 'Isoleucine or valine' 0 C--N 1.355 0.841 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 -176.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 3.3 p -152.16 165.38 34.99 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 105.794 -1.928 . . . . 0.0 105.794 177.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 40.7 t . . . . . 0 C--O 1.26 1.616 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.057 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 98.5 m . . . . . 0 CA--C 1.506 -0.718 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.5 m -133.65 -168.09 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 N-CA-C 103.495 -2.78 . . . . 0.0 103.495 167.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.4 t-105 -140.0 144.29 36.9 Favored 'General case' 0 N--CA 1.436 -1.162 0 N-CA-C 106.706 -1.59 . . . . 0.0 106.706 174.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.88 55.05 2.48 Favored Glycine 0 C--N 1.354 1.536 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.04 170.69 23.95 Favored Glycine 0 C--N 1.352 1.453 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -177.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -93.81 -38.06 11.44 Favored 'General case' 0 N--CA 1.442 -0.833 0 C-N-CA 124.393 1.077 . . . . 0.0 108.868 -174.101 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.5 p -105.86 -154.55 0.52 Allowed 'General case' 0 C--N 1.354 0.784 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 -169.318 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 37.8 m -139.39 144.53 38.19 Favored 'General case' 0 CA--C 1.504 -0.802 0 N-CA-C 105.913 -1.884 . . . . 0.0 105.913 -168.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.1 p30 -88.21 -99.17 0.09 Allowed 'General case' 0 C--N 1.366 1.323 0 N-CA-C 104.295 -2.483 . . . . 0.0 104.295 166.122 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.6 m-85 -92.23 151.76 20.18 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 169.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 9.0 mp -85.11 126.36 33.54 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 -176.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 101.64 -19.63 49.51 Favored Glycine 0 C--N 1.354 1.575 0 N-CA-C 110.144 -1.182 . . . . 0.0 110.144 -178.19 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 15.7 t -86.0 -69.0 0.7 Allowed 'General case' 0 N--CA 1.442 -0.875 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 -176.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.97 -164.13 29.21 Favored Glycine 0 CA--C 1.491 -1.444 0 N-CA-C 107.896 -2.082 . . . . 0.0 107.896 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.5 p -88.6 -173.47 4.16 Favored 'General case' 0 N--CA 1.418 -2.028 0 C-N-CA 126.108 1.763 . . . . 0.0 108.676 -177.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -138.61 158.41 44.3 Favored 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 105.817 -1.919 . . . . 0.0 105.817 170.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 30.8 m0 -100.36 -70.09 0.75 Allowed 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 105.26 -2.126 . . . . 0.0 105.26 178.521 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.1 tp -87.15 133.63 29.6 Favored 'Isoleucine or valine' 0 C--N 1.356 0.85 0 N-CA-C 106.127 -1.805 . . . . 0.0 106.127 171.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 1.4 p -151.58 -65.3 0.18 Allowed 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 105.189 -2.152 . . . . 0.0 105.189 -174.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 40.3 t . . . . . 0 C--O 1.26 1.606 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 177.646 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 86.1 m . . . . . 0 CA--C 1.506 -0.725 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 15.7 m -134.24 -171.95 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 N-CA-C 104.825 -2.287 . . . . 0.0 104.825 170.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 34.0 t90 -128.07 144.77 51.12 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.1 -1.815 . . . . 0.0 106.1 176.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 79.38 56.02 3.53 Favored Glycine 0 C--N 1.353 1.501 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 174.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.64 171.01 22.15 Favored Glycine 0 CA--C 1.49 -1.518 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -176.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 49.3 m-20 -91.1 -39.34 12.22 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 124.953 1.301 . . . . 0.0 109.939 -172.16 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.0 p -115.2 -143.88 0.38 Allowed 'General case' 0 C--N 1.355 0.813 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 -169.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 48.4 m -140.55 144.62 36.01 Favored 'General case' 0 C--N 1.354 0.804 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 -169.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -88.03 -98.55 0.09 Allowed 'General case' 0 C--N 1.367 1.346 0 N-CA-C 104.282 -2.488 . . . . 0.0 104.282 166.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -92.41 148.49 22.07 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 105.732 -1.951 . . . . 0.0 105.732 167.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.3 tp -84.77 125.01 32.19 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 -176.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.99 -20.9 37.29 Favored Glycine 0 C--N 1.353 1.476 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -177.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.9 t -85.61 -67.51 0.8 Allowed 'General case' 0 C--N 1.356 0.859 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -177.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.32 -164.67 29.65 Favored Glycine 0 CA--C 1.492 -1.389 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.7 p -89.08 -177.48 5.45 Favored 'General case' 0 N--CA 1.418 -2.044 0 C-N-CA 125.93 1.692 . . . . 0.0 108.593 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.58 162.19 36.11 Favored 'General case' 0 CA--C 1.489 -1.402 0 N-CA-C 104.395 -2.446 . . . . 0.0 104.395 167.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 14.9 m0 -89.25 -72.97 0.53 Allowed 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -172.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 42.5 mm -98.94 129.35 49.45 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 179.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 91.9 m -127.93 163.65 24.02 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 105.442 -2.058 . . . . 0.0 105.442 171.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 31.5 m . . . . . 0 C--O 1.261 1.687 0 CA-C-O 117.22 -1.371 . . . . 0.0 110.3 179.603 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.6 t . . . . . 0 CA--C 1.498 -1.052 0 CA-C-O 121.743 0.783 . . . . 0.0 109.138 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.2 m -127.66 -164.86 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 103.039 -2.948 . . . . 0.0 103.039 167.683 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.9 t-105 -139.55 143.85 37.56 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 106.53 -1.655 . . . . 0.0 106.53 175.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.66 51.45 3.64 Favored Glycine 0 C--N 1.354 1.534 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -133.58 170.44 22.36 Favored Glycine 0 C--N 1.353 1.48 0 N-CA-C 107.707 -2.157 . . . . 0.0 107.707 -177.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -91.74 -42.43 10.14 Favored 'General case' 0 N--CA 1.441 -0.919 0 C-N-CA 124.142 0.977 . . . . 0.0 109.119 -173.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 9.6 p -107.44 -141.6 0.38 Allowed 'General case' 0 C--N 1.354 0.8 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 -167.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 54.1 m -143.16 144.06 32.05 Favored 'General case' 0 C--N 1.356 0.85 0 N-CA-C 105.445 -2.057 . . . . 0.0 105.445 -170.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 p30 -88.9 -99.8 0.09 Allowed 'General case' 0 C--N 1.364 1.238 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 167.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -82.76 149.33 27.31 Favored 'General case' 0 N--CA 1.436 -1.149 0 C-N-CA 127.029 2.131 . . . . 0.0 106.994 173.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 76.5 mt -79.1 109.46 13.43 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 -178.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 89.0 52.46 2.76 Favored Glycine 0 C--N 1.354 1.539 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 -179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 12.0 t -145.93 -72.03 0.24 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 173.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -164.09 -163.07 16.21 Favored Glycine 0 C--N 1.353 1.482 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.1 p -89.67 -174.5 4.33 Favored 'General case' 0 N--CA 1.418 -2.029 0 C-N-CA 126.424 1.889 . . . . 0.0 109.129 -176.031 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.02 151.99 42.98 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 169.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 24.1 m0 -89.72 -48.91 6.96 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 -176.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 58.9 mt -82.27 118.81 30.65 Favored 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 105.851 -1.907 . . . . 0.0 105.851 177.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 84.8 m -123.83 165.9 16.53 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -173.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 30.0 m . . . . . 0 C--O 1.258 1.548 0 C-N-CA 123.787 0.835 . . . . 0.0 110.327 -179.739 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.3 m . . . . . 0 CA--C 1.505 -0.755 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.6 m -133.23 -166.84 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 103.533 -2.765 . . . . 0.0 103.533 167.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 60.5 t-105 -141.64 143.75 33.79 Favored 'General case' 0 N--CA 1.437 -1.106 0 N-CA-C 106.692 -1.595 . . . . 0.0 106.692 176.141 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 86.79 55.09 2.48 Favored Glycine 0 C--N 1.353 1.511 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 179.117 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -139.19 172.06 23.37 Favored Glycine 0 C--N 1.352 1.432 0 N-CA-C 107.999 -2.04 . . . . 0.0 107.999 -178.287 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -94.34 -37.95 11.23 Favored 'General case' 0 N--CA 1.44 -0.947 0 C-N-CA 124.446 1.098 . . . . 0.0 108.784 -174.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 2.0 p -104.14 -156.6 0.57 Allowed 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -169.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 41.1 m -139.55 144.19 37.72 Favored 'General case' 0 C--N 1.354 0.776 0 N-CA-C 105.923 -1.88 . . . . 0.0 105.923 -168.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p30 -88.04 -98.62 0.09 Allowed 'General case' 0 C--N 1.368 1.372 0 N-CA-C 104.189 -2.523 . . . . 0.0 104.189 166.121 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -92.55 147.86 22.55 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 105.778 -1.934 . . . . 0.0 105.778 167.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 46.6 tp -85.23 124.57 32.02 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 -177.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.27 -22.79 28.45 Favored Glycine 0 C--N 1.354 1.554 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -176.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 16.3 t -84.79 -67.19 0.82 Allowed 'General case' 0 C--N 1.357 0.905 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 -177.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.13 -163.73 29.18 Favored Glycine 0 CA--C 1.492 -1.4 0 N-CA-C 107.86 -2.096 . . . . 0.0 107.86 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.4 p -88.62 -173.35 4.11 Favored 'General case' 0 N--CA 1.416 -2.126 0 C-N-CA 126.028 1.731 . . . . 0.0 108.706 -178.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.82 161.13 36.82 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 105.718 -1.956 . . . . 0.0 105.718 170.154 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 33.1 m0 -107.77 -65.27 1.13 Allowed 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 104.993 -2.225 . . . . 0.0 104.993 177.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 59.8 mt -87.9 118.39 33.52 Favored 'Isoleucine or valine' 0 C--N 1.356 0.864 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 175.5 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 7.0 p -151.47 168.72 23.99 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 -175.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.262 1.716 0 CA-C-O 117.427 -1.273 . . . . 0.0 108.499 177.437 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 96.0 m . . . . . 0 N--CA 1.444 -0.753 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.2 m -134.33 -168.17 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.752 0 N-CA-C 103.938 -2.616 . . . . 0.0 103.938 169.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.3 t-105 -139.66 143.58 37.21 Favored 'General case' 0 N--CA 1.437 -1.119 0 N-CA-C 106.379 -1.712 . . . . 0.0 106.379 175.031 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 85.21 53.44 3.12 Favored Glycine 0 C--N 1.355 1.625 0 N-CA-C 108.789 -1.724 . . . . 0.0 108.789 -179.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -136.16 168.61 23.99 Favored Glycine 0 C--N 1.352 1.438 0 N-CA-C 107.99 -2.044 . . . . 0.0 107.99 -176.004 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -92.89 -34.22 13.89 Favored 'General case' 0 N--CA 1.442 -0.846 0 C-N-CA 124.278 1.031 . . . . 0.0 111.455 -170.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 86.1 m -115.8 -137.5 0.36 Allowed 'General case' 0 C--N 1.356 0.866 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 -174.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 33.0 m -144.24 145.97 32.37 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 105.392 -2.077 . . . . 0.0 105.392 -169.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p30 -89.38 -100.82 0.09 Allowed 'General case' 0 C--N 1.365 1.273 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 166.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -88.23 155.98 19.46 Favored 'General case' 0 N--CA 1.435 -1.195 0 C-N-CA 126.515 1.926 . . . . 0.0 107.119 172.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.3 mt -80.68 122.49 27.18 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 123.669 0.788 . . . . 0.0 109.048 -174.467 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 90.84 -3.94 81.41 Favored Glycine 0 C--N 1.354 1.579 0 C-N-CA 123.74 0.686 . . . . 0.0 111.663 178.159 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 22.8 t -90.91 -70.79 0.66 Allowed 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 -176.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -170.33 -165.29 27.45 Favored Glycine 0 CA--C 1.491 -1.419 0 N-CA-C 108.102 -1.999 . . . . 0.0 108.102 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 39.7 p -88.63 -173.17 4.04 Favored 'General case' 0 N--CA 1.418 -2.054 0 C-N-CA 126.036 1.734 . . . . 0.0 109.027 -177.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -143.08 148.53 36.8 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 169.587 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 24.0 m0 -88.54 -49.18 7.06 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 -176.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 40.2 mm -82.5 119.48 32.11 Favored 'Isoleucine or valine' 0 C--N 1.356 0.865 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 178.328 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 42.2 t -150.5 -52.42 0.14 Allowed 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 105.172 -2.158 . . . . 0.0 105.172 -176.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 35.4 t . . . . . 0 C--O 1.259 1.574 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 -178.781 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.3 t . . . . . 0 CA--C 1.5 -0.97 0 CA-C-O 121.763 0.792 . . . . 0.0 109.189 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.6 m -126.57 -164.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.855 0 N-CA-C 102.983 -2.969 . . . . 0.0 102.983 166.494 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.8 t-105 -139.4 142.15 37.5 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 176.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.91 58.16 2.55 Favored Glycine 0 C--N 1.354 1.565 0 N-CA-C 108.816 -1.713 . . . . 0.0 108.816 -179.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -134.93 174.83 20.94 Favored Glycine 0 CA--C 1.49 -1.479 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -174.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 47.3 m-20 -90.17 -42.94 10.76 Favored 'General case' 0 N--CA 1.44 -0.94 0 C-N-CA 124.415 1.086 . . . . 0.0 110.136 -170.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 74.8 m -119.32 -133.94 0.32 Allowed 'General case' 0 C--N 1.355 0.839 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -168.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 59.4 m -145.3 143.63 30.3 Favored 'General case' 0 C--N 1.356 0.883 0 N-CA-C 105.331 -2.1 . . . . 0.0 105.331 -168.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 p30 -89.05 -98.86 0.09 Allowed 'General case' 0 C--N 1.364 1.204 0 N-CA-C 104.554 -2.388 . . . . 0.0 104.554 166.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 -87.97 144.55 26.48 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 167.126 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 47.9 tp -83.62 123.89 30.25 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.245 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.01 -28.62 9.62 Favored Glycine 0 C--N 1.353 1.483 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.26 -65.14 1.04 Allowed 'General case' 0 C--N 1.358 0.937 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -174.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -172.98 -163.66 27.1 Favored Glycine 0 C--N 1.353 1.497 0 N-CA-C 109.551 -1.419 . . . . 0.0 109.551 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 36.9 p -89.91 -174.85 4.41 Favored 'General case' 0 N--CA 1.42 -1.931 0 C-N-CA 126.667 1.987 . . . . 0.0 109.361 -176.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -142.18 149.39 39.65 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 169.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 25.1 m0 -87.33 -50.61 6.46 Favored 'General case' 0 CA--C 1.5 -0.98 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -176.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 20.5 tt -79.18 134.14 28.44 Favored 'Isoleucine or valine' 0 C--N 1.354 0.776 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 175.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' CYS . . . . . . . . . . . . . 35.1 t -150.81 155.42 39.18 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 105.587 -2.005 . . . . 0.0 105.587 -175.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.259 1.58 0 C-N-CA 124.036 0.934 . . . . 0.0 108.574 178.238 . . . . . . . . 0 0 . 1 stop_ save_